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Abstract
Ghrelin is a peptide hormone primarily secreted by the stomach that acts as the
endogenous ligand for the GHSR1a G-protein-coupled receptor. This 28 amino acid peptide
stimulates appetite and has been associated with the cardiovascular, gastrointestinal,
neuroendocrine, and immune systems. Ghrelin requires a unique posttranslational modification
to be biological active. Ghrelin O-acyltransferase (GOAT) is responsible for catalyzing
octanoylation of the 3rd serine side chain of ghrelin to generate the active form of this hormone.
Thus, GOAT is considered as a potential therapeutic target for treatment of obesity and other
disorders linked to the peptide. Yet, the active site architecture and mechanism for GOATcatalyzed ghrelin acylation are presently undetermined. Purification of an active form of GOAT
has been challenging, impeding structural studies of this integral membrane protein. To improve
on these challenges, we have synergistically combined computational modeling and biochemical
validation to construct the first structural model of the eukaryotic membrane-bound human
GOAT protein. Our structure revealed an unforeseen strategy for transmembrane protein
acylation with catalysis occurring in an internal channel connecting the lumen and cytoplasm.
Structure-guided studies used in this work, have revealed essential amino acid responsible for
important substrate-enzyme interactions. Moreover, by using a tight-binding fluorescent ghrelinderived peptide, we demonstrate GOAT’s interaction with extracellular ghrelin and facilitation of
ligand cell internalization. Our work provides a new understanding of GOAT’s catalytic
mechanism, establishes key substrate-enzyme interactions, and advances structure-guided
inhibitor design to target therapeutically important but experimentally intractable membrane
proteins.

Structural and Functional Insights into Ghrelin Acylation by Ghrelin OAcyltransferase

by

María Belén Campaña

B.S., Florida International University, 2012
M.Phil., Syracuse University, 2016

Dissertation
Submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in Chemistry

Syracuse University
August 2020

Copyright © Maria B. Campaña 2020
All rights reserved

Acknowledgements
There are so many people who have touched my life and made significant impacts to my
career development these past couple of years. First, I want to give deep thanks to my mentor
and advisor Dr. James L. Hougland. I feel very fortunate to have the incredible opportunity to
learn under his mentorship. His guidance on both, research as well as on my career, have been
invaluable. His patience, motivation, enthusiasm, and immense knowledge is truly inspiring. He
has created the best laboratory environment for his students to thrive and learn, and I believe he
has been the catalysis to the development into the scientist I am today.
I would also like to thank my committee members for their contribution: Dr. Shikha
Nangia, Dr. Heidi Hehnly, Dr. Carlos Castañeda, Dr. Robert Doyle, Dr. Davoud Mozhdehi.
Their help and feedback into my project were very valuable. Thank you Dr. Carlos Castañeda
and Dr. Robert Doyle for supporting my research throughout my time at Syracuse University. I
also would like to acknowledge the Department of Chemistry at Syracuse University. My
graduate experience benefited greatly from my coursework, the expertise I gained from serving
as a teaching assistant, and the high-quality seminars that the department organized.
To my best friends and my lab family, thank you for creating the most friendly and
supportive atmosphere. Michelle, our lab mom, thank you for teaching me all I needed to know
to succeed and for our fascinating and long-lasting chats about science and life in general. Thank
you to all lab members: Joseph Darling, Susan Flynn, Soumyashree Gangopadhyay, Kayleigh
McGovern-Gooch, Elizabeth Cleverdon, Melanie Blanden, Sudhat Ashok, Tasha Davis, Jacob
Moose, Mariah Pierce, and Sadie Novak. We have shared A LOT of great times together, but
beyond that, it is who you are that makes me strive to be better. Thank you to the all my
undergraduate students, it was a great pleasure to have worked with such a greatly inspired

iv

group, whose motivation contributed significantly to this project: Alexandra C. Onlanescu,
Yasandra Morales-Rodriguez, Melissa Navarro, Najae R. Escoffery, Carlos Iñiguez, Mohammad
A. Ashkar, Natasha Tcheki-Jamgotchian.
To my friends, any person would be lucky to have any one of you in their life and I love
you all! To my best friend Gianni, you have been a true and great advocate of my life decisions.
Thank you for unconditionally loving me during my good and bad times. I am very lucky to have
such a kind-hearted individual walking by my side.
Finally, I would like to acknowledge my family who supported me during my time here.
To my parents Wilson and Amparito, who continue to lead through example of courage, hard
work, and selflessness. Who also had taught me the most valuable lessons, which I continue to
live my life by: “Do the right thing, not the easy thing”. Thank you for leaving everything and
giving us a better life. To my brother and partner in crime, Daniel. You are simply the nicest,
most inspiring person I know. Thank you for being my supporter and best friend. You truly
encourage me to be better, to reach for more, and to never settle. For more crazy adventures with
you!

v

Table of Contents
List of Figures

xiv

List of Tables

xviii

List of Abbreviations

xix

Chapter 1: Introduction
1.1

Protein post-translation modifications

2

1.2

Ghrelin – an acylated peptide hormone

4

1.2.1 Discovery of ghrelin as the endogenous ligand of the growth hormone secretagogue
receptor 1a

4

1.2.2 Ghrelin expression and binding to GHS-R1a receptor

5

1.2.3 Ghrelin signaling and regulation

6

1.2.4 Ghrelin maturation and acylation

9

1.3

Ghrelin O-acyltransferase (GOAT)

12

1.3.1 GOAT expression and distribution

14

1.3.2 GOAT topology and structure-activity analysis

15

1.3.3 Crystal structure of a membrane-bound O-acyltransferase

17

1.4

GOAT substrate selectivity/recognition

19

1.5

GOAT inhibitors/ therapeutic effects

20

1.6

Aims of this work

25

1.7

References

28

vi

Chapter 2: Biochemical analysis of predicted contacts within the hGOAT structural model
by alanine mutagenesis
2.1

Introduction

45

2.2

Results

47

2.2.1 Computational model for human GOAT structure

47

2.2.2 Features of the human GOAT structure

50

2.2.3 Mutagenesis analysis of hGOAT structural model

57

2.3

Discussion and conclusions

62

2.4

Experimental Procedures

64

2.4.1 Co-evolutionary contact analysis of hGOAT

64

2.4.2 Folding simulations

65

2.4.3 Refinement and relaxation using molecular dynamics

66

2.4.4 General experimental methods

66

2.4.5 Peptide substrate fluorescent labeling

67

2.4.6 Construction of hGOAT mutants

67

2.4.7 Expression and enrichment of hGOAT in membrane protein fraction

72

2.4.8 Membrane fraction enrichment

72

2.4.9 hGOAT expression analysis by anti-FLAG Western Blot

72

2.4.10 hGOAT activity assay

75

2.4.11 Statistical analysis of hGOAT alanine variant reactivity

76

2.5

78

References

vii

Chapter 3: Investigation of the acyl donor-binding site within hGOAT
3.1 Introduction

86

3.2 Results

89

3.2.1 Octanoyl-CoA: hGOAT-modeling complex

89

3.3.2 Octanoyl-CoA chemical interactions within the GOAT pocket

91

3.2.3 Single acyl donor investigation with alanine mutants

94

3.2.4 Competition experiments to define GOAT selectivity

97

3.3 Discussion and conclusion

102

3.4 Experimental Methods

105

3.4.1 Molecular docking and relaxation of octanoyl-CoA:hGOAT complex

106

3.4.2 Construction of hGOAT mutants

106

3.4.3 Expression and enrichment of hGOAT in membrane protein fractions

107

3.4.4 hGOAT expression analysis by anti-FLAG Western Blot

107

3.4.5 hGOAT activity assay - standard reaction conditions

109

3.4.6 Single acyl donor reactivity assay

110

3.4.7 Acyl donor competition assay

110

3.5 References

112

Chapter 4: Investigation of enzyme-substrate interactions using hGOAT variant reactivity
alteration with modified peptide substrates
4.1 Introduction

117

4.2 Results

122

4.2.1. hGOAT mutant reactivity enhancement and loss with mutated peptide substrates

122

viii

4.2.2 Identification of ghrelin’s binding site via ghrelin-GOAT cross mutation analysis

128

4.3 Discussion and Conclusions

131

4.4 Experimental Methods

138

4.4.1 General Methods

138

4.4.2 Peptide substrates fluorescent labeling

138

4.4.3 Construction of plasmids encoding wild type hGOAT and hGOAT alanine variants

139

4.4.4 Expression and enrichment of hGOAT in membrane protein fractions

140

4.4.5 Membrane fraction enrichment

140

4.4.6 GOAT activity assay

141

4.4.7 HPLC analysis of hGOAT octanoylation reactions

141

4.5 References

143

Chapter 5: Remarkable ligand specificity for ghrelin O-acyltransferase reveals unexpected
enzyme interaction with extracellular peptides
5.1 Introduction

147

5.2 Results and Discussion

149

5.2.1 Design of Dap-based ghrelin peptide ligand to bind GHS-R1a and hGOAT

149

5.2.2 Changes at the N-terminal amino acid (G1) and hGOAT recognition

152

5.2.3 Changes at E8

154

5.2.4 Changes at F4

156

5.2.5 Design of GHS-R1a and hGOAT-selective ligands

159

5.2.6 Creation of fluorescent high-affinity selective GOAT ligand

161

5.2.7 Analyzing interaction of GOAT compound 15 with cells expressing hGOAT

163

ix

5.3 Discussion

168

5.4 Experimental Methods

171

5.4.1 Peptide synthesis and characterization

171

5.4.2 GHS-R1a receptor binding assays

173

5.4.3 hGOAT inhibition assays

173

5.4.4 Construction of hGOAT WT and mutants

175

5.4.5 hGOAT (WT and mutants) transfection in HEK293 cells

175

5.4.6 GOAT ligand labeling and immunofluorescence imaging

176

5.4.7. Image analysis

177

5.4.8 Confirmation of hGOAT expression by Western blot

177

5.5 References

180

Chapter 6: Investigation of a Predicted Functionally Essential Loop Domain within Human
Ghrelin O-Acyltransferase
6.1 Introduction

191

6.2 Results

198

6.2.1 Design of hGOAT loop variants. Expression of CARLi loop domain via a synthetic split
mini-intein gene

198

6.2.2 Expression optimization of CARLi domain with flexible internal hexahistidine affinity-tag
201
6.2.3 Purification of cyclized CARLi domain

207

6.2.4 Circular dichroism analysis of CARLi_SM loop domain

210

6.3 Discussion and conclusions

212

x

6.4 Experimental Methods

214

6.4.1 Design of CARLi domain variants with flexible internal hexahistidine affinity-tag

214

6.4.2 Double digestion of pUC57-Amp and pET23a

214

6.4.3 DNA Ligation Procedure of insert gene for CARLi_constructs into pET23a(+)

215

6.4.4 Plasmid transformation into DH5-alpha competent E.coli cells

215

6.4.5 Plasmid transformation into BL21-DE3 E.coli cells

216

6.4.6 Expression of hGOAT CARLi_construct (Small, Medium, and Long) using autoinduction
media

216

6.4.7 Purification and refolding for the solubilization of CARLi_SM protein expressed in E.coli
217
6.4.8 SDS-PAGE analysis

218

6.4.9 Coomassie Blue staining procedure

219

6.4.10 Anti-His6 Western blotting of inclusion bodies in CARLi_SM purification

219

6.4.11 Circular dichroism spectroscopy of circularized hGOAT CARLi domain

220

6.5 References

221

Chapter 7: Conclusions and future directions
7.1 Introduction

228

7.2 Development of the first molecular-level structural model of human GOAT

229

7.3 Exploring the acyl donor-binding site within hGOAT

230

7.4 Identification of ghrelin binding to GOAT via cross-mutation analysis

232

7.5 Development of specific ghrelin O-acyltransferase ligand that exposed a new method of
GOAT detection with extracellular peptides

233

7.6 Define the structure and function of a catalytically required hGOAT loop domain

235

xi

7.7 Summary and future direction

236

7.8 References

239

xii

Appendices
Appendix I: Reprint permission for reference 86, Chapter 1

16

Appendix II: Reprint permission for reference 16, Chapter 2

48

Appendix III: Reprint permission for reference 16, Chapter 2

49

Appendix IV: Reprint permission for reference 16, Chapter 2

53

Appendix V: Reprint permission for reference 16, Chapter 2

54

Appendix VI: Reprint permission for reference 16, Chapter 2

55

Appendix VII: Reprint permission for reference 16, Chapter 2

58

Appendix VIII: Reprint permission for reference 16, Chapter 2

59

Appendix IX: Reprint permission for reference 16, Chapter 2

61

Appendix X: Reprint permission for reference 16, Chapter 2

65

Appendix XI: Reprint permission for reference 16, Chapter 2

74

Appendix XII: Reprint permission for reference 14, Chapter 3

93

Appendix XIII: Reprint permission for reference 14, Chapter 3

95

Appendix XIV: Reprint permission for reference 14, Chapter 3

96

Appendix XV: Reprint permission for reference 14, Chapter 3

98

Appendix XVI: Reprint permission for reference 14, Chapter 3

101

Appendix XVII: Reprint permission for reference 19, Chapter 6

195

Appendix XVIII: Reprint permission for reference 20, Chapter 6

196

Appendix XIX: Curriculum Vitae

248

xiii

List of Figures
Figure 1.1 Gut-brain connection: The physiological effects of ghrelin activation

8

Figure 1.2 Ghrelin synthesis, maturation and post-translational modification in stomach cells 11
Figure 1.3 Ghrelin octanoylation by Ghrelin O-Acyltransferase (GOAT)

13

Figure 1.4 Ghrelin O-Acyltransferase topology model

16

Figure 1.5 Crystal structure of a membrane-bound O-acyltransferase

18

Figure 1.6 Ghrelin O-acyltransferase inhibitors incorporating lipid mimetic groups and small
molecules

24

Figure 2.1 Co-evolutionary contact restraints used in hGOAT structural modeling

48

Figure 2.2 Overlay of top 10 lowest energy structures of hGOAT from folding simulations

49

Figure 2.3 Computational approach yields structural model of hGOAT

52

Figure 2.4 Third dimension computational organization of a membrane bound O-acyltransferase
protein molecules

53

Figure 2.5 GOAT model reveals an intermembrane channel within its core

54

Figure 2.6 Structural overlay of hGOAT and DltB showing the absolutely conserved histidine
residues molecules

55

Figure 2.7 Mutagenesis studies support the location and functional importance of the hGOAT
internal channel

58

Figure 2.8 hGOAT alanine variant octanoylation activity mapped onto the hGOAT topology
model

59

Figure 2.9 Octanoylation activity of hGOAT alanine variants for non-void contacting and voidcontacting mutations

61

Figure 2.10 Flow chart for computational modeling of hGOAT

xiv

65

Figure 2.11 hGOAT variant expression confirmation by anti-Flag Western blotting

74

Figure 3.1 Computational structural model complex of hGOAT and Acyl-CoA

90

Figure 3.2 Interactions between the octanoyl-CoA acyl donor and hGOAT residues

93

Figure 3.3 Acylation activity of WT hGOAT and selected hGOAT alanine variants using
octanoyl-, lauryl-, or myristoyl-CoA as the sole acyl donor

95

Figure 3.4 Acyl donor reactivity with WT hGOAT and hGOAT alanine variants with C8-CoA
(black), C12-CoA (purple), and C14-CoA (green) acyl donors

96

Figure 3.5 Acyl donor competition experiment

98

Figure 3.6 Acyl competition reactions with WT hGOAT and hGOAT alanine variants with C6CoA, C8-CoA, C10-CoA, and C12-CoA
Figure 3.7 Proposed pathway for transmembrane ghrelin octanoylation by GOAT

101
104

Figure 3.8 Acyl donor reactivity with WT hGOAT and hGOAT alanine variants with C8-CoA
(black), C12-CoA (purple), and C14-CoA (green) acyl donors

111

Figure 4.1 Schematic illustrations of known substrate-binding-site interactions within the
hGOAT active site

120

Figure 4.2 Structural modeling of human ghrelin O-acyltransferase reveals a transmembrane
channel within GOAT

121

Figure 4.3 Mutated peptide substrates for structure-activity studies of hGOAT alanine variants
124
Figure 4.4 Analyses to determine specific enhancement and loss of hGOAT variant reactivity
with mutated peptide substrates

125

Figure 4.5 Specific reactivity enhancement analysis of GOAT-ghrelin mutation pairs

129

Figure 4.6 Specific reactivity loss analysis of GOAT-ghrelin mutation pairs

130

xv

Figure 4.7 Proposed interactions between enzyme and substrate residues in the ghrelin-binding
site within hGOAT

136

Figure 4.8 Illustration of proposed ghrelin contacting residues within the hGOAT structural
model contacting the internal enzyme channel

137

Figure 5.1 Orthogonal GHS-R1a and hGOAT selective ligands with associated IC50
demonstrate a discriminatory binding effect towards modifications

160

Figure 5.2 Fluorescent ligand designed for strong binding to hGOAT

162

Figure 5.3 Cell imaging and scoring of ligand uptake by transfected HEK293 cells

166

Figure 5.4 Proposed interactions within the GOAT active site of Ser3 with H338 and Dap3 with
H338

170

Figure 5.5 Western blot verification of hGOAT expression in HEK 293 cells

179

Figure 6.1 Ghrelin octanoylation by Ghrelin O-Acyltransferase (GOAT)

193

Figure 6.2 GOAT model topology by Taylor et al. showing 11 transmembrane domains, one
reentrant loop, and multiple loops in both the cytoplasm and ER lumen

195

Figure 6.3 Membrane topology models for human Hhat (left) and GOAT (right)

196

Figure 6.4 CARLi loop domain binds the octanoyl-CoA acyl donor for ghrelin acylation

197

Figure 6.5 Circularization of CARLi by expression in a split intein construct

200

Figure 6.6 Optimization of loop domain constructs with flexible linkers

203

Figure 6.7 Expression analysis of CARLi constructs in autoinduction media by 14% Tris-tricineSDS-PAGE

204

Figure 6.8 Predicted protein splicing products of the CARLi_SM (Small Domain Loop)
construct with flexible peptide linker and genetically encoded internal His6 tag
Figure 6.9 Western blot analysis of small CARLi construct expression

xvi

205
206

Figure 6.10 SDS-PAGE analysis of Carli_SM purification from inclusion bodies

208

Figure 6.11 SDS-PAGE analysis of Carli_SM size exclusion purification

209

Figure 6.12 Circular dichroism analysis of circularized hGOAT CARLi domain

211

Figure 7.1 Proposed model for substrate interaction with ghrelin O-acyltransferase

238

xvii

List of Tables
Table 2.1. Statistics and parameters for sequence coevolution analysis of hGOAT

56

Table 2.2. hGOAT alanine variant octanoylation activity with the GSSFLCAcDan peptide
substrate under standard reaction conditions

60

Table 2.3 Primers for hGOAT alanine mutagenesis

69

Table 3.1 hGOAT alanine variant octanoylation activity

92

Table 4.1. Cross-reactivity between modified substrates and hGOAT mutants yields
enhancement signals of enzymatic activity at specific ghrelin positions

126

Table 4.2. Specific loss of enzyme ractivity between modified substrates and hGOAT variants
127
Table 4.3. Summary of specific enhancements and losses of reactivity identified through
analysis of hGOAT variant-mutated ghrelin substrate pairs

135

Table 5.1. Acyl changes within ghrelin peptide sequence

151

Table 5.2. G1 modifications within ghrelin peptide sequence

153

Table 5.3. E8 modifications within ghrelin sequence

155

Table 5.4. Ghrelin sequence changes at F4

157

Table 5.5. Summary of ligands devised for GOAT binding

158

Table 5.6 Cell imaging and scoring for GOAT transfection and ligand 15 uptake

167

Table 5.7. Analytical data for peptide ligands

172

xviii

List of Abbreviations
aa
ACAT
AcDan
Aib
Ala
BAP
BChE
C10-CoA
C10:0
C14-CoA
C14:0
C16-CoA
C16:0
C6-CoA
C8
C8:0
CARLi
cat-ELCCA
CD
CDDO
CDDO-Me
Cha
CMC
CoA
[Ca2+]i
Dap
DAPI
DCM
DIPEA
DltB
DMEM
DMF
DMSO
dNTP
DOPC
DPPC
DTP
DTT
EDTA
ELISA
ER
EV
EVs
FBS

Amino acid
Acetyl-coenzyme A acetyltransferase
Acrylodan
Aminoisobutyric acid
Alanine
Bacterial alkaline phosphatase
Butyrylcholinesterase
n-Decanoyl-CoA
Ten-carbon chain with no double bonds
n-Myristoyl-CoA
Fourteen-carbon chain with no double bonds
n-Palmitoyl-CoA
Sixteen-carbon chain with no double bonds
n-Hexanoyl-CoA
Octanoyl
Eight-carbon chain with no double bonds
Conserved Asp/Asn Required Loop, intracytoplasmic
Catalytic assay using enzyme-linked click chemistry
Circular dichroism
2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid
2-Cyano-3,12-dioxo-oleana-1,9-dien-28-oic acid methyl ester
Cyclohexylalanine
Critical micelle concentration
Coenzyme-A
Intracellular calcium concentration
2,3-Diaminopropanoic acid
4,6-diamidino-2-phenylindole
Dichloromethane
N,N-diisopropylethylamine
D-alanyl transferase protein
Dulbecco's modified eagle's medium
N,N-dimethylformamide
Dimethyl sulfoxide
Deoxyribonucleotide triphosphate
Dioleoyl phosphatidylcholine
Dipalmitoylphosphatidylcholine
Diversity Set IV library
Dithiothreitol
Ethylenediaminetetraacetic acid
Enzyme-linked immunosorbent assay
Endoplasmic reticulum
Empty vector
Extracellular vesicles
Fetal bovine serum

xix

FPLC
GH
GHS-R1a
GOAT
GST
GuHCl
Gup1p
CV
HA
HCTU
HDL
HEK
HEPES
hGOAT
Hhat
His
His6
HPLC
IB
IC50
IM
IMPs
Inp
Int
LB
LC
LDL
LPIAT1
MAFP
MALDI
MSA
MBOAT
MBP
mGOAT
MOI (pfu/cell)
mRNA
MS
Mut
MWCO
NaEDTA
Nal2
Nal1
Ni
NMP
NMR

Fast Protein Liquid Chromatography
Growth hormone
Growth-hormone secretagogue receptor 1a
Ghrelin O-Acyltransferase
Glutathione S-transferase
Guanidine hydrochloride
Glycerol uptake protein 1
Column volumes
Hemagglutinin
O-(6-chlorobenzotriazol-1-yl)-N,N,N′,N′tetramethyluronium hexafluorophosphate
High density lipoproteins
Human embryonic fibroblasts
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
Human ghrelin O-acyltransferase
Hedgehog acyltransferase
Histidine
Polyhistidine
High performance liquid chromatography
Inclusion bodies
Half maximal inhibitory concentration
Intramembrane domains
Integral membrane proteins
Isonipecotic acid
Intein
Luria broth
Liquid chromatography
Low density lipoproteins
Lysophosphatidylinositol-acyltransferase-1
Methoxy arachidonyl fluorophosphonate
Matrix assisted laser desorption ionization
Multiple sequence alignment
Membrane bound O-acyltransferase
Maltose binding protein
Mouse GOAT
Multiplicity of Infection (plaque forming unit/cell)
Messenger RNA
Mass Spectrometry
Mutated
Molecular weight cut-off
Sodium ethylenediamine
2-naphylalanine
1-naphylalanine
Nickel
N-methylpyrrolidinone
Nuclear magnetic resonance

xx

Octanoyl-CoA
P1 virus
P2 virus
PBS
PBSAT
PCa
PCR
PFPN
Phe
PORCN
PTMs
PVDF
RL
RP-HPLC
SDS-PAGE
SEC
Ser
SUP
T7RNAP
TAE
TAs
TBME
TBST
TCEP
TEV
TFA
TIS
TM
TMD
Trp
Tris
Val
VLDL
WT

Octanoyl coenzyme A
Passage 1 virus
Passage 2 virus
Phosphate-buffered saline
PBS + 1% bovine serum albumin-0.1% triton
Prostate cancer
Polymerase chain reaction
Pentafluorophenyl naphthoate
Phenylalanine
Porcupine
Post-translation modifications
Polyvinylidene fluoride
Re-entry loop
Reverse phase high performance liquid chromatography
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Size exclusion chromatography
Serine
Supernatant
T7 RNA polymerase
Tris-acetate
Teichoic acid
Tert-butyl methyl ether
Tris 10 buffered saline
tris(2-carboxyethyl)phosphine
Tobacco etch virus
Trifluoroacetic acid
Triisopropylsilane
Transmembrane domain
Transmembrane domain
Tryptophan
2-Amino-2-hydroxymethyl-propane-1,3-diol
Valine
Very low-density lipoproteins
Wild Type

xxi

Chapter 1: Introduction

1

Chapter 1: Introduction
1.1 Protein post-translation modifications
In the last few decades, scientists have identified a vast number of proteins forms in the
human proteome, well beyond that encoded in the genome. This proliferation in complexity is
created by subsequent chemical transformations in a process called post-translational
modification (PTM). PTMs chemically diversify the proteome beyond the standard
proteinogenic 20 amino acids to an enormous number of residues,1 changing the properties of a
protein by the addition of an altered chemical group or another protein to the polypeptide. These
modifications can create highly dynamic regulatory networks associated in almost all cellular
processes.2 These modifications can be required for protein folding, protein-protein interactions,
transcriptional adaptation, metabolism, and cell growth among other key cellular mechanisms.3
This immense number of known PTMs emphasizes the countless ways that cells can modify their
proteins to respond to diverse stimuli.
PTMs are abundant in the proteome with several hundreds of modifications described,4
ranging from small chemical modifications (e.g., phosphorylation and acetylation) to the addition
of proteins (e.g., ubiquitylation).5-6 Alterations such as phosphorylation, which conjugates a
phosphate group covalently to a serine, threonine, or tyrosine residue, play essential roles in
relaying a broad spectrum of regulatory oncogenic mechanisms in eukaryotic cells.7 On other
hand, some of these modifications are involved in correct protein folding, changing the
biophysical properties of the protein like glycosylation and lipidation.8-10 The addition of
hydrophobic lipid groups to proteins can play an essential role in regulating protein-membrane
and protein-protein interactions. Common lipidation modifications include fatty acylation,
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prenylation, palmitoylation, among others that modify charge, hydrophobicity, and other features
of protein chemistry inside the cell.9, 11
Protein acylation can occur on amino acid residues like Lys, Cys, and Ser/Thr bearing
nucleophilic side chains (-NH2, -SH, -OH) with these modifications referred as N-acylation
(amide linkage), S-acylation (thioester linkage) or O-acylation (ester linkage), respectively. Nacetylation, the transfer of an acetyl group to a specific site on a polypeptide chain from acetylcoenzyme A (CoA), is catalyzed by various acetyltransferases.9 This posttranslational
modification is broadly distributed in nature and conserved in all kingdoms as a key alteration to
control protein trafficking, intracellular localization, and other signaling pathways. 12-13 Other
types of acylation occur at the protein N-terminus, such as N-terminal acetylation, Nmyristoylation on Gly or S-palmitoylation on Cys residues.14 The addition of a 14-carbon fatty
acid myristate to a N-terminal glycine is a stable bond, which is co-translationally modified.15 In
contrast, palmitoylation is the posttranslational attachment of palmitic acid (16-carbon) to Nterminal or internal cysteine residues of proteins via a reversible thioester.11 Cycles of
palmitoylation and depalmitoylation occur in a controlled fashion for many proteins, implying an
important role for this acylation mode in the dynamic regulation of cellular processes. 16

3

1.2 Ghrelin – an acylated peptide hormone
1.2.1 Discovery of ghrelin as the endogenous ligand of the growth hormone secretagogue
receptor 1a
The peptide hormone ghrelin is one of several biological signaling molecules that require
a lipidation modification for biological function.17 This hormone is an orexigenic peptide that
acts directly on neurons in the hypothalamus, controlling appetite and energy balance.18 This
hormone was first identified in 1999 by Kojima and coworkers with numerous studies to
identifying the endogenous ligand for growth-hormone secretagogue receptor (GHS-R1a).17 The
ligand discovered was recognized to be the cognate agonist of this receptor when purified from
rat stomach.17, 19 These studies examined changes for the characteristic intracellular increase in
calcium concentrations ([Ca2+]i) induced by GHS-R1a activation in rat tissues and found the
highest to be in the stomach extract. Furthermore, by comparing synthetic 28-residue peptide
(desacyl ghrelin) to ghrelin extracted from rat stomach via reverse phase HPLC (high
performance liquid chromatography), there was delay in retention time of natural ghrelin by 10
minutes. This change in retention time was indicative of the presence of a large hydrophobic
group that was identified to be the hydroxyl group of the Ser3 residue in ghrelin modified by an
acyl group. 17 This modification revealed an uncommon eight-carbon fatty acid moiety
(octanoate) covalently acylated to the ghrelin hormone.
The post-translational octanoylation of ghrelin has been demonstrated to be absolutely
necessary for GHS-R1a receptor identification and activation.20 Desacyl ghrelin is unable to bind
and activate the receptor, preventing subsequent receptor activation.20 However, desacyl ghrelin
possesses a distinct profile of biological actions including promotion of bone marrow
adipogenesis,21 reduction of gastric emptying,22 and suppression of gonadotrophin secretion in
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male rats,23 but the exact nature and mechanism of this signaling by desacyl ghrelin remains
unclear.

1.2.2 Ghrelin expression and binding to GHS-R1a receptor
The GHS-R1 gene encodes for the human full-length seven transmembrane domain Gprotein coupled protein (GHS-R1a) and its truncated isoform (GHS-R1b).24-25 GHS-R1 mRNA
expression analysis revealed that the receptor type 1a is found mainly in pituitary with lower
levels of this receptor found also in the brain and peripheral tissues, thyroid gland, pancreas,
spleen, myocardium, and adrenal gland.24, 26 Meanwhile, ghrelin mRNA was identified via realtime PCR in the stomach and several other tissues studied (kidney, liver, colon, fat tissue, breast,
esophagus, among others).27 Ghrelin is primarily produced and secreted by X/A-like cells in the
oxyntic glands of the gastric mucosa in rats and P/D1 cells in human,28 with Wierup et al. also
describing expression of ghrelin in the pancreas of ε-cells.29 Ghrelin expression was also
identified in the pituitary gland and hypothalamus, where the highest concentration of its
receptor was determined.24 The widespread distribution of GHS-R1a and ghrelin indicates
broader implications beyond its well-known appetite stimulating (orexigenic) function.
In addition, ghrelin is described as a peptide hormone that can induce growth hormone
(GH) release from pituitary cells in dose-dependent fashion, without GHS-R1a activation
stimulating the release of other hormones even at high ghrelin concentrations.17, 30 To further
investigate specificity of ghrelin induced GH release, Kojima and coworkers injected ghrelin
intravenously in rats resulting in the high release of only GH.17 These results suggested that
ghrelin is a specific endogenous ligand for the GHS-R1a receptor.
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To reveal structural features of human ghrelin required to activate the GHS-R1a receptor,
ghrelin analogs containing aliphatic or aromatic groups in the side chain of residue 3 and
truncated peptides of ghrelin were synthesized and tested for activity.20 This study established
the importance of a large hydrophobic group in Ser3 required for efficient activation of GHSR1a. Moreover, ghrelin is the only peptide known to be octanoylated at serine 3 amino acid,
which is required for the release of growth hormone in human and rats.12,31,28 Ghrelin analogs
with shorter and less hydrophobic acyl groups in place of the n-octanoyl group showed decreased
in receptor binding and activation, whereas medium to long acyl groups up to 16 carbons
exhibited receptor activation.20 Interestingly, a truncated version of ghrelin only containing the
first five amino acids was sufficient to be recognized and activated the receptor equivalently to
that of full-length ghrelin. Moreover, the shorter tetrapeptide GSS(n-octanoyl)F still activated the
GHS-R1a receptor but to a lesser extent.

1.2.3 Ghrelin signaling and regulation
Originally linked to growth hormone secretion and stimulation of appetite18, 32, ghrelin
was also found to be a potent stimulator of food intake, energy storage, and adiposity.33-34
Studies had showed that the concentration of ghrelin in rat serum increased by fasting and
reduced by orally glucose intake.33 Peripheral (subcutaneous and intraperitoneal) daily
administration of ghrelin triggered weight gain by reduction of fat utilization in mice and rats.33
Interestedly, studies of ghrelin in humans also supported the stimulation of appetite and food
intake,35 but plasma ghrelin concentration was inversely related to body fat.36 Ghrelin was also
proven to increase food intake in obese as well as lean subject groups, with no significant
difference in basal ghrelin levels indicating that ghrelin sensitivity is preserved in obese groups.37
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Subsequently, it has been proposed that the dysregulation of ghrelin could be connected to the
development of obesity and other the metabolic related conditions.38
In addition to these functions, this hormone has been shown to be involved in addictive
behaviors, playing an important role in reward processing.39-40 Studies also linked ghrelin to
stress-related mechanisms, affecting psychological responses to prolonged exposure to
stressors.41-43 Moreover, ghrelin is involved in neuroprotection44 as well as memory and learning
process. 45, 46 All these reinforce the hypothesis of ghrelin’s connection with major brain systems,
consistent with proposed involvement of ghrelin in generation and/or progression of Alzheimer's
disease.47
Additionally, studies of ghrelin and ghrelin receptor agonists have shown connections to
other disorders including anorexia nervosa,48 cancer cachexia,49 chronic heart failure,50 and
regulation of inflammation and inflammatory cytokine expression in humans and rodents.
Uncovering of the roles that ghrelin and its cognitive receptor play in the immune system have
opened new treatment options for immunological disorders such as AIDS and organ damages
due to obesity/ageing-related chronic inflammation diseases (Figure 1.1).51
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Figure 1.1. Gut-brain connection: The physiological effects of ghrelin activation. Ghrelin is
mainly produced and released by the stomach with low amounts found in other tissues such as
the gastrointestinal tract, the pancreas, and the brain. Ghrelin, the “hunger hormone”, regulates
appetite and plays a significant role in controlling energy homeostasis, memory and learning
processes, immunological systems, stress mechanisms, among others.
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1.2.4 Ghrelin maturation and acylation
Ghrelin undergoes several maturation steps in a process required to produce functional
ghrelin peptide to bind and activate its receptor (Figure 1.2). The human ghrelin gene is found on
chromosome 3p25-26 within the human genome.52 Ghrelin is initially translated into a 117amino acid precursor known as preproghrelin that is trafficked to the endoplasmic reticulum
(ER) by signal recognition particle recognition of an N-terminal signal peptide.19 Following
translocation into the ER lumen, the 23 amino acid N-terminal signal peptide of preproghrelin is
cleaved by a signal peptidase,53-54 resulting in a 94 amino acid protein proghrelin.55 Proghrelin
undergoes a unique post-translation octanoylation modification on the third serine from the Nterminus of the 94-amino acid sequence.54 This addition of a n-octanoic acid group to the
hydroxyl group of the serine residue increases the hydrophobicity of the ghrelin molecule, which
is necessary for the biological activity of ghrelin through the GHS-R1a receptor.56 This 94amino-acid precursor is cleaved proteolytically by prohormone convertase 1/3 to release mature
28 amino acid ghrelin (Figure 1.2).54
The cleavage of proghrelin results into two different 28 amino acid forms of ghrelin:
acylated and des-acylated (no serine octanoyl ester) ghrelin. Both are released into the
bloodstream, with some earlier studies suggesting that des-acyl ghrelin represents the major form
of circulating peptide.57-60 Acylated ghrelin is inactivated by hydrolysis of the ester bond, leading
to a limited lifetime in circulation for the octanoyl serine ester modification. Ester hydrolysis was
studied in human serum with acylated ghrelin (1-28 and 1-23) peptides, yielding exclusive
production of des-acyl ghrelin in 240 minutes.61 Serum studies using carboxylesterase and
butyrylcholinesterase (BChE) demonstrated that these enzymes mediated the hydrolysis of acyl
ghrelin in vitro, as well as platelet-activating factor acetylhydrolase in human serum, and
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lysophospholipase 1 in fetal bovine serum.61-64 Therefore, more than one enzyme can contribute
to the hydrolysis of acyl ghrelin or there could be major unidentified ghrelin esterase responsible
for a bigger portion of the hydrolysis. This important enzyme may vary from species-to-species
and/or from tissue-to-tissue, and ghrelin-signaling control through esterase-mediated deacylation
remains an important area of study. 65
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Figure 1.2. Ghrelin synthesis, maturation and post-translational modification in stomach
cells. Preproghelin is translated and cleaved to produce proghrelin peptide. Proghrelin is
octanoylated on its Ser3 amino acid residue by ghrelin O-acyltransferase. The octanoylated
proghrelin is cleaved by prohormone convertase 1/3 (PC 1/3) after arginine-28 of proghrelin,
generating the mature 28 amino acid peptide to be secreted into plasma. Both acylated and desacylated ghrelin are released but only the octanoylated form can bind to its GHS-R1a receptor.
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1.3 Ghrelin O-acyltransferase (GOAT)
To be biologically active, ghrelin requires a unique posttranslational modification of the
third serine (Ser3) of the precursor des-acyl proghrelin, where this serine is acylated by an
octanoyl (C8) fatty acid group (Figure 1.3). The enzyme that catalyzes ghrelin octanoylation,
ghrelin O-acyltransferase (GOAT), was discovered by two research groups independently in
2008.66-67 GOAT is a 45-kDa multispanning integral membrane protein member of the
membrane bound O-acyltransferase (MBOAT) enzyme superfamily, with the alternate name
MBOAT4.68-70 Enzymes in this superfamily catalyze acylation of both protein and small
molecule substrates, often transferring fatty acids onto hydroxyl groups.68 Three MBOAT
members - porcupine (PORCN), Hedgehog acyltransferase (Hhat), and ghrelin O-acyltransferase
(GOAT) - exclusively catalyze the transfer of a fatty acyl moiety onto secreted signaling
proteins, trafficking through the secretory pathway in the ER lumen.66-67, 70-71 These family
members share a conserved homology domain that contains a highly conserved
asparagine/aspartic acid located within a hydrophilic region and invariant histidine (His) that is
surrounded by a long section of hydrophobic residues.68, 72-73 Mutational studies of the conserved
His residue has demonstrated a reduction catalytic activity in the respective enzymes. 66, 72, 74
Even though these residues have been shown to be essential and hypothesized to be involved in
catalytic activity, the location and nature of the active site within these enzymes remains
unknown.
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Figure 1.3. Ghrelin octanoylation by ghrelin O-acyltransferase (GOAT). Ghrelin Oacyltransferase catalyzes the acylation of proghrelin by adding an octanoyl moiety to its Ser3
amino acid residue. This modification activates ghrelin for subsequent receptor binging and
signaling. Ghrelin in circulation is converted to des-acyl ghrelin by serum esterases.
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1.3.1 GOAT expression and distribution
Ghrelin is the only known protein with an ester-linked octanoyl group and found to be
expressed mainly in the stomach and small intestine.17, 28, 75 GOAT is the key enzyme modifying
and regulating ghrelin’s activity.66-67 GOAT mRNA has been found to be highly expressed in the
stomach and GOAT has been identified within tissues known to express ghrelin as the stomach,
intestine, colon, and testis.66-67, 76 Similarly, co-expression of GOAT and ghrelin was found to
high degree in the same gastric mucosal cells and duodenal mucosal.77 Similarly, full length
monomeric and dimeric GOAT protein was identified in plasma during fasting in both mice and
humans; suggesting that GOAT can be released into circulation through a currently unknown
pathway.76, 78
GOAT has been found mainly to be expressed in the stomach and pancreas, but also in a
numerous other tissues, including breast and prostate tissue.79-80 Moreover, studies have detected
GOAT overexpression in some tumoral tissues (breast pituitary, and endocrine tissues).79, 81-82
Likewise, overexpression of GOAT was observed in prostate-cancer cells (PCa). It was
demonstrated that GOAT (mRNA/protein-level) is overexpressing in cancer prostatic tissues and
plasma/urine samples of PCa patients compared to healthy prostate tissues and plasma samples.83
Moreover, there was a correlation found between GOAT levels and aggressiveness of the disease
in PCa patients. This suggests that GOAT holds potential as non-invasive PCa biomarker to
provide a better PCa diagnosis.
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1.3.2 GOAT topology and structure-activity analysis
The active site structure and catalytic machinery of GOAT are not well understood.
Membrane proteins have been proven to be difficult to study owing to their hydrophobic
surfaces, flexibility, and lack of stability in the absence of membrane lipids.84-85 In particular,
crystallization of such membrane proteins is extremely difficult. However, Taylor and coworkers
constructed the first topological description of GOAT’s structure by combining computational
calculations, phylogeny, epitope mapping, and induced glycosylation.86 Their studies described
an 11 transmembrane domain (TMD) model with 1 hydrophobic domain that did not cross the
membrane, denoted as the re-entry loop (RL) (Figure 1.4). The C-terminus of GOAT was located
in the cytosol with a detectable 3xFLAG tag and the N-terminus located in the ER lumen.
Six MBOAT family members have been mapped topologically: human ACAT1 (acylCoA:cholesterol) acyltransferase, ACAT2, ghrelin O-acyltransferase (GOAT), hedgehog
acyltransferase (HHAT), yeast glycerol uptake protein 1 (Gup1p), and lysophosphatidylinositolacyltransferase-1 (LPIAT1). 73, 86-91 GOAT’s topology described is consistent with topological
investigations of Hhat and PORCN, the location of the invariant H338 was described lumenal
and a conserved Asn307 as cytosolic (Figure 1.4). 72-73, 89-90. The location of the invariant H338
and mutagenesis of this residue, which abolished ghrelin octanoylation, supported the
importance of this residue in GOAT catalytic activity.86 However, the position and conformation
of the substrate-binding site and catalytic core is uncertain for GOAT and other MBOAT family
members.
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Figure 1.4 Ghrelin O-Acyltransferase topology model. Proposed prototypical description of
GOAT by Taylor et al., showing 11- transmembrane domains (TMDs) and one reentrant loop.
Invariant residue H338 was found in the ER lumen, consistent with other family members, and
conserved amino acid N307 was found in the cytosol. Figure reproduced with permission from
Reference 86 (Appendix I). © 2013 American Society for Biochemistry and Molecular Biology
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1.3.3 Crystal structure of a membrane-bound O-acyltransferase
In addition to the eukaryotic family members, MBOATs are also found in bacteria.92-97
The bacterial MBOAT DltB (D-alanyl transferase protein B) is involved in the incorporation of
D-alanine into teichoic acids (TAs), major components of gram-positive bacterial cell wall.93, 96
Xu and coworkers determined the first crystal structure of an MBOAT family member in the
context of full-length DltB from Streptococcus thermophiles (Figure 1.5).98 In this structure,
DltB contains 11 peripheral transmembrane helices with both the N- and the C- termini located
in the extracellular space. Additionally, an extracellular funnel is described with a distinct tunnel
between the bottom of the extracellular side and the cytoplasmic side.98 Inside this tunnel, there
are highly conserved amino acids amongst DltB proteins as well as in other MBOAT proteins,
which supports that this tunnel is functionally essential. The conserved histidine found in all
MBOATs, His 336 in DltB, is located within this tunnel and interacts with other functionally
essential amino acids consistent with this residue acting as a general base. Mutation of DltB
residues corresponding either to the DltB His336 or to the DltC-binding site completely
abolished D-alanylation of TA,98 similar to the mutation of His338 eliminating acylation of
ghrelin in GOAT.67, 99 Despite a low overall sequence homology between other MBOATs and
DltB, the amino acid location and structural features of this model suggest a common or similar
catalytic mechanism for the MBOAT superfamily of proteins.
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a)

b)
Extracellular

90°

Intracellular
Figure 1.5 Crystal structure of a membrane-bound O-acyltransferase. DltB crystal structure
is shown in two orientations with rainbow colors from N-terminal (blue) to C-terminal (red)
termini: a. bottom view and b. side view inside membrane with extracellular top and intracellular
down. Figures were made with PyMol and the structure was obtained from the protein data bank
(PDB) with accession codes 6BUG (crystal form I).
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1.4 GOAT substrate selectivity/recognition
The discovery of the enzyme GOAT unlocked a new approach to manipulate the octanoyl
modification of ghrelin, aiding the development of drugs that can potentially treat obesity and
other ghrelin related disorders.100 To design GOAT inhibitors, a complete understanding of the
interactions between ghrelin (substrate) and GOAT (enzyme) is essential. The sequence of
ghrelin in the region near the acyl-modification is highly conserved throughout most vertebrate
species.18, 101-102 Yang and coworkers investigate important amino acids in the N-terminal
sequence of the pentapeptide GSSFL-NH2, necessary for GOAT recognition near the region of
the octanoylated serine.99 Residues glycine-1, serine-3, and phenylalanine-4 were mutated, with
these alterations resulting in a decrease of activity with GOAT. A much less inhibitory outcome
was detected with an alanine substitution of leucine-5 and serine-6, and no effect was observed
when proline-7 was replaced. This recognition specificity is consistent with the conservation of
these three amino acids in most vertebrate ghrelins.101 Surprisingly, studies made with a short
four amino acid peptide still demonstrated acyl-modification by GOAT.103 Accordingly, GOAT
has the ability to recognize the first N-terminal four amino acids motif of the ghrelin peptide.
Similarly, studies using structure-activity analysis of ghrelin-mimetic peptides showed the
importance of the α amino group of N-terminal glycine.104-105 Mutation of this amine entirely
abolished peptide octanoylation by hGOAT. Moreover, studies showed hGOAT does not accept
negative charge at any site at N-terminus of GSSFL ghrelin, requiring positive charge and/or
hydrogen bond donor character at its substrate.105
To investigate the binding efficiency of longer sequences than the pentapeptide,
intermediate lengths of ghrelin (5-mer), (10-mer), (18-mer), and (28-mer) peptide were studied
as competitive hGOAT inhibitors in an octanoylation reaction.105 As expected, the 18-mer and
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28-mer exhibited a greater inhibitory behavior than the smaller counterpart, with a tighter
binding affinity. Similar studies with in vitro microsomal ghrelin octanoylation of 10-mer and
27-mer ghrelin substrates by GOAT, displayed lower affinity towards the 10-mer substrate.106
These results indicate the potential importance of interactions downstream of the N-terminal
sequence of ghrelin, which is necessary for GOAT binding.
In addition to the ghrelin peptide, GOAT also recognizes the other substrate n-octanoylCoA to form the acylated product. Studies to determine the length of the acyl donor necessary
for ghrelin octanoylation used numerous n-acyl-CoAs, including n-hexanoyl-CoA (C6-CoA), ndecanoyl-CoA (C10-CoA), n-myristoyl-CoA (C14-CoA), and n-palmitoyl-CoA (C16-CoA).103
Octanoylation was observed with C6- and C10-CoA, demonstrating that GOAT can accept a
range of acyl-CoA substrates. However, longer acyl donors like myristoyl-CoA or palmitoylCoA are not efficiently accepted by GOAT,99, 103, 107 contrasting behavior observed with other
MBOAT family members.68, 108 In a different study implementing acylated product-mimetic
inhibitors with a amide-linked chain, acyl length effect was monitored by binding affinities of 2
(acetyl) to 10 (decanoyl) carbons in the acyl chain. Inhibition binding affinities increased as the
acyl chain was extended from 0 to 8-carbon and decreased from 9 to 10-carbons.105 These studies
support the existence of a discrete acyl group-binding site within GOAT that selects for medium
chain fatty acids, with a particular preference for octanoyl groups.

1.5 GOAT inhibitors/ therapeutic effects
Since GOAT is essential for the production of the active form of ghrelin for signaling
through the GHS-R1a receptor, inhibition of GOAT represents a novel approach to control
ghrelin-signaling activity. Yang and coworkers reported the first peptide-based analogue
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inhibitors of GOAT by using an octanoylated peptapeptide (1-5) [Dap3]-ghrelin ([2,3diaminopropanoic acid]-ghrelin) (Figure 1.6a) and the entire 28-amino acid sequence [Dap3]ghrelin, both of which exhibited GOAT inhibition (IC50 = 1 µM and IC50 = 0.2 µM,
respectively).99 However, these substrate mimetics can also bind to the ghrelin receptor, acting as
potent agonists and posing a challenge as a target for further inhibitor development. Zhao and
coworkers investigated more biostable and potentially cell permeable inhibitor analogues of
acylated ghrelin mimetics.109 These inhibitors are triazole-linked peptapetide ghrelin mimetics
created using an azidoalanine at the Ser3 residue. Diverse inhibitors with a triazole-linked
hydrophobic group and aromatic side chain at F4 position of the GSSF ghrelin site were tested
for activity against GOAT, with the inhibitor containing a phenylpropyl triazole moiety (Figure
1.6a) having the highest potency (IC50 = 0.7 µM).109 This class of [Dap3]-ghrelin inhibitors
displayed tolerance of a triazole linkage in place of the hydrolytically vulnerable ester and amide
linkages while maintaining potency. A peptide based bi-substrate analog derived from the HIV
Tat-peptide (GO-CoA-Tat) was developed which demonstrated inhibition of GOAT activity for
mammalian cells and mice (Figure 1.6a).110 GO-CoA-Tat inhibits synthesis of acyl-ghrelin and
reduces body weight gain, but as another peptide-base inhibitor GO-CoA-Tat also faces serious
pharmacodynamic and pharmacokinetic challenges.
Moving towards non-peptide small molecule inhibitors of GOAT, Garner and Janda
identified small molecule inhibitors employing a catalytic assay using enzyme-linked click
chemistry (cat-ELCCA). Using this assay to screen a small compound library, two compounds
were discovered (3a and 3b) (Figure 1.6b) as potential GOAT antagonist with IC50 = 7.5 µM and
13.1 µM, respectively.111 Structural analysis of these small molecules suggests that they inhibit
the acylation of ghrelin by blocking binding of octanoyl-CoA to GOAT.
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“Druglike” small molecule analogues of CDDO family compounds from the Diversity
Set IV library (Developmental Therapeutics Program / NIH) were tested for inhibition of ghrelin
acylation of the hGOAT using a fluorescence-based in vitro assay. CDDO derivatives effectively
inhibited hGOAT in the micromolar range, functioning as covalent reversible inhibitors of
hGOAT.112 CDDO compounds have been showed to covalently modify nucleophilic thiols in a
reversible manner113, these studies can provide insight of the interaction of these compounds to a
functionally essential cysteine residue in ghrelin octanoylation by hGOAT (Figure 1.6b). CDDO
(2-cyano-3, 12-dioxooleana-1,9-dien-28-oic acid) and its derivatives, which are created by
manipulation of functional groups within naturally occurring triterpenoids like oleanolic acid,
have proven to improve diabetes in high fat diet-fed type 2 diabetic mice and reduced total body
fat which potentially supports effects in ghrelin signaling.114 Nakajima and coworkers
investigated the inhibitory effect of triterpenes on octanoylated ghrelin production in the ghrelinexpressing cell line (AGS-GHRL8). Asiatic acid, corosolic acid, glycyrrhetinic acid, oleanolic
acid, and ursolic acid suppressed octanoyl ghrelin production in these cells as well as
octanoylated ghrelin in mice,115 but similar derivatives lacking cysteine-reactive groups proved
ineffective against GOAT in enzyme-based assays.112
Presently, there are at least two classes of small molecule inhibitors targeting GOAT
acylation that have been developed by industrial research groups at Takeda Pharmaceuticals and
Eli Lilly.104-106 With a high-throughput assay system and enzyme-linked immunosorbent assay
(ELISA), Takeda researchers identified multiple inhibitor hits in an in-house compound
library.116 The novel lead compound (4-chloro-6-{[2-methyl-6-(trifluoromethyl)pyridin-3yl]methoxy}-1-benzothiophen-3-yl)acetic acid) was synthesized and demonstrated to be a GOAT
inhibitor with high biochemical potency and bioavailability, showed to decrease acyl ghrelin
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concentrations in the plasma and stomach of mice (Figure 1.6b).116 The Eli Lilly team reported a
potent piperidyl-ethyl-pyrimidine GOAT inhibitor discovered using a high-throughput GOAT
activity-screening assay. The information in their patent denotes that this compound (Figure
1.6b) has potency in enzymatic and animal findings; however, further in vivo studies are needed
for these compounds to understand binding to GOAT and mode of action.
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a)

[Dap3] Octanoyl-ghrelin (1-5)-NH2

[Dap3] Propylphenyl triazole ghrelin (1-5)-NH2

GO-CoA-Tat

b)

Garner & Janda

Others CCDO derivatives

Eli Lily
Patented
compound

Takeda
compound

CCDO derivatives

Figure 1.6 Ghrelin O-acyltransferase inhibitors incorporating lipid mimetic groups and
small molecules. a) Peptide-based inhibitors of GOAT prior to this work. b) Small molecule
GOAT inhibitors.
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1.6 Aims of this work
Ghrelin, the 28 amino acid “hunger hormone”, provides a neuroendocrine connection
between the brain and the digestive system as it regulates metabolism and energy homeostasis.
GOAT is the enzyme that modulates ghrelin signaling by octanoylation of ghrelin’s 3rd serine in
the peptide sequence. The involvement of GOAT in ghrelin’s maturation presents an attractive
target of inhibition for the treatment of ghrelin-related diseases like type II diabetes and other
metabolic disorders. This protein post-translational octanoylation is unique to ghrelin, but little is
known about the mechanism of GOAT-ghrelin modification, or other related MBOAT proteins.
Purification of soluble, active form of the membrane-bound proteins like GOAT has been
challenging. However, many in vitro analyses have established active preparations of the GOAT
enzyme using microsomes from insect cells and humans. 66, 86, 104-105, 110-111, 117 These previous
studies have determined important aspects of ghrelin such as the N-terminal sequence
requirement for recognition by GOAT, and have enabled identification of numerous peptide and
small-molecule inhibitors. However, mechanistic and structural information regarding the
machinery of catalysis of GOAT is still sorely lacking. Determination of the structure of
functionally important domains within GOAT is a critical step to define how GOAT binds its
substrate and catalyzes its octanoylation.
The main goal of the research detailed in this thesis is to understand the biological
structure and activity of human GOAT. Towards this goal, we have engineered an
interdisciplinary computational-biochemical approach to generate a structural model of GOAT
with biochemical validation. This computationally derived structure of GOAT was parallel with
the published topological model of the mouse GOAT ortholog86 and revealed significant
similarities with the crystal structure of a bacterial MBOAT alanyl transferase, DltB.98 Our
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model has exposed a contiguous internal channel through the enzyme core that transposes from
the ER lumen to the cytoplasm. Not only this channel possesses the conserved H338, but we
were able to demonstrate a range of significant amino acids affecting GOAT’s activity within
this pore.
Computational docking experiments into our hGOAT structure have described a binding
site for octanoyl-CoA, underlying contacts with both the coenzyme A and acyl chain fragments
of the acyl-CoA substrate. Alanine mutagenesis of residues with predicted contact to the acyl
donor has led the alteration of acyl donor selectivity, providing constraints defining the acyl
chain-binding site within hGOAT.
We have also identified hGOAT residues contacting ghrelin substrate by a cross-mutation
alanine contact approach. Rescue of hGOAT alanine mutations by altered substrates was
established by reactivity enhancements for each enzyme-substrate mutation pair relative to the
wild type enzyme and substrate. Rescue signals of hGOAT alanine variants by mutated
substrates were obtained, revealing significant hGOAT residues in or near the ghrelin-binding
site.
To understand fundamental contributions for enzymatic function of a conserved hGOAT
loop domain linking helices 7 and 8 of the enzyme, we designed a bacterial expression system of
the circularized loop protein to determine loop’s function in the ghrelin acylation process. The
circularized loop was expressed in high levels and we were able to obtain a functional
characterization with circular dichroism (CD) of the purified domain, demonstrating a partial αhelical structure.
We have developed a selective peptide ligand with nanomolar binding affinity for GOAT
through sequence mutagenesis and chemical modifications. This potent ligand confirmed high
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selectivity for ghrelin O-acyltransferase (GOAT) over the ghrelin GHS-R1a receptor.
Furthermore, we optimized this inhibitor to create a fluorescent ghrelin-derived peptide for
ligand detection. By utilizing transiently transfected HEK 293 cells, we were able to
demonstrate GOAT’s interaction with extracellular fluorescent ghrelin peptide and potential
facilitation of ligand cell internalization.
The studies proposed in this work have facilitated the elucidation of the acyl donor and
ghrelin binding sites within hGOAT. Functional essential amino acids within the GOAT core has
been analyzed and identified as potential interactions with substrate binding. Likewise, these
analyses have been focusing in the investigation of the mechanism for acylation of the ghrelin
serine residue and the involvement of a catalytic general base or other associated residues. These
studies have provided the first molecular-scale structural information of this important enzyme,
accelerated inhibitor development aiming ghrelin signaling, and possibly identify new
sites/modes for inhibition.
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Chapter 2: Biochemical analysis of predicted contacts within
the hGOAT structural model by alanine mutagenesis
Portions of this chapter, including figures and experimental results have been
previously published and reprinted with permission from the publisher, reference
16, Campaña, M. B.; Irudayanathan, F. J.; Davis, T. R.; McGovern-Gooch, K. R.;
Loftus, R.; Ashkar, M.; Escoffery, N.; Navarro, M.; Sieburg, M. A.; Nangia, S.;
Hougland, J. L., The ghrelin O-acyltransferase structure reveals a catalytic channel
for transmembrane hormone acylation. J Biol Chem 2019, Vol: 294, 14166-14174.
Copyright © 2019 The American Society for Biochemistry and Molecular
Biology, Inc.
All computational modeling including co-evolutionary contact analysis of hGOAT
structures, folding simulations, and molecular dynamic analysis were performed by
Flaviyan Jerome Irudayanathan (Shikha Nangia Laboratory, Biomedical and
Chemical Engineering at Syracuse University). There was also a contribution from
Professor Jason D. Fridley (Professor of Biology, Syracuse University) with
statistical analysis of hGOAT alanine variant reactivity.
In this chapter, I performed all the biochemical validation and experimentation
including peptide labeling, construction, expression and analysis of hGOAT
mutants, and hGOAT activity assays.
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2.1 Introduction
The understanding of the structural organization at a molecular level of integral
membrane proteins (IMPs) has been one of the major targets in the field of structural biology.1
Exemplified by enzymes, receptors, transporters, among others; these proteins have a large range
of key functions in cellular physiology and are important targets for pharmaceutical
development.2-3 A comprehensive understanding of protein structure and function is imperative
for drug design and the implementation of new modes of cell regulation for the treatment of
various diseases. However, membrane proteins have been proven to be difficult to study owing
to their hydrophobic nature, lack of solubility, and dependence on lipids for structural stability.4-5
Ghrelin O-acyltransferase (GOAT) is an example of an integral membrane protein that is
involved in the activation of the ghrelin hormone and it is a member of the membrane bound Oacyltransferase (MBOAT) enzyme family.6-7 While GOAT is a current therapeutic target for the
treatment of obesity and diabetes,8-9 little was known prior to this work about its structure or the
acylation process of ghrelin due to the challenging protein solubilization from the membrane
bilayer.
Substantial methods improvements have been developed to overcome membrane protein
purification difficulties such as engineering fusion partners,10 developing new detergents,11-12
innovative crystallization techniques,13 improvements in cryo-electron microscopes detectors,14
among other advancements.15 In this work, we are reporting an innovative structural approach to
develop a structural model of the unpurified integral membrane protein hGOAT by combining
co-evolutionary contact constraints and computational modeling with biochemical validation.16
Previous computational studies of the structure and dynamics of claudins, integral membrane
proteins which participate in tight junctions forming the blood-brain barrier, identified distinctive
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dimer interfaces that correlate with cross-linking experiments.17 In this analysis, the authors
implemented a synergistic approach utilizing in silico multiscale dynamics and in vitro crosslinking experiments to study claudin-5 interactions.17 Using similar studies and metagenomics
information available of human GOAT (hGOAT) and related proteins,18 we generated a set of
co-evolutionary contacts to guide our hGOAT structural modeling to generate a threedimensional structural model for hGOAT. Building solely upon the protein’s primary sequence
and a biochemical assay for its function, the approach provides an accessible and efficient route
to build structural models of intractable membrane protein targets.
Our human hGOAT structure determined is highly consistent with a recently reported
crystal structure for the bacterial MBOAT homolog D-alanyl transferase DltB,19 supporting the
novelty of our strategy to aid with the challenge of structure investigation of transmembrane
proteins. Furthermore, our model was biochemically validated via alanine mutagenesis of amino
acids predicted to reduce/eliminate enzyme function due to removal of energetically beneficial
contacts and sites with no impact in GOAT-catalyzed acylation. These computationally targeted
mutations were tested using our hGOAT activity assay,20-21 resulting in high percentage of the
mutations matching the predictions of the hGOAT structural computational model.16
Surprisingly, a structural investigation of our model predicts a contiguous internal void
channel within the hGOAT enzyme. Ghrelin octanoylation is proposed to occur in this channel
where the binding sites for ghrelin (endoplasmic reticulum (ER) exposed pore) and octanoylCoA (cytoplasm exposed) can interact. These studies place the basis for structure-based inhibitor
design targeting GOAT and other MBOAT family members, while opening a window of
application for the investigation of other structurally unpurified membrane proteins in hand with
therapeutic prospective.
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2.2 Results
2.2.1 Computational model for human GOAT structure
In generating our hGOAT structural model, we utilized state-of-the-art co-evolutionary
contact predictions with computational protein folding and structure optimization methods
previously described.18, 22 Co-evolutionary contact analysis exploits the tendency of residues
interacting with each other within folded proteins to co-evolve to maintain energetically
beneficial interactions.23-25 Analysis of many protein sequences employing a multiple-sequence
alignment identifies pairs of co-evolving residues, from which it is inferred that these residues lie
in proximity to each other. Assigning pairs of residues as co-evolving supports assignment of
spatial interactions between them, providing constraints that can define major features of protein
structure. Using metagenomics protein databases, we generated a multiple-sequence alignment to
predict residues that are potentially in contact (defined as Cβ-Cβ < 8Å) with each other in the
folded structure of hGOAT.18, 22-26 This set of contacts, represented by the contact map (Figure
2.1a-b), guided our hGOAT structural modeling.23, 26-27
Experimental information on the membrane topology of mouse GOAT and coevolutionary contact constraints were iteratively combined in protein folding simulations to
generate ~30,000 potential hGOAT structures.23, 28-29 The generated structures were clustered,
and the lowest energy structures that satisfied the contact maps were isolated (Figure 2.2).29
Representative structures from the top five clusters were then subjected to further structural
refinement to yield the optimal hGOAT model.30 The optimal model was embedded in a lipid
membrane and subjected to structural relaxation in explicit solvent using all-atom molecular
dynamics simulations.17, 31-32 This simulation used an ER-mimetic lipid bilayer to ensure
optimization of hydrophobic protein-lipid interactions.33
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a)

b)

Figure 2.1 Co-evolutionary contact restraints used in hGOAT structural modeling. a)
Contact map for hGOAT showing the probability for a coevolutionary contact from GREMLIN
analysis. b) Heat map of co-evolutionary contact constraints mapped onto hGOAT structure (red:
highest number of co-evolutionary constraints per residue, white: no co-evolutionary
constraints). Figure is reproduced with permission from Reference 16 (Appendix II). Copyright
© 2019 The American Society for Biochemistry and Molecular Biology, Inc.
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Side View

Cytoplasmic Face

Figure 2.2. Overlay of top 10 lowest energy structures of hGOAT from folding simulations.
Figure is reproduced with permission from Reference 16 (Appendix III). Copyright © 2019 The
American Society for Biochemistry and Molecular Biology, Inc.
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2.2.2 Features of the human GOAT structure
Our computationally-derived structure for hGOAT is consistent with the previously
reported topological model of the mouse GOAT ortholog containing a total of eleven
transmembrane helices with slightly altered helix boundaries (Figure 2.3),28 indicating the two
sets of constraints from our co-evolutionary contact analysis and previous topological studies
support a common hGOAT structural model. To determine how strongly our hGOAT structure
depends on the experimental topological constraints from mouse GOAT,28 we excluded these
constraints and repeated our analysis, which generated an identical hGOAT membrane topology.
This indicates co-evolutionary contact constraints alone are sufficient to predict the membrane
topology of hGOAT, suggesting this approach for topology modeling of integral membrane
proteins to complement established algorithms for predicting membrane protein topology.
Our model forms an ellipsoidal cone composed of transmembrane helices, with the
narrow end facing the ER lumen (Figure 2.4). The exposed ends of five transmembrane helices
(TM1, TM4, TM5, TM7, and TM11) converge to form a pore through which the interior of
hGOAT is connected to the ER lumen. At the cytoplasmic membrane interface, the predicted
cytoplasmic loops fold up to form a core region bounded by the lipid contacting perimeter
helices. As a result, there is minimal cytoplasmic exposure of hGOAT residues beyond the plane
of the membrane. Moreover, the hGOAT structure contains a contiguous internal channel
through the enzyme core that transits from the ER lumen space to the cytoplasm (Figure 2.5).
The channel is bent within hGOAT, with the restriction formed by the C-terminal end of helix
TM8 and N-terminal end of TM9. This positions an absolutely conserved histidine residue
(H338) in direct contact with the internal channel,34 consistent with proposals for this histidine to
serve as a general base for catalyzing ghrelin acylation. 35
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Following completion of our hGOAT structure and during subsequent biochemical
validation experiments (described in section 2.2.3), the release of a crystal structure for the
bacterial MBOAT DltB alanyl transferase provided an independent basis for comparison and
validation of our hGOAT structure.19 The H338 residue in hGOAT closely matches the location
of the analogous histidine residue (H336) in the DltB structure (Figure 2.6).7, 19 Further
comparison of the hGOAT model and the DltB structure reveals remarkable similarities in
overall topology and structure, with an TM-Score of 0.6 and RMSD of 2.23 Å for ~100 aligned
conserved residues between the structural models for these distantly related MBOAT family
members (12.3% sequence identity, 26.8% sequence similarity, EValue 2.7x10−8 and bit score
48.7; (Table 2.1).36 However, the low overall homology between DltB and hGOAT leads to very
poor structure prediction for non-homologous sequence positions as would be expected for this
type of comparison. The demonstrated ability of our hGOAT modeling based on co-evolutionary
contact restraints to arrive at the same protein fold as DltB, in the absence of any experimental
structural information, underscores the power of this approach to accurately predict protein
structures.
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Figure 2.3. Computational approach yields structural model of hGOAT. Schematic of
ghrelin octanoylation by hGOAT showing the predicted transmembrane topology of hGOAT
containing eleven transmembrane helix domains (TM1-11), two intramembrane domains
(IM1-2), and loop regions generated with Protter.37
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N-terminus

N-terminus

180°
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C-terminus
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Cytoplasm

Figure 2.4. Three-dimension computational organization of a membrane bound Oacyltransferase protein. Structure of hGOAT in an ER mimetic lipid membrane, correlated to
color-coded membrane topology in Figure 2.3. Figure is reproduced with permission from
Reference 16 (Appendix IV). Copyright © 2019 The American Society for Biochemistry and
Molecular Biology, Inc.
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Figure 2.5. GOAT model reveals an intermembrane channel within its core. Illustration of
internal channel within hGOAT (green) transiting from the ER lumen to the cytoplasm, with the
channel determined by CAVER 3.0 plugin in PyMOL.38 Figure is reproduced with permission
from Reference 16 (Appendix V). Copyright © 2019 The American Society for Biochemistry
and Molecular Biology, Inc.
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Figure 2.6. Structural overlay of hGOAT and DltB showing absolutely conserved histidine
residues (hGOAT H338, teal; DltB H336, purple, PDB ID 6BUG:C) within these
acyltransferases. Figure is reproduced with permission from Reference 16 (Appendix VI).
Copyright © 2019 The American Society for Biochemistry and Molecular Biology, Inc.
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Table 2.1. Statistics and parameters for sequence coevolution analysis of hGOAT.
Human ghrelin O-acyltransferase
Query sequence
Homo sapiens MBOAT (UniProt Q96T53)
Alignment window
1-435 (15-420)
Alignment
Jackhmmer, HHblits, hhmsearch
metaclust_2018_01, Uniref100.
Filtering
90% identity 75 % coverage and filtered columns with >50%
gaps
Meff
Meff at various identity cut-off of the MSA
Identity
Meff
50.0%
726
55.0%
1450
60.0%
2714
65.0%
4516
70.0%
6809
75.0%
9193
80.0%
11507
85.0%
13701
90.0%
16114
95.0%
16555
551.7
Meff-0.8/√N
Sequences / L
>45; Sequence diversity (√N/L): 0.296

Coevolution algorithm
Significance cut-off

Comparison with DltB

Raptor-X (machine Learning) and Gremlin (Markov Random
Field pseudo-likelihood maximization)
Of the 3L/2 direct Co-evolutionary contacts predicted by
GREMLIN 93% of the contacts were observed at or below 10Å
in the final structure; 86% of the contacts were observed at or
below 8Å
Distant homolog within the same family
CA-RMSD of aligned 98 residues is 2.23 Å

56

2.2.3 Mutagenesis analysis of hGOAT structural model
To validate our computational hGOAT structural model biochemically, we mutated
approximately 10% of the residues within hGOAT to alanine. We determined the impact of these
mutations on hGOAT octanoylation activity in a fluorescence peptide-based assay, via reversephase HPLC with fluorescence detection (described in experimental procedures section).20, 39
These 42 alanine mutations were spread across a range of amino acids and degrees of
conservation, with the majority of sites chosen conserved at >75% among GOAT orthologs. In
narrowing the pool of mutations to ~40 positions, residues with surface-exposed side chains were
deemphasized compared to residues predicted to lie within the enzyme interior. Approximately
half of the mutation sites were selected based on the residue’s side chain contacting the internal
void, as we propose this channel will likely contain the substrate binding sites and catalytic
residues within hGOAT.
In this pool of alanine mutants, we observed a range of activities from near wild type
ghrelin octanoylation activity to complete loss of detectable activity (Figure 2.7, 2.8, and Table
2.2). When mapped onto the hGOAT structural model, mutations leading to a marked decline
(>3-fold, purple) or loss of enzyme activity (red) appear clustered within the core of hGOAT
(Figure 2.7). For quantitative analysis of the impact of these mutations, we determined whether
alanine mutagenesis of residues contacting the internal void is more likely to yield reduced
enzyme activity compared to non-void contacting mutations. Within the pool of mutations, the
void-contacting alanine mutations were significantly more likely to result in loss of enzyme
activity (p<0.03, Figure 2.9). This mutation activity mapping defines a functionally essential core
within hGOAT and expands the number of residues within hGOAT known to be required for
enzyme activity.6-7, 28
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Figure 2.7. Mutagenesis studies support the location and functional importance of the
hGOAT internal channel. A-C) Alanine mutations mapped onto the hGOAT structure, with
each sphere denoting the alpha carbon of the mutated residue; spheres colored as follows: Blue,
alanine variants with octanoylation activity within 3-fold of WT hGOAT; purple, alanine
variants with impaired octanoylation activity (>3-fold loss compared to WT hGOAT); red,
inactive alanine variants. A) View from lumenal face; B) view from cytoplasmic face; C) side
view in the plane of the ER membrane. Figure is reproduced with permission from Reference 16
(Appendix VII). Copyright © 2019 The American Society for Biochemistry and Molecular
Biology, Inc.
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Figure 2.8. hGOAT alanine variant octanoylation activity mapped onto the hGOAT
topology model. Blue squares, alanine variants with octanoylation activity within 3-fold of WT
hGOAT; purple diamonds, alanine variants with impaired octanoylation activity (>3-fold loss
compared to WT hGOAT); red squares, inactive alanine variants. Figure is reproduced with
permission from Reference 16 (Appendix VIII). Copyright © 2019 The American Society for
Biochemistry and Molecular Biology, Inc.
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Table 2.2. hGOAT alanine variant octanoylation activity with the GSSFLCAcDan peptide
substrate under standard reaction conditions. Reactions were performed, analyzed, and
normalized as described in the Experimental Methods. Errors reflect the average of a minimum
of three independent experimental trials.

Active Variants
(100 - 33% of WT Activity)
Variant
% Activity
S179A
60 ± 8
Q191A
92 ± 30
H258A
56 ± 8
D262A
61 ± 12
E281A
74 ± 3
D289A
58 ± 3
E294A
43 ± 3
H297A
56 ± 4
Q320A
94 ± 2
H341A
44 ± 7
F348A
67 ± 5
F364A
94 ± 13
R370A
62 ± 10
L381A
128 ± 5
L423A
106 ± 19

Impaired Variants
(33 - 1% of WT Activity)
Variant
% Activity
L96A
27 ± 4
L135A
8.3 ± 0.9
C181A
20 ± 1
S182A
2.4 ± 0.7
F183A
2.4 ± 0.1
Y255A
21 ± 1
D287A
6±2
S300A
4±1
F302A
27.4 ± 0.9
F331A
18.2 ± 0.6
W351A
4.7 ± 0.9
H362A
29 ± 7

Inactive Variants
(Undetectable Activity)
Variant
% Activity
H98A
0
S132A
0
Y168A
0
L180A
0
D234A
0
C235A
0
D263A
0
E282A
0
Y284A
0
R304A
0
W306A
0
N307A
0
R315A
0
H338A
0
D358A
0
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Figure 2.9. Octanoylation activity of hGOAT alanine variants for non-void contacting (black,
N=21) and void-contacting mutations (green, N=21), with dotted lines denoting the average
acylation activity for each group; *, p < 0.03. Figure is reproduced with permission from
Reference 16 (Appendix IX). Copyright © 2019 The American Society for Biochemistry and
Molecular Biology, Inc.
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2.3 Discussion and conclusions
While structural studies play a central role in understanding protein functions for
improved inhibitor development, a complete description of the structure and mechanism of
GOAT is still unknown. A map of the topology of GOAT has described the GOAT's active site
face near the ER lumen where ghrelin resides like other MBOATs that acylate secreted proteins.7
Moreover, the description of how acyl-CoA, localized predominantly in the cytoplasm, gain
access to the ER lumen is still undetermined. The conserved essential residues N307 and
H338 have been described as “catalytic residues” but with no mechanistic data firmly proving
this point. The recent crystal structure of the bacterial MBOAT DltB positions the conserved
histidine (H336) residue in this enzyme within an active site funnel, consistent with this residue
acting as a potential general base.19 In this work, we demonstrated the development and
validation of a structural model for the integral membrane human GOAT that utilizes
bioinformatics constraints from co-evolutionary contact analysis, and model evaluation by
biochemical analysis while circumventing the requirement of protein purification.
To biochemically confirm the computational hGOAT model developed here, we chose
multiple amino acid sites where alanine incorporation was anticipated to reduce or abolish
enzyme activity due to elimination of energetically beneficial contacts. We were able to
accurately match predicted deleterious or inactive residues mutations to experimental data of
targeted mutations. The remarkable accuracy of predictions obtained from our computational
model provides strong support for the ability of our approach to generate a representative
hGOAT structural model. Additionally, our model revealed a striking feature of a contiguous
internal void space that is located topologically to feasibly serve as the binding region for ghrelin
and octanoyl-CoA substrates, where most of our mutants reside (Figure 2.7). The analysis of 42
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residues whose side chains line within this channel space demonstrated to be functionally
essential residues, supporting this region as a potential substrate-binding site region (Figure 2.8,
Figure 2.9, Table 2.2).
Our model provides indispensable and novel insights into several long-standing questions
regarding the mechanism for MBOAT-catalyzed transmembrane protein acylation. In this
structure, the essential conserved H338 residue lies ~20 Å below the ER lumen interface.
Surprisingly the other essential conserved MBOAT residue (N307) was shown to reside at the
other end of this void towards the proposed octanoyl-CoA binding site (discussed in Chapter 3).
The topological separation of these two conserved residues is explained by the two residues
playing roles distinct roles of GOAT activity. Moreover, the location of H338 is within the
central channel of GOAT, identical to the position observed for the analogous histidine in DltB.19
This result is consistent with this residue acting as a general base to activate the ghrelin serine
hydroxyl side chain for octanoyl transfer (Figure 2.6). Comparison to the DltB crystal structure
supports the accuracy of both, the overall enzyme architecture and location of specific amino
acids in our hGOAT model that potentially interact with ghrelin and octanoyl-CoA. The role of
other alanine mutants in the catalytic mechanism of ghrelin acylation and or ghrelin binding will
be investigated in later chapters.
With the combination of computational and biochemical methods, we were able to
develop a structural model for hGOAT that accurately reflects the molecular interactions
essential for substrate interaction. This understanding is crucial for mechanistic studies and
inhibitor development, targeting multiple members of the MBOAT enzyme superfamily.
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2.4 Experimental Procedures
2.4.1 Co-evolutionary contact analysis of hGOAT
Note: All computational sequence and contact prediction analysis was performed by
collaborator Flaviyan Jerome Irudayanathan (BMCE, Syracuse University).
A multiple sequence alignment (MSA) was performed with the hGOAT sequence against
the UniRef90 database utilizing the jackhammer tool.40 The MSA parameters were set to eight
iterative searches (n=8) with an e-value threshold of 1x10-40. The resulting alignment was filtered
to exclude highly similar sequences using the HHfilter tool with 90% identity and 75% sequence
coverage cut-offs. This MSA was used as the input for the hmmbuild tool to construct a hidden
Markov model (hmm) curated specifically for the MSA,41 which would represent the consensus
sequence of hGOAT and its closest homologs. This hmm was then utilized to search against a
master database that included uniref100 and metagenome database (metaclust_2018_01) using
the hmmsearch tool with a bit score cut-off of 27.18, 27 The resulting MSA was filtered again
using the HHfilter tool with 90% identity and 75% sequence coverage against hGOAT.
Furthermore, sequences with unidentified amino acids (X, this is to accommodate for RaptorX)
and sequence positions with >50% gaps were also filtered from the MSA using trimAL.42 The
resulting MSA for hGOAT was primarily used to perform co-evolutionary contact analysis using
the RaptorX server and GREMLIN.18, 23, 26, 43 The resulting contact maps are provided as Figure
2.1a (GREMLIN). The resulting MSA had a Meff0.8/√𝑁 of 551.7 which is greater than the
recommended value of 64 for reliable model prediction using co-evolutionary contacts.18, 23
These contacts were used to guide the hGOAT folding. The MSA analysis and curations were
performed using in-house python scripts and conkit python library.44
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2.4.2 Folding simulations
Note: Folding simulations were performed by collaborator Flaviyan Jerome Irudayanathan
(BMCE, Syracuse University).
The folding simulations were performed in two stages as shown in Figure 2.10. In both
stages, contact restraints were used and the models were iteratively clustered, refined and scored
based on their overall backbone energy.

Figure 2.10. Flow chart for computational modeling of hGOAT. Figure is reproduced with
permission from Reference 16 (Appendix X). Copyright © 2019 The American Society for
Biochemistry and Molecular Biology, Inc.
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2.4.3 Refinement and relaxation using molecular dynamics
Note: All molecular dynamic analysis was performed by collaborator Flaviyan Jerome
Irudayanathan (BMCE, Syracuse University).
The optimized hGOAT model from stage 2 was oriented with respect to a membrane
bilayer using the PPM server.32 The calculated hydrophobic thickness of the hGOAT structural
model is 25.2 ± 2.4 Å and the tilt angle of 3° relative to the membrane normal vector. The
oriented protein was then embedded in a ER-mimetic lipid bilayer (1:1
dipalmitoylphosphatidylcholine (DPPC) : dioleoyl phosphatidylcholine (DOPC)) using the
CHARMM-GUI webserver and subject to an allatom equilibration at 310.15 K in explicit solvent
and 150 mM NaCl counter ions.31, 45 The simulation was carried out for 500 ns using
GROMACS 2016.4 and the structural deviations were monitored.46 The equilibrated structure
was isolated and utilized for prediction of internal channels and docking studies.

2.4.4 General experimental methods
Data plotting and curve fitting were carried out with Kaleidagraph (Synergy Software,
Reading, PA, USA). Membrane topology schematics were generated using Protter
(http://wlab.ethz.ch/protter/start/),37 and structural figures were generated using Chemdraw
Prime 15.1 and PyMol. Octanoyl coenzyme A (octanoyl-CoA, free acid) were solubilized to 5
mM in 10 mM TrisHCl (pH 7.0), aliquoted into low-adhesion microcentrifuge tubes, and stored
at −80 °C. Methoxy arachidonyl fluorophosphonate (MAFP) was purchased from Cayman
Chemical (Ann Arbor, MI) and solubilized with dimethyl sulfoxide (DMSO). Unlabeled
GSSFLCNH2 peptide was synthesized by Sigma-Genosys (The Woodlands, TX), solubilized in
1:1 acetonitrile:H2O, and stored at -80 °C. Acrylodan (Anaspec) for peptide substrate labeling
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was solubilized in acetonitrile with the stock concentration determined by absorbance at 393 nm
in methanol (ε393 = 18,483 M–1 cm–1 , per the manufacturer’s data sheet). GSSFLCNH2 peptide
concentrations were determined by reaction of the cysteine thiol with 5,5’-dithiobis(2nitrobenzoic acid) and absorbance at 412 nm, using ε412 = 14,150 M–1 cm–1.47

2.4.5 Peptide substrate fluorescent labeling
The GSSFLCNH2 peptide substrate used in the hGOAT acylation assay is derived from the
N-terminal sequence of ghrelin (GSSFLS) with the C-terminal serine of this peptide (Ser 6)
mutated to cysteine to allow chemoselective attachment of an acrylodan fluorophore using our
previously reported protocols.39, 48 Acrylodan-labeled peptides were purified by semipreparative
reverse phase HPLC (Zorbax Eclipse XDB column, 9.4 x 250 mm) using a gradient mobile
phase of 30%-100% acetonitrile in aqueous 0.05 % trifluoroacetic acid (TFA) over 30.2 minutes,
at a flow rate of 4.2 mL/min. Labeled peptide elution was detected by absorbance at 360 nm, and
collected fractions containing the labeled peptides were dried under vacuum at room temperature
and resuspended in 1:1 H2O: acetonitrile. GSSFLCNH2 labeling was confirmed by MALDI-TOF
mass spectrometry (Bruker Autoflex III) using a matrix containing sinapinic acid in 0.1 % TFA
and 50 mM ammonium phosphate. The concentration of acrylodan labeled GSSFLCNH2 was
calculated using absorbance of acrylodan at 360 nm (ε= 13,300 M-1cm-1) per previous reports.39,
49

2.4.6 Construction of hGOAT mutants
PCR primers for site-directed mutagenesis were designed from our previously reported
hGOAT expression construct (Table 2.3).39 This construct was commercially synthesized by

67

Integrated DNA Technologies (Coralville, IA) containing a C-terminal FLAG epitope tag, a
polyhistidine (His6) tag, and 3x human influenza hemagglutinin (HA) tags appended downstream
of a TEV protease site.50 Primers were dissolved in H2O and concentrations were measured by
UV absorbance at 260 nm. PCR mutagenesis reactions (50 μL total volume) contained the
following components: 10x Pfu reaction buffer (5 μL), template plasmid DNA (10 ng), forward
primer (125 ng), reverse primer (125 ng), dNTPs (1 μL, 1 mM stock), and Pfu Turbo DNA
polymerase (1 μL, Agilent). The thermocycler program for PCR mutagenesis proceeded as
follows: initial denaturation (95 °C, 1 min); 18 cycles of denaturation (95 °C, 50 sec); annealing
(60 °C, 50 sec); extension (68 °C, 12 min); and final extension (68 °C, 12 min). Reaction were
digested with DpnI (New England BioLabs, R0176S, 10 units) at 37 °C for 2 hours. After DpnI
digestion, the PCR reaction mixture (5 μL) was transformed into a 100 L aliquot of chemically
competent Z-competent DH5 cells (Zymo Research) followed by incubation on ice for 30
minutes. Transformed bacteria were spread on LB-ampicillin plates (100 μg/mL) and incubated
at 37 C overnight. Following overnight incubation at 37 °C, single colonies were inoculated into
LB media (5 mL) containing ampicillin (100 μg/mL) in sterile culture tubes. These cultures were
incubated overnight at 37 C with shaking (225 rpm). Following overnight growth, plasmids
were purified from the saturated cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic
Inc.) per manufacturer’s instructions. Single site mutations were verified by DNA sequencing
(Genewiz).
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Table 2.3 Primers for hGOAT alanine mutagenesis
Mutation
L96A
H98A
S132A
L135A
Y168A
S179A
L180A
C181A
S182A
F183A
Q191A
D234A
C235A
E239A
Y255A
H258A
D262A
D263A

Primers
Forward: CAAACAGCTTGTCACCTGGGACTCCAC
Reverse: GTGGAGTCCCAGGTGACAAGCTGTTTG
Forward: GCTGGCAAACACTGTGTGCTCTGGGACTCCACTAC
Reverse: GTAGTGGAGTCCCAGAGCACACAGTGTTTGCCAGC
Forward: CTCAGCGCGTGACAGCTTTGTCTCTGGACATC
Reverse: GATGTCCAGAGACAAAGCTGTCACGCGCTGAG
Forward: GTGACATCCTTGTCTGCTGACATCTGTGAGGGC
Reverse: GCCCTCACAGATGTCAGCAGACAAGGATGTCAC
Forward: CTGCCCTACTTCTCCGCTCTGCTCTTCTTCCC
Reverse: GGGAAGAAGAGCAGAGCGGAGAAGTAGGGCAG
Forward: GCCTTGCTGGGAGGTGCTCTCTGTTCATTCCAG
Reverse: CTGGAATGAACAGAGAGCACCTCCCAGCAAGGC
Forward: GCTGGGAGGTAGCGCTTGTTCATTCCAGCG
Reverse: CGCTGGAATGAACAAGCGCTACCTCCCAGC
Forward: CTGGGAGGTAGCCTCGCTTCATTCCAGC
Reverse: GCTGGAATGAAGCGAGGCTACCTCCCAG
Forward: GAGGTAGCCTCTGTGCTTTCCAGCGTTTCCAAG
Reverse: CTTGGAAACGCTGGAAAGCACAGAGGCTACCTC
Forward: GGTAGCCTCTGTTCAGCTCAGCGTTTCCAAGC
Reverse: GCTTGGAAACGCTGAGCTGAACAGAGGCTACC
Forward: CAAGCTAGAGTCGCTGGATCGTCCGCTC
Reverse: GAGCGGACGATCCAGCGACTCTAGCTTG
Forward: GCCGGACTGACTGCTTGCCAGCAATTCGAATG
Reverse: CATTCGAATTGCTGGCAAGCAGTCAGTCCGGC
Forward: GGAGCCGGACTGACTGATGCCCAGCAATTCGAATG
Reverse: CATTCGAATTGCTGGGCATCAGTCAGTCCGGCTCC
Forward: GATTGCCAGCAATTCGCTTGTATCTACGTTG
Reverse: CAACGTAGATACAAGCGAATTGCTGGCAATC
Forward: GGTTGTTCAAGCTGACCGCTTACTCACACTGGATC
Reverse: GATCCAGTGTGAGTAAGCGGTCAGCTTGAACAACC
Forward: GCTGACCTACTACTCAGCCTGGATCCTCGACG
Reverse: CGTCGAGGATCCAGGCTGAGTAGTAGGTCAGC
Forward: CACACTGGATCCTCGCCGATTCGCTCTTGC
Reverse: GCAAGAGCGAATCGGCGAGGATCCAGTGTG
Forward: CTGGATCCTCGACGCTTCGCTCTTGCACG
Reverse: CGTGCAAGAGCGAAGCGTCGAGGATCCAG
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E281A
E282A
Y284A
D287A
D289A
E294A
H297A
S300A
F302A
R304A
W306A
N307A
R315A
Q320A
F331A
H338A
H341A
F348A
W351A
D358A

Forward: GACAGTCACCAGGAGCGGAAGGTTACGTTCC
Reverse: GGAACGTAACCTTCCGCTCCTGGTGACTGTC
Forward: GTCACCAGGAGAGGCAGGTTACGTTCCTG
Reverse: CAGGAACGTAACCTGCCTCTCCTGGTGAC
Forward: CCAGGAGAGGAAGGTGCTGTTCCTGACGCTGATATC
Reverse: GATATCAGCGTCAGGAACAGCACCTTCCTCTCCTGG
Forward: GGTTACGTTCCTGCCGCTGATATCTGGACC
Reverse: GGTCCAGATATCAGCGGCAGGAACGTAACC
Forward: CGTTCCTGACGCTGCTATCTGGACCCTGG
Reverse: CCAGGGTCCAGATAGCAGCGTCAGGAACG
Forward: GATATCTGGACCCTGGCAAGGACTCACAGAATC
Reverse: GATTCTGTGAGTCCTTGCCAGGGTCCAGATATC
Forward: CCCTGGAAAGGACTGCCAGAATCTCGGTCTTC
Reverse: GAAGACCGAGATTCTGGCAGTCCTTTCCAGGG
Forward: GGACTCACAGAATCGCTGTCTTCTCCCGTAAG
Reverse: CTTACGGGAGAAGACAGCGATTCTGTGAGTCC
Forward: CACAGAATCTCGGTCGCTTCCCGTAAGTGGAAC
Reverse: GTTCCACTTACGGGAAGCGACCGAGATTCTGTG
Forward: GAATCTCGGTCTTCTCCGCTAAGTGGAACCAAAGC
Reverse: GCTTTGGTTCCACTTAGCGGAGAAGACCGAGATTC
Forward: GTCTTCTCCCGTAAGGCTAACCAAAGCACTGCTC
Reverse: GAGCAGTGCTTTGGTTAGCCTTACGGGAGAAGAC
Forward: CTCCCGTAAGTGGGCCCAAAGCACTGCTCGC
Reverse: GCGAGCAGTGCTTTGGGCCCACTTACGGGAG
Forward: CTGCTCGCTGGCTCGCTCGCTTGGTGTTCC
Reverse: GGAACACCAAGCGAGCGAGCCAGCGAGCAG
Forward: CGCTTGGTGTTCGCTCACAGCCGTGCTTG
Reverse: CAAGCACGGCTGTGAGCGAACACCAAGCG
Forward: CCACTGCTCCAAACAGCTGCTTTCTCAGCTTGG
Reverse: CCAAGCTGAGAAAGCAGCTGTTTGGAGCAGTGG
Forward: CAGCTTGGTGGGCCGGACTGCACCCTGG
Reverse: CCAGGGTGCAGTCCGGCCCACCAAGCTG
Forward: GCACGGACTGGCCCCTGGACAGGTTTTCGG
Reverse: CCGAAAACCTGTCCAGGGGCCAGTCCGTGC
Forward: GACAGGTTTTCGGTGCTGTGTGCTGGGCTGTTATG
Reverse: CATAACAGCCCAGCACACAGCACCGAAAACCTGTC
Forward: CGGTTTCGTGTGCGCTGCTGTTATGGTGGAG
Reverse: CTCCACCATAACAGCAGCGCACACGAAACCG
Forward: GTTATGGTGGAGGCCGCCTACCTGATCCAC
Reverse: GTGGATCAGGTAGGCGGCCTCCACCATAAC

70

H362A
R370A
L381A
L395A
L423A

Forward: GCCGACTACCTGATCGCCTCCTTCGCTAACGAG
Reverse: CTCGTTAGCGAAGGAGGCGATCAGGTAGTCGGC
Forward: GCTAACGAGTTCATCGCTTCTTGGCCAATGAGG
Reverse: CCTCATTGGCCAAGAAGCGATGAACTCGTTAGC
Forward: CTTCTACAGAACAGCTACCTGGGCCCAC
Reverse: GTGGGCCCAGGTAGCTGTTCTGTAGAAG
Forward: GCTTACATCATGGCTGCCGTCGAGGTTAG
Reverse: CTAACCTCGACGGCAGCCATGATGTAAGC
Forward: GATGGTTTACTGTATCGCTTTGCTGCTCTTG
Reverse: CAAGAGCAGCAAAGCGATACAGTAAACCATC
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2.4.7 Expression and enrichment of hGOAT in membrane protein fractions
hGOAT wildtype and mutants were expressed in insect (Sf9) cell membrane fractions
using previously published procedures.39, 51-52

2.4.8 Membrane fraction enrichment
Sf9 insect cell expression cultures were transferred to 50 mL conical tubes and harvested
by centrifugation (500 xg, 5 min, 4°C); the resulting supernatant was discarded. The cell pellet
was resuspended in 2.5 mL lysis buffer (50 mM Tris-HCl pH 7.0, 150 mM sodium chloride
(NaCl), 1 mM sodium ethylenediamine (NaEDTA), 1 mM dithiothreitol (DTT), 0.01 μg/mL
pepstatin A, 10 μM bis (4-nitrophenyl)phosphate, and 1 mini Roche protease inhibitor cocktail
tablet/10 mL). The cells were then lysed with a 7 mL dounce homogenizer on ice, using 20
strokes with a small pestle and 20 strokes with a large pestle. Intact cells and cell debris were
removed by centrifugation (3000 x g, 10 min, 4°C). The supernatant was transferred to a pretared ultracentrifuge tube and the membrane fraction was isolated by centrifugation (100,000 x g,
1 hour, 4°C). The resulting supernatant was discarded, and the pellet was solubilized in 50 mM
HEPES (pH 7.0) to reach 4 μL/mg of microsomal pellet. Membrane fraction suspensions are
distributed into 80 μL aliquots in low-adhesion tubes and stored at -80°C. 39

2.4.9. hGOAT expression analysis by anti-FLAG Western Blot
hGOAT membrane fractions were thawed on ice and homogenized by passing through an
18-gauge needle ten times. Membrane fraction protein concentrations were determined by
Bradford assay using the Quick Start Bradford 1X Dye Reagent (BioRad). Samples for
polyacrylamide gel analysis and Western blotting were prepared containing 50 μg membrane
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fraction protein from Sf9 cells transfected with hGOAT, 1x sample buffer (0.33 M Tris HCl, pH
6.8, 0.1 M SDS, 14% glycerol, and 0.5 M DTT) and 50 mM HEPES pH 7.0 in a total volume of
45 μL. Protein samples were heated to 50.2 °C for 5 minutes and then incubated at room
temperature for 15 min prior to gel loading. Samples were loaded onto a 12 % Tris-glycine
SDS-polyacrylamide gel and run at 110 V for 1.5 hrs. Each gel contained an empty vector (EV)
microsomal protein as negative control and amino-terminal FLAG-BAP Fusion protein as a
positive control (Millipore Sigma, P7582-100UG, 1:150 dilution, 30 μL total volume) (See
Figure 2.11).
Following electrophoretic separation, proteins were transferred to a PVDF membrane for
Western blotting (BioRad, Trans-Blot turbo RTA transfer kit), with the PVDF membrane
activated by immersion in methanol for 30 seconds followed by equilibration in transfer buffer
(20% v/v methanol, 48 mM Tris base, 39 mM glycine and 0.034% v/v SDS) prior to transfer.
Proteins were transferred to the membrane for 30 minutes at 1.3 A / 25 V using the transfer kit
per manufacturer’s instructions. Following electroblotting, the PVDF membrane was blocked
for 4 hours in 10% v/v nonfat milk in TBST buffer (Tris buffered saline (TBS, 0.05M Tris and
0.14M NaCl) with 0.1% v/v Tween 20). The membrane was then probed with a Flag antibody
(HRP-conjugated DYKDDDDK Tag Antibody, Invitrogen catalog number PA1-984B-HRP,
1:1000 dilution, 10 mL total volume) in 5% nonfat milk in TBST buffer overnight at 4 °C. The
membrane was washed with TBST (6 x 5 mL) and treated with West Pico Chemiluminescent
substrate-imaging reagent (Thermo Scientific), followed by imaging on a ChemiDoc XRS+ gel
documentation system (BioRad).
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Variant
L96A
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Y168A
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Blot
b
a
c
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c
b
b

Variant
C235A
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D262A
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b
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a
d
d
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Blot
e
e
e
e
c
e
c
f
f
f
f
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f
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e
g
g
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Figure 2.11. hGOAT variant expression confirmation by anti-Flag Western blotting.
Western blots were performed as described in Materials and Method. WT, wild type hGOAT;
EV, empty vector baculoviral expression; Flag, Flag-BAP fusion protein. Figure is reproduced
with permission from Reference 16 (Appendix XI). Copyright © 2019 The American Society for
Biochemistry and Molecular Biology, Inc.
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2.4.10. hGOAT activity assay
Membrane fractions of hGOAT expressed from Sf9 cells were thawed on ice and
homogenized by passing through an 18-gauge needle ten times. hGOAT activity assays under
standard conditions were performed with 50 μg of membrane protein, 1.5 μM fluorescent peptide
substrate, 300 μM octanoyl-CoA, 1 μM MAFP, and 50 μM HEPES pH 7.0 in a total volume of
50 μL. All components except for the peptide and acyl-CoA substrates were incubated at room
temperature for 30 minutes prior to reaction initiation by addition of peptide and acyl-CoA
substrates. Reactions were incubated at room temperature for 2 hour in the dark and then stopped
by addition of 50 μL of 20% acetic acid in isopropanol. Reaction solutions were clarified by
protein precipitation with 16.7 μL of 20% trichloroacetic acid followed by centrifugation (1,000
x g, 2 min). The resulting supernatant was then analyzed by reverse phase HPLC. hGOAT assay
samples were analyzed on an Agilent 1260 HPLC with a C18 reverse phase HPLC column
(Zorbax Eclipse XDB, 4.6 x 150 mm) using a gradient of 30% acetonitrile in 0.05 % aqueous
TFA to 100 % acetonitrile over 30.2 minutes. Fluorescent peptide substrate and acylated
products were detected by UV absorbance at 360 nm and fluorescence (ex 360 nm, em 485 nm),
with the peptide substrate eluting with a retention time of 5-6 minutes and the octanoylated
peptide eluting with a retention time of 11-12 minutes. Chromatogram analysis and peak
integration was performed using Chemstation for LC (Agilent Technologies).39 Product
conversion was calculated by dividing the integrated fluorescence for the product peak by the
total integrated peptide fluorescence (substrate and product) in each run. Percent activity for each
hGOAT mutant was calculated by normalizing the product conversion for the mutant to that of
wild type hGOAT in a reaction run in parallel on the same day using the same reagents.
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2.4.11. Statistical analysis of hGOAT alanine variant reactivity.
Note: This statistical analysis was performed by Professor Jason D. Fridley (Associate
Professor of Biology, Syracuse University).
Each alanine mutation site was assigned as “void contacting” or “non-void contacting” by
inspection of the hGOAT structural model. The two populations were compared using a
Wilcoxon signed-rank test (n=42, test statistic W=294.5) and yielded a p-value = 0.02978 against
the null hypothesis of both populations of alanine mutations being equally likely to yield reduced
hGOAT activity. The statistical test was executed using the script below executed in R.53
str(dat)
median(dat$Y)
#overall median is 13.25
sum(dat$group)
#21 values in interest group
median(dat$Y[dat$group==1])
#interest group median is 4.41
median(dat$Y[dat$group==0])
#median of other group is 33.72
actual.diff = median(dat$Y[dat$group==0]) - median(dat$Y[dat$group==1])
#difference of group medians is 29.3
#are the group medians significantly different?
#procedure: randomly shuffle group membership vector, calculate median difference as
test statistic
Nperm = 10000 #number of random permutations
test.stat = rep(0,Nperm) #holding vector
for(i in 1:Nperm) {
rgroup = sample(dat$group)
test.stat[i] = median(dat$Y[rgroup==0]) - median(dat$Y[rgroup==1])
}
hist(test.stat); abline(v=actual.diff,lwd=3,col="red")
length(test.stat[test.stat>actual.diff])/Nperm #P value of null hypothesis of no difference
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#P ~ 0.04 (one-tailed)
#compare to t.test of mean difference assuming unequal variances, one-tailed
t.test(dat$Y[dat$group==0],dat$Y[dat$group==1],alternative="greater")
#P=0.013
#compare to wilcoxon rank sum test (nonparameteric)
wilcox.test(dat$Y[dat$group==0],dat$Y[dat$group==1],alternative="greater")
#P=0.030
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Chapter 3: Investigation of the acyl donor-binding site
within hGOAT
Portions of this chapter, including figures and experimental results have been
previously published and reprinted with permission from the publisher, reference
14, Campana, M. B.; Irudayanathan, F. J.; Davis, T. R.; McGovern-Gooch, K. R.;
Loftus, R.; Ashkar, M.; Escoffery, N.; Navarro, M.; Sieburg, M. A.; Nangia, S.;
Hougland, J. L., The ghrelin O-acyltransferase structure reveals a catalytic channel
for transmembrane hormone acylation. J Biol Chem 2019, Vol: 294, 14166-14174.
Copyright © 2019 The American Society for Biochemistry and Molecular Biology,
Inc.
All computational modeling including molecular docking and relaxation of
octanoyl-CoA: hGOAT complex were performed by Flaviyan Jerome
Irudayanathan (Shikha Nangia Laboratory, Biomedical and Chemical Engineering
at Syracuse University).
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3.1 Introduction
The 28-amino acid peptide hormone ghrelin is involved in multiple signaling pathways
by binding the growth hormone secretagogue receptor (GHS-R1a).1-4 Following expression of
the 117-amino acid ghrelin precursor preproghrelin, this peptide undergoes several processing
steps for maturation prior to secretion. One key and unique step essential to activate ghrelin’s
receptor is the modification of the third serine amino acid (Ser3) in the peptide sequence by the
addition of an n-octanoic acid catalyzed by GOAT (ghrelin O-acyltransferase).1, 5-6 In humans
and rodents, the predominant form of the acyl chain that is coupled to ghrelin is a saturated eightcarbon chain (C8:0).1, 7-8 Other forms of acyl-CoA (acyl coenzyme A) substrates has been
determined to be accepted by GOAT including n-decanoyl (C10:0), a saturated 10-carbon chain)
or n-decanoyl (C10:1, a 10-carbon chain with one alkene bond).9-10 Unexpectedly, one early
study suggested GOAT prefers n-hexanoyl-CoA (C6:0) for acylation of ghrelin over n-octanoylCoA.11 However, the concentration of n-hexanoyl-CoA in ghrelin secreting cells in the stomach
is thought to be very low compared with that of n-octanoyl, explaining the primarily production
of the n-octanoyl form of ghrelin.11 Longer acyl donors like myristoyl-CoA (C14:0) or
palmitoyl-CoA (C16:0) are much less efficiently accepted by GOAT compared to other MBOAT
(membrane bound O-acyltransferase) members that utilize these longer chain substrates, which
marks GOAT unique amongst this enzyme superfamily.8, 11-12 The preference of GOAT for
medium-length fatty acid chains is distinctive, which opens a latent backbone to the design of
more potent GOAT inhibitors. Previous inhibition studies have described the use of acylated
ghrelin mimetics with different acyl chain lengths to inhibit the acylation of GOAT by using a
(1-5) penta-ghrelin peptide with a [Dap3] ((S)-2,3-diaminopropionic acid); replacing the ester
linkage of the acyl group for an octanoyl-amide stable linkage.8, 21 Inhibitors ranging from 2 to
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10 carbon chain lengths were able to block GOAT acylation activity with the 8-carbon chain
exhibiting the highest potency, demonstrating that the acyl chain binds a distinct pocket in the
hGOAT active site that most tightly binds an 8-carbon acyl chain.
Despite the importance of hGOAT in ghrelin signaling, little is understood about the
identity of catalytically essential amino acids. Topological studies of hGOAT have established
locations of transmembrane-spanning domains and loops of GOAT.13-14 Topology of Hhat,
another MBOAT family protein that acylate proteins, have shown remarkable similarities to
GOAT’s structure.15-16 In both topologies, the invariable His residue was luminal, and the
conserved Asn/Asp was cytosolic, further augmenting the consensus that all MBOATs have this
construction for their proposed active sites.15, 17-18 Moreover, it has been predicted the active site
of GOAT to reside in the ER (endoplasmic reticulum) where ghrelin is trafficked through the
secretory pathway.19-20 As acyl-CoA synthesis occurs in the cytoplasm, the transmembrane
topology of GOAT and potential ER-localized active site raises the question of how is the acylCoA donor transported to the ER lumen for acyl transfer? It has been suggested that GOAT and
other MBOAT enzymes could participate in the transportation of the acyl donor inside the ER to
the lumenal side or there is an intermediate protein or lipid capable to transfer the acyl-CoA,
collaborating with GOAT.5, 13 However, such intermediate hosts or mechanisms have not been
identified.
In this chapter, we have investigated the mechanistic construction of GOAT, aiming to
define the location and nature of the acyl donor-binding site. As described in chapter 2, we have
developed the first structural model of membrane bound GOAT by combination co-evolutionary
constraints and computational modeling alongside with mutagenesis validation. 14, 22-23
Employing these modeling and docking studies, we developed a GOAT structure with the
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octanoyl-CoA acyl donor showed significant interactions of the 8-carbon chain and coenzyme A
with multiple GOAT residues within a solvent-exposed binding site.14 Moreover, we have
utilized a range of acyl-CoA co-substrates in combination with enzyme mutagenesis to
chemically investigate and validate interactions with amino acids that are predicted to form the
acyl-binding pocket within GOAT. The development of this first structural model of a MBOAT
family protein acyltransferase has provided insights into catalysis by GOAT and can potentially
decipher the architecture of other MBOAT transmembrane acyltransferase, aiding the
development of new therapeutic methodologies.
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3.2 Results
3.2.1. Octanoyl-CoA: hGOAT-modeling complex
Note: All computational modeling and docking analysis were performed by collaborator
Flaviyan Jerome Irudayanathan (BMCE, Syracuse University).
To study potential interactions between GOAT and acyl-CoA to accommodate this
molecule within its structure, we have developed a molecular docking complex for octanoylCoA: hGOAT arrangement by using YASARA software with our model described in chapter
2.14, 24-25 We expected the octanoyl-CoA acyl donor to enter the hGOAT active site through
interaction with the cytoplasmic face of the enzyme based on the predicted availability of acylCoAs within the cell. When docked into our hGOAT model, octanoyl-CoA was found to bind in
an exposed site on the cytosolic exposed face of GOAT, with portions of the acyl-CoA solvent
exposed (Figure 3.1b).14 The acyl-CoA: GOAT complex shows interactions of both its coenzyme
A and octanoyl chain regions with residues in the transmembrane domains TM6, the TM7-TM8
connecting loop, TM8, and TM9 as shown in Figure 3.1.
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a)

b)

Figure 3.1 Computational model complex of hGOAT and Octanoyl-CoA. a) Pymol structure
of octanoyl-CoA bound within hGOAT from a side view in the plane of the ER membrane. b)
View from the cytoplasmic face of hGOAT showing the solvent-exposed portions of the
coenzyme A component of octanoyl-CoA with TM6, the TM7-TM8 connecting loop, TM8, and
TM9 interactions.
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3.3.2. Octanoyl-CoA interactions within the GOAT pocket
In the docked complex, the phosphoadenosine group binds into a discrete pocket while
the phosphopantetheine chain is in contact with multiple amino acid side chains (Figure 3.2a-b).
The coenzyme A portion forms both polar and nonpolar interactions with several hGOAT
residues while remaining exposed to the cytoplasm as shown in Figure 3.1. To biochemically
investigate the impact of these amino acids interacting with the acyl-CoA donor, we performed
alanine mutagenesis with investigation of hGOAT octanoylation activity in our peptide-based
assay (Table 3.1).26 Mutations R304A, W306A, N307A, R315A, and D358A (in red) all
abolished acylation activity of GOAT, consistent with these residues forming functionally
essential interactions with octanoyl-CoA. Mutations F331A and W351A (in purple) led to
reductions of GOAT activity, and the mutation shown in blue (H297A) had minimal impact on in
GOAT acylation activity. Moreover, in the docked complex the acyl chain of octanoyl-CoA
makes a sharp turn upward from the coenzyme A binding regions on the cytoplasmic face of
hGOAT following a channel that terminates at W351 and F331 amino acids in GOAT (Figure
3.2). This channel is spatially distinct from the pocket where the phosphoadenosine group binds,
defining two distinct spaces where acyl-CoA binds and interacts with GOAT.
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Table 3.1 hGOAT alanine variant octanoylation activity
Active Variants
(100 - 33% of WT
Activity)
Variant
% Activity
H297A
56 ± 4

Impaired Variants
(33 - 1% of WT
Activity)
Variant
% Activity
F331A
18.2 ± 0.6
W351A
4.7 ± 0.9

Inactive Variants
(Undetectable Activity)
Variant
R304A
N307A
R315A
W306A
D358A

% Activity
0
0
0
0
0
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Figure 3.2 Interactions between the octanoyl-CoA acyl donor and hGOAT residues. a) Polar
and nonpolar interactions of octanoyl-CoA with hGOAT. b) Pymol depiction of hGOAT
residues shown in purple that reduced acylation activity under standard reaction conditions when
mutated to alanine, residues shown in red abolished acylation activity upon alanine mutation, and
black residues were not tested. Figure is reproduced with permission from Reference 14
(Appendix XII). Copyright © 2019 The American Society for Biochemistry and Molecular
Biology, Inc.
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3.2.3. Single acyl donor investigation with alanine mutants
Given the unique preference of hGOAT for an octanoyl acyl donor,6, 8 we examined
alanine mutagenesis of predicted contacts within this acyl-binding pocket to determine the
impact of those mutations on hGOAT acyl donor selectivity. As alanine mutagenesis would
provide additional space within the acyl-binding site, we determined the ability of hGOAT
alanine variants to accept twelve carbon (lauryl-CoA) and fourteen carbon (myristoyl-CoA) acyl
donors in place of octanoyl CoA. As described in the Experimental Methods section, we
incubated hGOAT mutants with ghrelin substrate peptides and a range of acyl donors to
determine acyl donor preferences. The wild type enzyme and the majority of hGOAT alanine
variants exhibited the expected preference for an eight-carbon acyl donor, but alanine
mutagenesis of W351 and F331 resulted in loss of appreciable reactivity with octanoyl-CoA but
engendered new activity with the longer acyl donors (Figure 3.3 and Figure 3.4). The F331A
variant gained activity with the C12 donor while W351A mutant could acylate a ghrelin-derived
peptide with both C12 and C14 acyl chains. This altered selectivity supports the modeled
positions of W351 and F331 as forming the end “cap” of the acyl binding pocket site.
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Figure 3.3. Acylation activity of WT hGOAT and selected hGOAT alanine variants using
octanoyl-, lauryl-, or myristoyl-CoA as the sole acyl donor. Activities are normalized to the
most reactive hGOAT variant with each acyl donor, and error bars reflect the standard deviation
from a minimum of three independent trials. Reference 14 (Appendix XIII). Copyright © 2019
The American Society for Biochemistry and Molecular Biology, Inc.
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c)

% hGOAT activity (Normalized
for each acyl donor)
% hGOAT activity (Normalized
for each acyl donor)

b)

% hGOAT activity (Normalized
for each acyl donor)

a)

Figure 3.4. Acyl donor reactivity with WT hGOAT and hGOAT alanine variants with C8CoA (black), C12-CoA (purple), and C14-CoA (green) acyl donors. Single acyl donor
reactions were performed, analyzed, and normalized as described in Experimental Methods. a)
Reactivity with C8-CoA; b) Reactivity with C12-CoA; c) Reactivity with C14- CoA. Three
independent experimental trials are indicated by individual data points, with a dotted horizontal
line denoting the average of the three independent trials. Activities are normalized to the most
reactive hGOAT variant with each acyl donor. Reference 14 (Appendix XIV). Copyright © 2019
The American Society for Biochemistry and Molecular Biology, Inc.
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3.2.4 Competition experiments to define GOAT acyl donor selectivity
The altered preference for longer acyl donors exhibited by the F331A and W351A
variants was also observed in a direct competition assay where hGOAT variants were provided
acyl donors ranging from six to twelve carbons (Figure 3.5). This altered selectivity was not
observed for any other alanine variants with detectable ghrelin acylation activity (Figure 3.6).
Acyl donor reengineering upon targeted alanine mutagenesis further supports localizing F331
and W351 to the distal end of the acyl donor-binding site within hGOAT and provides further
biochemical validation of our hGOAT structural model.

97

Fluorescence (AU)

Time (min)

Time (min)

Figure 3.5. Acyl donor competition experiment. Acyl donor competition demonstrates altered
selectivity to a longer acyl donor for F331A and W351A hGOAT variants compared to the wild
type enzyme, consistent with the predicted interaction of these amino acid side chains with the
distal end of the octanoyl acyl chain. Reference 14 (Appendix XV). Copyright © 2019 The
American Society for Biochemistry and Molecular Biology, Inc.
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Figure 3.6 Acyl competition reactions with WT hGOAT and hGOAT alanine variants with
C6-CoA, C8-CoA, C10-CoA, and C12-CoA. Reactions were performed, analyzed, and
normalized as described in the Experimental Methods section. a) WT; b) H98A; c) L135A; d)
Y168A; e) S179A; f) L180A; g) S182A; h) F183A; i) Y255A, j) Y284A; k) S300A; l) F302A;
m) W306A; n) R315A; o) F331A; p) F348A; q) W351A; r) R370A. Reference 14 (Appendix
XVI). Copyright © 2019 The American Society for Biochemistry and Molecular Biology, Inc.
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3.3 Discussion and conclusion
GOAT selection of an octanoyl-CoA as its acyl substrate is unusual compared to other
related acylation enzymes that preferably accept longer acyl groups such as 14- or 16-carbons.18,
27

Previous work has shown hGOAT discrimination against acyl chains both longer and shorter

than eight carbons,8 representative of a distinct acyl binding pocket within hGOAT. We have
introduced alanine mutations that stretched the computational predicted acyl group-binding site
of our model. We have determined acyl-binding preferences using a range of acyl donors with
different acyl chain lengths and reengineer hGOAT acyl pocket by mutating W351 and F331 to
alanine. Studies of F331A and W351A hGOAT mutants revealed a significant alteration in acyl
donor, preferring the longer (decanoyl-CoA (C-10) and dodecanoyl-CoA (C-12)) substrates for
ghrelin acylation. This result confirmed the interaction to the last carbon in the carbon chain to
these amino acids, acting as a “cap” at the end of the phosphopantetheine chain pocket.
Significant polar and non-polar interactions of the fatty acid CoA with GOAT were
identified by our computational modeling method. Mutations in the predicted binding site for the
acyl donor (R304A, W306A, D358A, N307A, and R315A) were shown to completely eliminate
GOAT activity, describing functional residues that are potentially interacting with the acyl-CoA
substrate. Likewise, this hGOAT: octanoyl-CoA model implicates that the highly MBOAT
conserved amino acid N307 is in the binding site for the acyl donor, answering the long-lasting
question of the spatial position of this conserved amino acid. Moreover, the location of the
binding site for octanoyl-CoA supports the hypothesis of the acyl donor binding to GOAT from
the cytosolic face of the enzyme; where the acyl-CoA substrate extends through transmembrane
domains TM6, 7 and 9 to reach the center of the hGOAT.
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Based on hGOAT: octanoyl-CoA complex model described in chapter 2 and 3, we
propose that hGOAT catalyzes transmembrane acylation of ghrelin by binding both substrates
within the hGOAT internal channel and “handing off” the octanoyl group from CoA to ghrelin
within the revealed channel (Figure 3.7). Ghrelin (GSSFL-ghrelin) and octanoyl-CoA enter the
GOAT internal channel from the ER lumenal pore and cytoplasmic acyl donor binding sites
respectively, followed by acyl transfer to the ghrelin serine side chain hydroxyl. Octanoylated
ghrelin dissociates to the ER lumen resulting in the octanoyl chain transiting through the GOAT
interior, and coenzyme A is released back to the cytoplasm. While many aspects of this proposed
pathway such as the ghrelin binding site and location of catalytic residues remain to be
functionally validated by ongoing studies, the established ability of our hGOAT model to
efficiently guide biochemical studies demonstrates a novel approach to advance investigations of
similar membrane proteins that are intractable to current structural approaches.
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Figure 3.7. Proposed pathway for transmembrane ghrelin octanoylation by GOAT. The red
and blue cylinders represent perimeter helices, the green cylinder represents intramembrane
domains forming the cytoplasmic surface of hGOAT, and dotted lines represent binding
interactions between the octanoyl-CoA acyl donor and its binding site within hGOAT.
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3.4 Experimental Methods
General methods
Data plotting and curve fitting were carried out with Kaleidagraph (Synergy Software,
Reading, PA, USA). Membrane topology schematics were generated using Protter
(http://wlab.ethz.ch/protter/start/),28 and structural figures were generated using Chemdraw
Prime 15.1 and PyMol. Hexanoyl coenzyme A (hexanoyl-CoA, free acid) (Crystal Chem Inc.),
octanoyl coenzyme A (octanoyl-CoA) (AdventBio), decanoyl coenzyme A (decanoyl-CoA, free
acid) (Crystal Chem Inc.), lauroyl coenzyme A (lauroyl-CoA, dodecanoyl-CoA, free acid)
(Crystal Chem Inc.), and myristoyl coenzyme A (myristoyl-CoA, tetradecanoyl-CoA, free acid)
(Crystal Chem Inc.) were solubilized to 5 mM in 10 mM Tris-HCl (pH 7.0), aliquoted into lowadhesion microcentrifuge tubes, and stored at −80 °C. Methoxy arachidonyl fluorophosphonate
(MAFP) was purchased from Cayman Chemical (Ann Arbor, MI) and solubilized with dimethyl
sulfoxide (DMSO). Unlabeled GSSFLCNH2 ghrelin peptide was synthesized by Sigma-Genosys,
solubilized in 1:1 acetonitrile:H2O, and stored at -80 °C. Acrylodan (Anaspec) for peptide
substrate labeling, was solubilized in acetonitrile with the stock concentration determined by
absorbance at 393 nm after dilution in methanol (ε393 = 18,483 M–1cm–1, per the manufacturer’s
data sheet). GSSFLCNH2 peptide concentrations were determined by reaction of the cysteine thiol
with 5,5’-dithiobis(2-nitrobenzoic acid) and absorbance at 412 nm, using ε412 = 14,150 M–1 cm–
1 29

.
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3.4.1 Molecular docking and relaxation of octanoyl-CoA: hGOAT complex
Note: All docking and relaxation analysis was performed by collaborator Flaviyan Jerome
Irudayanathan (BMCE, Syracuse University).
To build a model of the octanoyl-CoA•hGOAT bound complex, we performed docking
using Autodock Vina implemented in the YASARA software suite.24-25 One hundred docking
runs were carried out with the search space defined as 8 Å cube around the residue lining the
void space in the model. The top docking pose was further refined with a local search run. The
final docked ligand-receptor complex was subject to a short energy minimization and molecular
dynamics refinement for 1ns using the YASARA suite, with the backbone positions being fixed.

3.4.2 Construction of hGOAT mutants
PCR primers were designed and then synthesized by Integrated DNA Technologies as
demonstrated in Chapter 2, as previously reported hGOAT expression construct.30 Primers were
dissolved in upH20 and concentrations were measured by UV absorbance at 260 nm. PCR
mutagenesis reactions (50 μL total volume) contained the following components: 10x Pfu
reaction buffer (5 μL), pFBD_MBOT4ix3Tag_RFP template (10 ng), forward primer (125 ng),
reverse primer (125 ng), dNTPs (1 μL, 1 mM stock), and Pfu Turbo DNA polymerase (1 μL,
Agilent). The thermocycler program for PCR mutagenesis proceeded as follows: initial
denaturation (95 °C, 1 min); 18 cycles of denaturation (95 °C, 50 sec); annealing (60 °C, 50 sec);
extension (68 °C, 12 min); and final extension (68 °C, 12 mins). Reaction were digested with
DpnI (1 μL, 10 units) at 37 °C for 2 hours. After DpnI digestion, the PCR reaction mixture (5
L) were then transformed into a 100 L aliquot of chemically competent Z-competent DH5
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cells (Zymo Research) followed by incubation on ice for 30 minutes. Transformed bacteria were
spread on LB-ampicillin plates (100

g/mL) and incubated at 37 C overnight. Following

overnight incubation at 37 oC, single colonies were inoculated into LB media (5 mL) containing
ampicillin (100 g/mL) in sterile culture tubes. These cultures were incubated overnight at 37 C
with shaking (225 rpm). Following overnight growth, plasmids were purified from the saturated
cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic Inc.) per manufacturer’s
instructions. Single site mutations were verified by DNA sequencing (Genescript).

3.4.3 Expression and enrichment of hGOAT in membrane protein fractions
hGOAT wildtype and alanine mutants were expressed in insect (Sf9) cell membrane
fractions using previously published procedures with a baculovirus expression system. 8, 30-31

3.4.4. hGOAT expression analysis by anti-FLAG Western Blot
hGOAT membrane fractions were thawed on ice and homogenized by passing through an
18-gauge needle ten times. Membrane fraction protein concentrations were determined by
Bradford assay using the Quick Start Bradford 1X Dye Reagent (BioRad). Samples for
polyacrylamide gel analysis and Western blotting were prepared containing 50 μg membrane
fraction protein from Sf9 cells transfected with hGOAT, 1x sample buffer (0.33 M Tris HCl, pH
6.8, 0.1 M SDS, 14% glycerol, and 0.5 M DTT) and 50 mM HEPES pH 7.0 in a total volume of
45 μL. Protein samples were heated to 50.2 °C for 5 minutes and then incubated at room
temperature for 15 min prior to gel loading. Samples were loaded onto a 12 % Tris-glycine
SDS-polyacrylamide gel and run at 110 V for 1.5 hrs. Each gel contained an empty vector (EV)
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microsomal protein as negative control and amino-terminal FLAG-BAP Fusion protein as a
positive control (Millipore Sigma, P7582-100UG, 1:150 dilution, 30 μL total volume).
Following electrophoretic separation, proteins were transferred to a PVDF membrane for
Western blotting (BioRad, Trans-Blot turbo RTA transfer kit), with the PVDF membrane
activated by immersion in methanol for 30 seconds followed by equilibration in transfer buffer
(20% v/v methanol, 48 mM Tris base, 39 mM glycine and 0.034% v/v SDS) prior to transfer.
Proteins were transferred to the membrane for 30 minutes at 1.3 A / 25 V using the transfer kit
per manufacturer’s instructions. Following electroblotting, the PVDF membrane was blocked
for 4 hours in 10% v/v nonfat milk in TBST buffer (Tris buffered saline (TBS, 0.05M Tris and
0.14M NaCl) with 0.1% v/v Tween 20). The membrane was then probed with a Flag antibody
(HRP-conjugated DYKDDDDK Tag Antibody, Invitrogen catalog number PA1-984B-HRP,
1:1000 dilution, 10 mL total volume) in 5% nonfat milk in TBST buffer overnight at 4 °C. The
membrane was washed with TBST (6 x 5 mL) and treated with West Pico Chemiluminescent
substrate-imaging reagent (Thermo Scientific), followed by imaging on a ChemiDoc XRS+ gel
documentation system (BioRad) (Western blots for alanine mutants in these chapter are
presented in Chapter 2).
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3.4.5 hGOAT activity assay - standard reaction conditions
Membrane fractions of hGOAT expressed from Sf9 cells were thawed on ice and
homogenized by passing through an 18-gauge needle ten times. hGOAT activity assays under
standard conditions were performed with 50 μg of membrane protein, 1.5 μM fluorescent peptide
substrate, 300 μM octanoyl-CoA, 1 μM MAFP, and 50 μM HEPES pH 7.0 in a total volume of
50 μL. All components except for the peptide and acyl-CoA substrates were incubated at room
temperature for 30 minutes prior to reaction initiation by addition of peptide and acyl-CoA
substrates. Reactions were incubated at room temperature for 2 hour in the dark and then stopped
by addition of 50 μL of 20% acetic acid in isopropanol. Reaction solutions were clarified by
protein precipitation with 16.7 μL of 20% trichloroacetic acid followed by centrifugation (1,000
x g, 2 min). The resulting supernatant was then analyzed by reverse phase HPLC. hGOAT assay
samples were analyzed on an Agilent 1260 HPLC with a C18 reverse phase HPLC column
(Zorbax Eclipse XDB, 4.6 x 150 mm) using a gradient of 30% acetonitrile in 0.05 % aqueous
TFA to 100 % acetonitrile over 30.2 minutes. Fluorescent peptide substrate and acylated
products were detected by UV absorbance at 360 nm and fluorescence (ex 360 nm, em 485 nm),
with the peptide substrate eluting with a retention time of 5-6 minutes and the octanoylated
peptide eluting with a retention time of 11-12 minutes. Chromatogram analysis and peak
integration was performed using Chemstation for LC (Agilent Technologies).30 Product
conversion was calculated by dividing the integrated fluorescence for the product peak by the
total integrated peptide fluorescence (substrate and product) in each run. Percent activity for each
hGOAT mutant was calculated by normalizing the product conversion for the mutant to that of
wild type hGOAT in a reaction run in parallel on the same day using the same reagents.
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3.4.6. Single acyl donor reactivity assay
To determine the reactivity of hGOAT variants with different length acyl donors,
hGOAT activity was measured in the presence of 100 μM of a single acyl donor (octanoyl -CoA,
lauryl (dodecanoyl) -CoA, or myristoyl (tetradecanoyl) - CoA). Characteristic retention times for
each acylated form of the peptide substrate provided confirmation of the nature of the attached
acyl chain, with dodecanoyl -GSSFLCAcDan eluting at ~17 minutes and tetradecanoyl GSSFLCAcDan eluting at ~19 minutes. For each acyl donor, relative activity was calculated
normalized to the highest activity observed across the panel of wildtype hGOAT and hGOAT
variants (Figure 3.8).

3.4.7 Acyl donor competition assay
To determine the relative preference of each hGOAT variant for acyl donors ranging
from six to twelve carbons, hGOAT activity was measured in the presence of 100 μM each of
four potential acyl donors (hexanoyl -CoA, octanoyl -CoA, decanoyl -CoA, and lauryl
(dodecanoyl) -CoA). Each potential product peak was assigned by retention time compared to a
standard reaction containing only one acyl donor for each potential product. Competition
experiments including myristoyl -CoA were unsuccessful, potentially due to low critical micelle
concentration (CMC) for this acyl donor lying near 100 μM.
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Figure 3.8 Acyl donor reactivity with WT hGOAT and hGOAT alanine variants with C8CoA (black), C12-CoA (purple), and C14-CoA (green) acyl donors. Single acyl donor
reactions were performed, analyzed, and normalized as described in the Experimental Methods.
Error bars reflect the average of a minimum of three independent experimental trials.
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Chapter 4: Investigation of enzyme-substrate interactions
using hGOAT variant reactivity alteration with modified
peptide substrates
The work in this chapter is unpublished. In this chapter, there was an experimental
contribution from Najae Escoffery (Syracuse Chemistry REU summer
undergraduate researcher) and Melissa Navarro (Syracuse University
undergraduate researcher) who assisted with reactivity investigation of ghrelin and
hGOAT mutants.
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4.1 Introduction
Ghrelin acylation is catalyzed by ghrelin O‐acyltransferase (GOAT), which adds an
octanoyl (eight-carbon) fatty acid group to the third serine in ghrelin’s sequence.1-2 Structural
understanding of ghrelin acylation is still unknown due to GOAT’s resistance to purification in
active form. Yet, structural determination is crucial for the development of ghrelin-based
therapeutics for the treatment of conditions involving this hormone. 3-4 Previous studies of the
interaction of ghrelin and GOAT have established important chemical signals for the recognition
of the N-terminal “GSSF” sequence of ghrelin. In an in vitro biochemical assay, alanine
mutations in the ghrelin peptide sequence revealed that GOAT recognizes the amino acids
glycine (G1), serine (S3), and phenylalanine (F4) within the ghrelin N-terminal sequence.5
Conversely, mutation of S2 to alanine resulted in no effect on ghrelin acylation by the mouse
isoform of GOAT.5 More targeted structure-activity analysis of GOAT reactivity demonstrated
the α amino group of the essential N-terminal glycine residue of ghrelin to be required for
substrate recognition. Acetylation of this group reduced reactivity and elimination of this amine
completely abolished peptide recognition.6-7 Likewise, replacement of glycine 1 with
methoxyacetic acid which removes the nitrogen atom of the amino group resulted in the loss of
peptide reactivity with GOAT.6 These studies suggested that a positive charge or/and a hydrogen
bond is required for GOAT recognition at the G1 position of ghrelin.
Investigation of the recognition pattern for the second serine (S2) in ghrelin by GOAT
revealed a potential steric contact at S2, where the enzyme did not tolerate mutations that
introduced large amino acids like phenylalanine and tryptophan.7 There is a negative effect in
increasing the volume of the residue at S2, consisting with a small binding pocket at this site.
Additional investigation of reactivity with positive charged amino acids like histidine and lysine
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demonstrated reduced activity but still detectable octanoylation with hGOAT, with this loss of
activity ascribed to the known steric selectivity at this position rather than the side chain positive
charge.7 Mutation of S2 to threonine resulted in no loss of reactivity, which supports recognition
of the hydroxyl group at S2, potentially through hydrogen bonding.
Mutagenesis studies of phenylalanine-4 (F4) with alanine substitution resulted in a loss of
substrate octanoylation in both in vitro and cell-based ghrelin octanoylation assays using mouse
GOAT.5 Alanine modification in the human isoform of GOAT similarly resulted in reduced
reactivity.6 Surprisingly, analysis of an array of mutations at this position revealed broad
tolerance for steric/bulky residues, in contrast to the steric discrimination detected at G1 and S2
sites. However, introduction of charged amino acids glutamate and lysine led to a loss of
detectable activity.6 These results reflect a sterically accommodating binding site with tolerance
towards uncharged amino acids.
Ghrelin sequence studies identified an amphibian form of ghrelin in the stomach of
bullfrog, which is also modified with an n-octanoic acid group.8-10 However, this modification
take place on a unique threonine amino acid at position 3 (T3) in bullfrog. This amino acid varies
from the serine present in mammalian ghrelin counterparts.9 A S3T mutation in the human
ghrelin-derived peptide substrate (GSTFLCAcDan) was investigated based on bullfrog ghrelin.
Threonine substitution at serine 3 reduced peptide octanoylation but did not entirely abolish it,6
indicating that hGOAT tolerates a methyl substituent in place of one of the hydrogens on the β
carbon in serine at this position.
These previous studies have generated a profile of chemical properties for ghrelin
recognition by hGOAT at each location in the N-terminal “GSSF” sequence of ghrelin (Figure
4.1). In this analysis, we have used our biochemical tools and previous understanding of
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hGOAT-substrate interactions to examine our computationally predicted substrate binding sites
within hGOAT described in chapter 2 of this work. Initial investigations of our model revealed
an internal channel with two contiguous voids (Figures 2.5 and 4.2). These spaces are proposed
to be topologically arranged to serve as binding sites for ghrelin (blue, ER lumen exposed) and
octanoyl-CoA (red, cytoplasm exposed) (Figure 4.2). Using the profiles for ghrelin recognition
by hGOAT described above coupled with simultaneous mutations in both enzyme and substrate,
we have identified a subset of residues within this internal channel that play functional roles in
ghrelin interaction and binding. These interactions between ghrelin and GOAT can serve as
constraints for validating and refining our hGOAT structure to understand ghrelin binding and
catalysis by this enzyme. Similarly, these findings lay the foundation for the identification of the
GOAT active site and facilitate rational design of inhibitors targeting ghrelin acylation by
GOAT.
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Figure 4.1 Schematic illustration of identified substrate-binding-site interactions within the
hGOAT active site. This diagram summarizes important interactions between hGOAT active
site and the ghrelin peptide. Recognition of the N-terminal amine, the α carbon of G1, the sidechain hydroxyl of S2, the β carbon of S3, and the side chain of F4 of the ghrelin peptide are
described and indicated as dotted lines.
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Figure 4.2. Structural modeling of human ghrelin O-acyltransferase reveals a
transmembrane channel within GOAT. An internal void was discovered with potential
binding sites for ghrelin (blue) and octanoyl-CoA (red). These proposed binding sites are
topologically connected by a channel passing through the protein from the ER lumen to the
cytoplasm, with this model allowing identification of amino acids within hGOAT that contact
this void space. This figure was created using PyMOL.11
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4.2 Results
4.2.1. hGOAT mutant reactivity enhancement and loss with mutated peptide substrates
As described above, previous studies have shown that GOAT recognizes the size of the
amino acid at several sites within ghrelin. 6-7 For example, increasing the size of the amino acid
at the second position (S2) of the GSSFL sequence led to a loss of enzyme activity with the
mutated substrate.6 To investigate regions of hGOAT predicted by our structural model to
potentially interact with the ghrelin substrate, we have investigated the reactivity of peptide
substrates containing site-specific mutations with both wild type hGOAT and hGOAT variants
containing alanine mutations within the enzyme core. By comparing the reactivity of these
hGOAT alanine variants with both the mutated and wild type peptide substrates, hGOAT
residues that specifically alter reactivity of the mutated substrates can be identified. Such specific
enhancement or loss of reactivity with a mutated substrate will thereby identify hGOAT residues
contacting ghrelin at the site of the substrate mutation. The peptide substrates for these studies
were designed by altering the “GSSF” sequence (G1, S2, and F4) as shown in Figure 4.3.
For these studies, hGOAT alanine variants described in chapter 2 were selected to
investigate their reactivity with mutated peptide substrates. These hGOAT variants exhibit a
wide range of activity with the wild type (unmutated) peptide substrate (GSSFLCacdan); from
comparable to wild type hGOAT to complete loss of detectable activity (Table 2.2 or Figure 2.7
in chapter 2).12 Rescue or enhancement of acylation activity was determined by measurements of
reactivity for each hGOAT variant-mutant substrate pair relative to the wild-type enzyme and
mutant substrate as shown in Figure 4.4. To calculate this enhancement, we described the change
in reactivity between the alanine (ala) variant and WT (wild type) hGOAT enzymes with each
mutated ghrelin peptide substrate and then subsequent measurements of reactivity of alanine
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variant and WT hGOAT with the unmutated ghrelin peptide (GSSFLCacdan) (Figure 4.4a). The
ratio of these two measurements will indicate the specific impact on reactivity with the mutated
substrate due to each alanine mutation within hGOAT. An illustration of this analysis is shown in
Table 4.1, where fold enhancement has been calculated for different hGOAT ala variants.
Likewise, reactivity loss was calculated by inverting the equation described above to identify
variants that are detrimental to hGOAT acylation activity towards specific mutated substrates
(Figure 4.4b). Similarly, activity loss calculations are shown in Table 4.2. Activity of each
hGOAT variant was determined using our fluorescently-labeled ghrelin mimetic substrates,
monitoring octanoylation by an increase in retention time on reverse-phase HPLC as described in
the Experimental Methods section.13
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Figure 4.3. Mutated peptide substrates for structure-activity studies of hGOAT alanine
variants. Peptide substrates used in this study to establishing GOAT’s selectivity within the
“GSSF” ghrelin sequence. Model of the GSSFL substrate indicating the G1, S2, and F4 positions
with specified modifications. An alanine (Ala) mutation was introduced at the G1 position.
Valine (Val), phenylalanine (Phe), and tryptophan (Trp) mutations were added at S2 position. At
the F4 position Tryptophan (Trp), unnatural amino acids cyclohexylalanine (Cha), and a
cysteine-conjugated acrylodan fluorophore were introduced.
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a)

b)

Figure 4.4. Analyses to determine specific enhancement and loss of hGOAT variant
reactivity with mutated peptide substrates. Detection of specific hGOAT variant reactivity a)
enhancement or b) loss with a mutated peptide substrate provides evidence of a biochemical
interaction between the alanine mutation site in hGOAT and the mutation site in the peptide
substrate.
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Table 4.1. Cross-reactivity between modified substrates and hGOAT mutants yields
enhancement signals of enzymatic activity at specific ghrelin positions. Enhancement
calculations of hGOAT alanine variants with mutated substrates for each enzyme-substrate
mutation pair relative to the wildtype enzyme. Blue, alanine variants with octanoylation activity
within 3-fold of WT hGOAT with an unmutated substrate; purple, alanine variants with impaired
octanoylation activity (>3-fold loss compared to WT hGOAT) with an unmutated substrate; red,
inactive alanine variants with an unmutated substrate. Errors indicate the average of a minimum
of three independent experimental trials.
Fold Enhancement
G1
S2
F4
Steric ASSFLC
GVSFLC acdan GFSFLC acdan GWSFLC acdan GSS[Cha]LCacdan GSSWFLCacdan
acdan
Size
H98A
0
0
0
0
0
0
Y168A
0
0
0
0
0
0
S179A
1.1 ± 0.4
7.4 ± 4.1
1.2 ± 0.3
0.5 ± 0.01
0.7± 0.4
1.3 ± 0.1
S182A
0
0
0
0
0
0
F183A
0
0
0
0
0
0
Y255A
0
0.7 ± 0.2
0
0.9 ± 0.2
2.6 ± 0.1
1.0 ± 0.2
Y284A
0
0
0
0
0
0
S300A
1.5
0.4 ± 0.2
0.3
0
0.6 ± 0.4
2.0 ± 0.4
F302A
0
0.4 ± 0.1
0.1
0.2 ± 0.03
1.7 ± 0.4
0.8 ± 0.4
W306A
0
0
0
0
0
0
F331A
0
0
0
0
1.3
0
F348A
2.1 ± 0.3
0.7 ± 0.2
1.7
0
0
0.5 ± 0.3
W351A
0
0.7 ± 0.1
0.8
0
0.6 ± 0.1
0
R370A
1.4 ± 0.5
0.7 ± 0.3
0.2
0.7
0.9 ± 0.1
0.7 ± 0.3

GSSCacdan LS
0
0
0.6 ± 0.04
0
0
0.3
0
0
0.2 ± 0.1
0
0.2
0.3 ± 0.2
0
0.6 ± 0.2
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Table 4.2. Specific loss of enzyme ractivity between modified substrates and hGOAT
variants. Fold loss calculations of hGOAT alanine variants with modified substrates for each
enzyme-substrate mutation pair relative to the wildtype enzyme. hGOAT variants are colored
coded as in Table 4.1. Errors indicate the average of a minimum of three independent
experimental trial
Fold Loss
S2

G1
Steric
Size
H98A
Y168A
S179A
S182A
F183A
Y255A
Y284A
S300A
F302A
W306A
F331A
F348A
W351A
R370A

F4

ASSFLCacdan GVSFLC acdan GFSFLC acdan GWSFLCacdan GSS[Cha]LCacdan GSSWFLCacdan GSSCacdan LS
0
0
1.0 ± 0.4
0
0
0
0
0.7
0
0
0
1.3 ± 0.2
0
0.8 ± 0.2

0
0
0.2 ± 0.1
0
0
1.5 ± 0.4
0
2.4 ± 0.3
2.7 ± 0.7
0
0
2.2 ± 0.8
1.4 ± 0.3
1.5 ± 0.5

0
0
0.9 ± 0.2
0
0
18.2 ± 7.9
0
3.2
6.7
0
0
0.6
1.2
4.9

0
0
1.9 ± 0.05
0
0
1.2 ± 0.2
0
0
6.6 ± 1.2
0
0
0
0
1.5

0
0
0.4 ± 0.02
0
0
0.4 ± 0.02
0
3.1 ± 3.1
0.6 ± 0.2
0
0.8
30.0 ± 18.1
1.7 ± 0.2
1.2 ± 0.2

0
0
0.8 ± 0.06
0
0
1.0 ± 0.2
0
0.5 ± 0.1
1.8 ± 0.8
0
0
2.3 ± 1.2
0
1.6 ± 0.5

0
0
1.8 ± 0.1
0
0
3.4
0
0
5.5 ± 1.6
0
0
2.2 ± 0.4
1.8 ± 2.2
1.8 ± 0.6
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4.2.2 Location of ghrelin binding site within hGOAT suggested by ghrelin-GOAT cross
mutation reactivity analysis
To qualitatively understand the significance of a detected rescue, enhancement signals for
every pair was compared to the average and standard deviation of all enhancement values in this
study. For example, the average enhancement (0.4) plus the standard deviation (0.9) for the
entire enhancement study was determined to be 1.3, as shown in Figure 4.5. Consequently, any
enhancement measured larger than 1.3 is interpreted as evidence that supports interaction of the
enzyme and substrate mutation sites. Through analysis of specific enhancement data, we
identified interaction pairs corresponding to S179A with GVSFLC, Y255A with GSS[Cha]LC,
S300A with GSSWLFC and ASSFLC, F302A with GSS[Cha]LC, and F348A with ASSFLC as
all show specific enhancement of reactivity higher than any other reactivity signal rescue.
Similarly, specific losses of reactivity were calculated and are shown in Figure 4.6. for loss of
reactivity, the average (1.3) plus standard deviation (3.7) of fold loss was calculated to be 5.0.
Analysis of specific loss of reactivity supports the following interaction pairs: Y255A with
GFSFLC; F302A with GFSFLC, GWSFLC, GSSCLS; and F348A with GSS[Cha]LSC.
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Figure 4.5. Specific reactivity enhancement analysis of GOAT-ghrelin mutation pairs. All
enhancement data points were plotted (shown in blue dots), with the overall average (0.4, black)
denoted by a thick black dotted line and the number for baseline for considering enhancement
significance (1.3, gray) shown with the thin black dotted line. Data points above the threshold for
consideration are labeled with the specific hGOAT alanine variant and mutated substrate.

129

Figure 4.6. Specific reactivity loss analysis of GOAT-ghrelin mutation pairs. All
enhancement data points were plotted (shown in orange), with the overall average (1.3, black)
denoted by a thick black dotted line and the number for baseline for considering enhancement
significance (5.0, gray) shown with the thin black dotted line. Data points above the threshold for
consideration are labeled with the specific hGOAT alanine variant and mutated substrate.
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4.3 Discussion and Conclusions
Uncovering GOAT’s substrate binding site and mechanistic identification of protein
acylation remains a difficult challenge notwithstanding successes in experimentally
determination of GOAT topology and the recent report of a computational structural model for
GOAT.12, 14 Addressing this challenge, previous studies have applied structure−activity
examination to determine components within ghrelin and acyl-donor substrates of hGOAT that
are important for enzyme recognition. These studies provided the first molecular-level
understanding of the chemical properties that hGOAT recognizes in the ghrelin GSSF target
sequence.5-6, 15 Defining the interactions between hGOAT and ghrelin used to bind and recognize
this peptide hormone will provide insight into the structure of the hGOAT active site and
substrate binding sites. In this work, we applied mutational analysis of hGOAT to determine
potential residues involved in ghrelin octanoylation activity. Cross mutation analysis of hGOAT
variants and mutated peptide substrates has revealed a number of residues within the human
isoform of GOAT that specifically impacted the reactivity of mutated ghrelin peptide substrate,
providing functional linkages between amino acids in ghrelin and hGOAT.
Among these functionally linked residues, we investigated the partial rescue produced by
the interaction of the N-terminal glycine in the GSSFL sequence of ghrelin and GOAT residues
S300 and F348. In this study, the alanine mutation introduced in the context of the ASSFLC
peptide substrate exhibited partially enhancement in reactivity with the S300A and F348A
hGOAT variants. The ability of these alanine mutations within hGOAT to alter substrate
specificity suggest that the insertion of a slightly larger residue than Gly in the substrate was
functionally complemented by the space created upon alanine mutation of the S300 or F348
residues. The specific enhancement of reactivity upon incorporation of the methyl group at the α-
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carbon in the ASSFLC substrate suggests that the N-terminal glycine of ghrelin contacts residues
S300 and F438 within hGOAT.
For the second serine in the ghrelin sequence (S2), we observed functional linkages of
amino acids S179 and F384 with the mutated peptide substrates GVSFLC and GFSFL sequence,
respectively. S179A exhibited the strongest enhancement effect in our analysis when ghrelin
peptide was mutated to GVSFLC. The elimination of the -OH group on GOAT potentially
provided space for valine’s aliphatic group to be accommodated within the alanine-altered
enzyme. This result, which indicates contact between S179 and the S2 residue in ghrelin, is
intriguing in that the side chain hydroxyl of S179 could also interact with S2 via hydrogen
bonding to its hydroxyl group, consistent with previous studies implicating such a contact in
ghrelin recognition by hGOAT.6 The GOAT residue F348 also generated an enhancement with
the S2 modified-substrate with a phenylalanine in place of S2 (GFSFLC). The F348A variant
also provided reactivity enhancement activity with mutations at the G1 position as discussed
above, further linking the F348 residue to the ghrelin substrate-binding site within GOAT.
Mutation of the fourth amino acid (F4) in the ghrelin sequence led to several different
signals corresponding to interactions with hGOAT residues. Two enhancements were observed
from hGOAT alanine variants Y255A and F302A with the substrate containing a modification
on ghrelin’s F4 residue to the non‐natural Phe‐derivative amino acid, cyclohexylalanine (Cha),
bearing a saturated alkyl 6‐member ring (GSS[Cha]LC). These results establish the interaction
of residue Y255 and F302 with the ghrelin substrate at the F4 position probably by aromaticaromatic interactions. Similarly, S300A hGOAT variant showed reactivity enhancement rescued
by a peptide substrate that incorporating a bigger tryptophan (GSSWLC) residue at the fourth
position of the GSSFLC ghrelin sequence. This rescue of activity presents an essential amino
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acid near the substrate-binding site of hGOAT that has been rescued by filling the space
available after an alanine mutation in the enzyme.
Analyzing losses of reactivity induced by alanine hGOAT variants, we observed a
significant loss of hGOAT reactivity signal with F348A hGOAT variant and (F4)
cyclohexylalanine (Cha)-ghrelin peptide (GSS[Cha]LC). Previous studies have demonstrated
that hGOAT is tolerant to large side chains mutations of F4 in ghrelin substrate, 6 which is not in
accordance with the loss of activity observed here by the addition of bulky group at this F4 site.
Yet, F348A variant did show enhancement of activity (Figure 4.5) with ghrelin mutations at
positions G1 and S2 in the sequence. Therefore, we suggest that the GOAT residue F348 is
possibly interacting with the end N-terminal sequence of ghrelin predominantly, rather than
interacting with farther amino acids like F4. Similarly, interaction of (S2) peptide GFSFLC and
Y255A variants resulted in a loss on reactivity, indicating no interaction at this position. Finally,
the F302A variant demonstrated two loses of rescue reactivity with peptide (S2)-GWSFLC and
(F4) peptide substrate GSSCLS, exhibiting no ability to accommodate the mutations. Combining
these enhancement and loss of reactivity analyses together, we can generate a schematic
illustrating the arrangement and nature of interactions between the hGOAT active site and its
ghrelin substrate as depicted in Table 4.3 and Figure 4.7.
To gain a three-dimensional perspective of the arrangement of the residues implicated in
the ghrelin binding site by these studies, we considered the position of these residues in our
GOAT structural model. The residues whose mutation to alanine produced strong enhancement
of activity with mutated substrates lie in or near the internal channel in our hGOAT model, as
shown in Figure 4.8. The location of these residues within the channel support this region as a
potential substrate-binding site for ghrelin within hGOAT. The linkages identified in this work
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provide new constraints between hGOAT and ghrelin for refinement of the hGOAT structural
model and will enable the development of further models of the hGOAT-ghrelin complex. This
approach has proven robust in the prediction of the octanoyl-CoA substrate binding site as
demonstrated in our published studies.12
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Table 4.3. Summary of specific enhancements and losses of reactivity identified through
analysis of hGOAT variant-mutated ghrelin substrate pairs.

Ghrelin Sequence: G1 S2 S3 F4
Enhancement Reactivity

Loss Reactivity

GOAT Residue Ghrelin site
S300
G1
F348
G1
S179
S2
F348
S2
Y255
F4
S300
F4
F302
F4

GOAT Residue
Y255
F302
F302
F348

Ghrelin site
S2
S2
F4
F4
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Figure 4.7. Proposed interactions between enzyme and substrate residues in the ghrelinbinding site within hGOAT. Proposed interactions between hGOAT residues and specific
amino acids in the ghrelin N-terminal sequence are denoted as dashed lines.
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Figure 4.8. Illustration of proposed ghrelin contacting residues within the hGOAT
structural model contacting the internal enzyme channel. Amino acid residues (color code
defined in table) that whose alanine variants exhibited specific enhancement of reactivity with
mutated peptide substrates at specific ghrelin sites.
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4.4 Experimental Methods
4.4.1 General Methods
Data plotting and curve fitting were carried out with Kaleidagraph (Synergy Software,
Reading, PA, USA). Octanoyl coenzyme A (octanoyl-CoA) was solubilized to 3 mM in 10 mM
Tris-HCl (pH 7.0), aliquoted into low-adhesion microcentrifuge tubes, and stored at −80 °C.
Methoxy arachidonyl fluorophosphonate (MAFP) was purchased from Cayman Chemical (Ann
Arbor, MI) and solubilized with dimethyl sulfoxide (DMSO). Unlabeled peptide GSSFLCNH2
was synthesized by Sigma-Genosys (The Woodlands, TX), solubilized in 1:1 acetonitrile:H2O,
and stored at -80 °C. The ghrelin-mimetic peptides with substitutions at the S2, S3, and F4
position were synthesized by Pepmic (Suzhou, China) and purified to >90% purity by HPLC,
with peptide mass verified by mass spectrometry. Peptides were solubilized in a 1:1 mixture of
acetonitrile/H2O and stored at −80 °C. Peptide concentrations were determined by reaction of
the cysteine thiol with 5,5’-dithiobis(2- nitrobenzoic acid) and absorbance at 412 nm, using ε412 =
14,150 M–1 cm–1.16

4.4.2 Peptide substrate fluorescent labeling
Peptide substrates used in this hGOAT acylation assay contain a cysteine mutation in the
desired site to allow chemoselective attachment of an acrylodan fluorophore using our previously
reported protocols.7, 17 Acrylodan-labeled peptides were purified by semipreparative reverse
phase HPLC (Zorbax Eclipse XDB column, 9.4 x 250 mm) using a gradient mobile phase of
30%-100% acetonitrile in aqueous 0.05 % trifluoroacetic acid (TFA) over 30.2 minutes, at a flow
rate of 4.2 mL/min. Labeled peptide elution was detected by absorbance at 360 nm, and collected
fractions containing the labeled peptides were dried under vacuum at room temperature and

138

resuspended in 1:1 H2O: acetonitrile. GSSFLCNH2 labeling was confirmed by MALDI-TOF mass
spectrometry (Bruker Autoflex III) using a matrix containing sinapinic acid in 0.1 % TFA and 50
mM ammonium phosphate. The concentration of acrylodan labeled peptide was calculated using
absorbance of acrylodan at 360 nm (ε= 13,300 M-1cm-1) per previous reports.7, 18

4.4.3 Construction of plasmids encoding wild type hGOAT and hGOAT alanine variants
A gene encoding hGOAT with a C-terminal triple tag (FLAG, HA, His6) was cloned into
the pFastBacDual vector (Invitrogen) using EcoRI and XbaI restriction sites, with the resulting
vector used to produce the baculovirus expression system protocol (Invitrogen) as described
previously (Chapter 2.4.6, table 3.1).7 PCR primers for site-directed mutagenesis are described in
chapter 2.4.6. PCR mutagenesis reactions (50 μL total volume) contained the following
components: 10x Pfu reaction buffer (5 μL), template plasmid DNA (10 ng), forward primer
(125 ng), reverse primer (125 ng), dNTPs (1 μL, 1 mM stock), and Pfu Turbo DNA polymerase
(1 μL, Agilent). The thermocycler program for PCR mutagenesis proceeded as follows: initial
denaturation (95 °C, 1 min); 18 cycles of denaturation (95 °C, 50 sec); annealing (60 °C, 50 sec);
extension (68 °C, 12 min); and final extension (68 °C, 12 min). Reaction were digested with
DpnI (New England BioLabs, R0176S, 10 units) at 37 °C for 2 hours. After DpnI digestion, the
PCR reaction mixture (5 μL) was transformed into a 100 L aliquot of chemically competent Zcompetent DH5 cells (Zymo Research) followed by incubation on ice for 30 minutes.
Transformed bacteria were spread on LB-ampicillin plates (100 μg/mL) and incubated at 37 C
overnight. Following overnight incubation at 37 °C, single colonies were inoculated into LB
media (5 mL) containing ampicillin (100 μg/mL) in sterile culture tubes. These cultures were
incubated overnight at 37 C with shaking (225 rpm). Following overnight growth, plasmids
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were purified from the saturated cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic
Inc.) per manufacturer’s instructions. Single site mutations were verified by DNA sequencing
(Genewiz).

4.4.4 Expression and enrichment of hGOAT in membrane protein fraction
Sf9 insect cells (5.0 x 108 cells in a 500 mL total culture volume) were infected with
hGOAT baculovirus at a multiplicity of infection of 10 followed by protein expression for 40 hr
at 28 °C shaking 150 rpm described in previously published procedures. 6-7, 19

4.4.5 Membrane fraction enrichment
Sf9 insect cell expression cultures were transferred to 50 mL conical tubes and harvested
by centrifugation (500 xg, 5 min, 4°C); the resulting supernatant was discarded. The cell pellet
was resuspended in 2.5 mL lysis buffer (50 mM Tris-HCl pH 7.0, 150 mM sodium chloride
(NaCl), 1 mM sodium ethylenediamine (NaEDTA), 1 mM dithiothreitol (DTT), 0.01 μg/mL
pepstatin A, 10 μM bis (4-nitrophenyl) phosphate, and 1 mini Roche protease inhibitor cocktail
tablet/10 mL). The cells were then lysed with a 7 mL dounce homogenizer on ice, using 20
strokes with a small pestle and 20 strokes with a large pestle. Intact cells and cell debris were
removed by centrifugation (3000 x g, 10 min, 4°C). The supernatant was transferred to a pretared ultracentrifuge tube and the membrane fraction was isolated by centrifugation (100,000 x g,
1 hour, 4°C). The resulting supernatant was discarded, and the pellet was solubilized in 50 mM
HEPES (pH 7.0) to reach 4 μL/mg of microsomal pellet. Membrane fraction suspensions are
distributed into 80 μL aliquots in low-adhesion tubes and stored at -80°C. 7
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4.4.6 GOAT acylation activity assay
Membrane fractions from Sf9 cells expressing hGOAT mutants and wildtype were
thawed on ice and passed through an 18-gauge needle ten times. Membrane fractions were then
added to reaction mixtures. Assays were performed with 50 μg concentrations of membrane
protein, 1.5 μM fluorescent peptide substrate, 3 mM octanoyl-CoA, 1 mM MAFP, and 50 μM
HEPES pH 7.0 in a total volume of 50 μL and then incubated at room temperature for 30 min.
Reactions were initiated by addition of 1.5 μM fluorescent peptide substrate and 300 μM
octanoyl-CoA, then incubated at room temperature for 2 hours in the dark. Reactions were
stopped with 50 μL of 20% acetic acid in isopropanol. The solutions were clarified by protein
precipitation with 16.7 μL of 20% trichloroacetic acid, followed by centrifugation (1,000 x g, 2
min). The resulting supernatant was then analyzed by reverse phase HPLC.

4.4.7 HPLC analysis of hGOAT octanoylation reactions
hGOAT assay samples were analyzed on an Agilent 1260 HPLC with a C18 reverse
phase HPLC column (Zorbax Eclipse XDB, 4.6 x 150 mm) using a gradient of 30% acetonitrile
in 0.05 % TFA in upH2O to 100 % acetonitrile over 30.2 minutes. Fluorescent peptides were
detected by UV absorbance at 360 nm and fluorescence (ex 360 nm, em 485 nm), with the
peptide substrate eluting with a retention time of 6 minutes and the octanoylated peptide eluting
with a retention time around 12 minutes. Chromatogram analysis and peak integration was
performed using Chemstation for LC (Agilent Technologies).7 Product conversion was
calculated by dividing the integrated fluorescence for the product peak by the total integrated
peptide fluorescence (substrate and product) in each run. Percent activity for each hGOAT
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mutant was calculated by normalizing the product conversion for the mutant to that of wild type
hGOAT in a reaction run in parallel on the same day using the same reagents.
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Chapter 5: Remarkable ligand specificity for ghrelin Oacyltransferase reveals unexpected enzyme interaction with
extracellular peptides
The work presented in this chapter is unpublished.
Syntheses of all ligand peptides were completed by collaborator Marina Childs
from the Luyt Laboratory (University of Western Ontario). Similarly, Marina
Childs performed all GHS-R1a receptor-binding assays described here.
Immunofluorescence imaging was performed with help of Erin Curtis (Hehnly
Laboratory, Syracuse University). During these cell-imaging studies, we consulted
Professor Heidi Hehnly for guidance in improving image quality and cell labeling
protocols.
In this chapter, there was also an experimental contribution from Yasandra
Morales (Syracuse University undergraduate researcher) who assisted with
hGOAT receptor-binding assays and IC50 calculations.
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5.1 Introduction
The regulation of hunger is controlled by many signals released in the bloodstream in the
form of free fatty acids, glucose, and hormones.1-2 Ghrelin, the appetite stimulant hormone,
regulates feeding-associated behaviors affecting energy homeostasis and fat storage while
stimulating appetite and food intake.3-5 Research in the last decade has shown that ghrelin plays
additional regulatory roles, with studies linking this peptide hormone to addictive behaviors
through impact on reward processing within the brain.6-7 Other studies associated ghrelin with
stress-related mechanisms, which affect psychological responses to prolonged exposure to
stressors.8-10 Moreover, ghrelin is involved in neuroprotection11 as well as memory and learning
processes.12, 13
Ghrelin is a 28 amino acid peptide mainly released in the stomach14 but has also been
found in other tissues like small intestine, pancreas, kidney, pituitary, ovaries, and
lymphocytes.15-16 In the bloodstream, ghrelin exists in two forms: the acylated ghrelin with an
uncommon eight-carbon fatty acid octanoate (C8:0) covalently linked to its third N-terminal
serine and des-acylated ghrelin.17 Ghrelin is the only known peptide that undergoes this noctanoylation modification and it is required for binding to its endogenous receptor, growth
hormone secretagogue receptor type 1 (GSH-R1a).16
The human GHS-R1 gene encodes for the seven transmembrane domain G-protein
coupled protein (GHS-R1a), which functions in regulation of pituitary growth hormone
release.18-19 GHS-R mRNA expressions revealed that the receptor type 1a is found in the
pituitary region, brain, thyroid gland, pancreas, spleen, myocardium, and adrenal gland.18, 20-21
Remarkably, higher levels of expression for this receptor have been identified in unhealthy
tissues and tumors like prostate cancer,22 testicular and ovarian tumors,23-24 breast carcinomas,25
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neuroendocrine tumors,26-27 among others.28 Expression of ghrelin and the GHS receptor shows
to be widely distributed throughout the body, representing a potential functional role of ghrelin
and its receptor in hormone-dependent cancers. Moreover, the specific interaction of ghrelin with
the receptor creates a valuable imaging probe for tissues in which GH-R1a is highly expressed.
Previous studies have developed ligands for GHS-R1a imaging as diagnostics using ghrelin
analogs for in vivo imaging for heart tissues,29 prostatic neoplasms,30 and ovarian carcinomas.31
Novel ghrelin probes specific to prostate cancer (PCa) cells with no association of normal
prostate tissue were developed with high receptor affinity.30 Moreover, a truncated fluorescently
labeled ghrelin was generated for probing of biopsies and distribution analysis of ovarian cells,
with higher specificity and sensitivity compared to immunohistochemical approaches.31
To bind and activate the GHS-R1a receptor, ghrelin requires the acylation modification
of its third serine (Ser3) by an octanoyl (C8) fatty acid group.17, 32 Des-acyl ghrelin or other
ghrelin-related peptide such as obestatin, do not interact nor stimulate the GHSR1a receptor. The
enzyme that catalyzes this acylation, ghrelin O-acyltransferase (GOAT)33-34, is the only known
enzyme to modify ghrelin in the human proteome.35 GOAT is mainly expressed in the stomach
and pancreas, but also in a numerous other tissues, including breast and prostate tissues.36-37
Moreover, studies have detected GOAT overexpression in some tumor and cancer tissues like
breast,36 pituitary, and endocrine tissues.38-39 Similarly, overexpression of GOAT was observed
in prostatic cancer tissues and plasma/urine samples of PCa patients compared to healthy
samples.37, 40-41 Additionally, detection studies of GOAT in circulation suggest that PCa cells can
produce extracellular vesicles (EVs) encompassing integral membrane GOAT, which can be
used as an attractive biomarker in cancer patients that frequently present increased numbers of
circulating EVs.42-43 While canonical localization of GOAT has been recognized to the
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endoplasmic reticulum ER,44 recent studies proposed GOAT expression and exposure to
extracellular space through plasma membrane localization.45-46 Similar to the GHS-R1a receptor,
GOAT possesses a potential target for imaging and diagnosis by exploiting the specificity of
binding of ghrelin peptide to GOAT. While displaying high potency, peptide analogs for GOAT
have pharmacologic challenges for in vivo applications due to their low ability to enter cell
membranes and they can also act as potent agonists of the GHS-R1a receptor.
The goal of this work was to develop potent, specific, and biostable peptide ligands to
enable GOAT detection by developing ghrelin-mimetic hGOAT inhibitors with no distinctive
ability to have an agonist effect via binding the ghrelin receptor. We have optimized the
synthetic peptide binding to hGOAT through sequence mutagenesis and chemical modification
with a lead compound that demostrated high GOAT binding. We have constructed ligands for
the detection of hGOAT in biological samples using a range of detection / imaging modalities.

5.2. Results and Discussion
5.2.1 Design of Dap-based ghrelin peptide ligand to bind GHS-R1a and hGOAT
The high affinity and specificity of ghrelin binding to the GHS-R1a receptor creates a
significant tool for the development of ghrelin imaging agents targeting this receptor. Previous
studies had developed a high affinity fluorine-containing ghrelin (1–8) analogue capable of
binding this receptor.47-48 Similarly, GOAT participation in ghrelin activation creates a useful
target for controlling ghrelin signaling and binding for the development of imaging agents;
however, inhibitor GOAT design has been challenging due to the lack of information regarding
the enzyme active site and substrate binding sites. There have been GOAT inhibitors reported
that mimic acylated ghrelin peptide, with the first study describing a pentapeptide mimetic with
an amidated C-terminal.49 The same study designed a potent ghrelin (1-5) peptide inhibitor with
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a [Dap] ((S)-2,3-diaminopropionic acid), creating an octanoyl-amide that replaced the ester
linkage of the acyl group.49 This modification significantly increased peptide stability and
potency for binding to GOAT. Compilation of these results has guided our development of a 6mer (1-6) and 8-mer (1-8) derived human ghrelin-bearing peptides, with a Dap moiety to
generate imaging agents that can target GOAT overexpressing cells. Table 5.1 demonstrates how
the potency of Dap peptides changes minimally (1.4-fold less potent) from 6-mer to 8-mer
peptide comparing compounds 1 and 2 against GOAT. Binding of Dap peptides 1 and 2 to the
GHS-R1a receptor was not detected, demonstrating important interactions of the Dap moiety
with GOAT. The development of an 8-mer peptide allows direct comparison against ligands with
proven affinity for GHS-R1a receptor47, like the fluorine-bearing aromatic group of ghrelin (1-8)
developed previously with very strong affinity to the GHS-R1a receptor (compound 4). By
eliminating the 6-fluoro-2-pentafluorophenyl naphthoate (PFPN) prosthetic group at the serine 3
position of GHS-R1a ligand 4, loss of affinity to the receptor was obtained while improving
GOAT binding (compound 3). Similarly, structure activity analysis of the acyl group length at
the serine 3 of ghrelin has demonstrated that octanoyl chain and large lipophilic groups
contributes strongly to GOAT binding.35 Nevertheless, the addition of a C8 group to the amine in
the octanoylated peptide (compound 3), restored binding to GHS-R1a and GOAT with similar
potency.
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Table 5.1. Acyl changes within ghrelin peptide sequence. Substitutions of the acyl group with
various Dap-bearing moieties affect GOAT and receptor binding.

Compound
No.
1
2
3
4

Peptide Sequence
H-GS-Dap-FLS-NH2
H-GS-Dap-FLSPY-NH2
H-GS-(C8-Dap)-FLSPY-NH2
H-GS-(6FN-Dap)-FLSPY-NH2

IC50 against
GHSR-1a
>100 μM
>100 μM
65 nM
9.9 nM

IC50 against
GOAT
74 ± 7 nM
104 ± 43 nM
64 ± 21 nM
>100 μM

LCE
identifier
Hougland lab
LCE00496
LCE00495
LCE00491
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5.2.2. Changes at the N-terminal amino acid (G1) and hGOAT recognition
GOAT recognizes the first four amino acids in the N-terminal motif of the native ghrelin
peptide, near the site of octanoylation at serine 3. In a previous study, these four amino acids
were shown to comprise the substrate recognition motif required for octanoylation by GOAT.49
Particularly, structure-activity analysis of ghrelin-mimetic peptides has showed the importance
of the N-terminal glycine,35, 49-50 where amino acid mutations entirely abolished peptide acylation
by GOAT. To investigate importance of the first amino acid (G1) in our developed Dap peptides,
the N-terminal glycine was replaced with two unnatural amino acids: aminoisobutyric acid (Aib)
and isonipecotic acid (Inp). As shown in Table 5.2, incorporation of either Aib or Inp at the Nterminus (compound 5 and 6) had a pronounced negative effect in peptide binding to GOAT
when compared to ghrelin (1-8) [Dap]-mimetic (compound 2) that is consistent with previous
SAR studies of G1 recognition.35, 49, 51 Conversely, GHS-R1a tolerated replacement of G1 with
2-aminoisobutyric acid and isonipecotic acid as shown in previous work,47 where compound 7
and 8 containing the PFPN prosthetic group for receptor binding demonstrated strong affinity
towards GHS-R1a with no observable binding to the GOAT enzyme (Table 5.2). These results
confirmed GOAT specificity towards G1, with possible substrate interactions occurring at the Nterminal site of our ghrelin Dap ligand that can be exploited to increase specificity for GOAT
binding.
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Table 5.2. G1 modifications within ghrelin peptide sequence. Modifications of the N-terminal
glycine of ghrelin eliminates hGOAT recognition.
Compound
No.
2
5
6
7
8

Peptide Sequence
H-GS-Dap-FLSPY-NH2
H-Aib-S-Dap-FLSPY-NH2
H-Inp-S-Dap-FLSPY-NH2
H-Aib-S-(6FN-Dap)-FLSPY-NH2
H-Inp-S-(6FN-Dap)-FLSPY-NH2

IC50 against IC50 against
LCE
GHSR-1a
GOAT
identifier
>100 μM
104 ± 43 nM
LCE00496
>100 μM
>100 μM
LCE00498
>100 μM
>100 μM
LCE00497
9.2 nM
ND
9.6 nM
ND
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5.2.3. Changes at E8
Previous alanine scanning investigation of a (1–14) ghrelin peptide with the recombinant
human ghrelin receptor demonstrated that mutating native glutamic acid at position 8 to alanine
resulted into the most potent ghrelin analogue against the GHS-R1a receptor.52 To investigate the
effect in binding to GOAT at position 8 of the native ghrelin sequence (GSSFLSPE), ghrelin (18) with a C8-Dap moiety peptide was modified with hydrophobic amino acid: tyrosine (Y) and
polar uncharged amino acids: asparagine (N) and threonine (T). As shown in Table 5.3, the
native sequence bearing glutamic acid (E) at position 8 (compound 9) demonstrated high affinity
to the receptor and GOAT comparably. An E8T mutation (compound 11) increased binding
potency to both GOAT and receptor. Likewise, E8Y and E8N mutations improved binding
affinity to GOAT compared to the native peptide; however, all these mutations also improved
binding to the GHSR-1a receptor. These findings suggested that the negative charge of E amino
acid is detrimental towards ghrelin binding to both GOAT and GHS-R1a, with a polar uncharged
side chain appearing optimal for stronger receptor and GOAT binding.
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Table 5.3. E8 modifications within ghrelin sequence. Substitution of residue 8 in the ghrelin
peptide shown to increase affinity to GOAT enzyme when threonine replaced the natural
occurring glutamic acid.
Compound
No.
3
9
10
11

Peptide Sequence
H-GS-(C8-Dap)-FLSPY-NH2
H-GS-(C8-Dap)-FLSPE-NH2
H-GS-(C8-Dap)-FLSPN-NH2
H-GS-(C8-Dap)-FLSPT-NH2

IC50 against
GHSR-1a
65 nM
200 nM
31.9 nM
3.3 nM

IC50 against
GOAT
64 ± 21 nM
580 ± 60 nM
59 ± 6nM
27 ± 8 nM

LCE
identifier
LCE00495
LCE00488
LCE00489
LCE00490

155

5.2.4. Changes at F4
Alanine or tyrosine modifications of phenylalanine at the 4 position (F4) in ghrelin have
led to a decrease GHS-R1a binding affinity, illustrating the importance of phenylalanine at
residue 4 for interaction with the receptor.47, 52-53 Preceding investigation of GOAT tolerance for
mutations at residue 4 has identified a preference for a large hydrophobic/aromatic amino acid at
the F4 position in ghrelin.35, 51 In this study, we explored the effects of larger and more
hydrophobic side chains modifications at this position on binding of our Dap ligand to hGOAT.
As shown in Table 5.4, substitution with 1-naphylalanine (Nal1) (compound 12) or 2naphylalanine (Nal2) of the phenylalanine in the ghrelin sequence (compound 13) increases
binding to GOAT when compared to our previously described compound 2. Nal1 provides a 7fold increase in binding compared to F amino acid chain at position 4 (adjusted for 2.4 fold effect
from Y-> T at E8). Binding of compounds 12 and 13 to the receptor was undetectable, likely due
to the lack of a hydrophobic group at the acylation site on the Dap residue. These results further
demonstrate a strong interaction of F4 aromatic groups with GOAT and show this interaction can
be exploited to create more potent GOAT ligands (Table 5.5).
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Table 5.4. Ghrelin sequence changes at F4. GOAT enzyme indicates strong affinity to large
hydrophobic/aromatic amino acid groups at F4 position of ghrelin Dap analogue.

Compound
No.
2
12
13

Peptide Sequence
H-GS-Dap-FLSPY-NH2
H-GS-Dap-Nal1-LSPT-NH2
H-GS-Dap-Nal2-LSPT-NH2

IC50 against
GHSR-1a
>100 μM
>100 μM
>100 μM

IC50 against
GOAT
104 ± 43 nM
6 ± 1 nM
16 ± 5 nM

LCE
identifier
LCE00496
LCE00500
LCE00501
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Table 5.5. Summary of ligands devised for GOAT binding. Ghrelin-derived peptide ligand
binding to GHS-R1a and hGOAT
Compound
No.

Peptide Sequence

IC50 against
GHSR-1a

IC50 against
GOAT

1

H-GS-Dap-FLS-NH2

>100 μM

74 ± 7 nM

2
3
4
5
6
7
8
9
10
11
12
13
14

H-GS-Dap-FLSPY-NH2
H-GS(C8-Dap)-FLSPY-NH2
H-GS(6FN-Dap)-FLSPY-NH2
H-Aib-S-Dap-FLSPY-NH2
H-Inp-S-Dap-FLSPY-NH2
H-Aib-S-(6FN-Dap)-FLSPY-NH2
H-Inp-S-(6FN-Dap)-FLSPY-NH2
H-GS(C8-Dap)-FLSPE-NH2
H-GS(C8-Dap)-FLSPN-NH2
H-GS(C8-Dap)-FLSPT-NH2
H-GS-Dap-Nal1-LSPT-NH2
H-GS-Dap-Nal2-LSPT-NH2
H-Inp-S(6FN-Dap)-1Nal-LSPT-NH2

>100 μM
65 nM
9.9 nM
>100 μM
>100 μM
9.2 nM
9.6 nM
200 nM
31.9 nM
3.3 nM
>100 μM
>100 μM
0.11 nM

104 ± 43 nM
64 ± 21 nM
>100 μM
>100 μM
>100 μM
ND
ND
580 ± 60 nM
59 ± 6nM
27 ± 8 nM
6 ± 1 nM
16 ± 5 nM
>100 μM

LCE
identifier
Hougland
Lab
LCE00496
LCE00495
LCE00491
LCE00498
LCE00497

LCE00488
LCE00489
LCE00490
LCE00500
LCE00501
LCE00492
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5.2.5. Design of GHS-R1a and hGOAT-selective ligands
Towards the design of a specific GOAT recognizing ghrelin ligand, we have explored the
chemo- and stereoselectivity of ghrelin recognition. By comparative binding studies, we
identified key interactions for ligand selectivity for either GOAT or GHS-R1a binding and
designed GOAT-specific peptide ligands such as compound 12 (Figure 5.1 and Table 5.5).
Combining the most successful substitutions resulted in a lead peptide analogue with two
chemical changes engendering ligand-binding orthogonally for hGOAT and GHS-R1a. First,
compound 12 bearing a 2,3-diaminopropanoic acid (Dap) group at the site equivalent to serine 3
and coupled with Nal-1 at phenylalanine at position 4 demonstrated preferential binding towards
GOAT compared to the receptor. Compound 14 containing an acyl fluoronapthyl substitution
shows strong binding to the receptor without detectable interaction with GOAT when assayed as
an inhibitor. Second, substitutions at G1 exploited the discriminatory effect GOAT has towards
alterations in this N-terminal amino acid compared to GHS-R1a, which is more tolerant to
unnatural amino acid incorporation at this site (Figure 5.1). Finally, having a non-native
threonine at position 8 of the ghrelin peptide sequence increased binding to both the receptor and
GOAT. The developing of these selective peptide ligands resulted in a very potent and selective
nanomolar inhibitor for GOAT (12), providing a peptide-based platform for creating GOAT
detection and imaging agents.
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a)

b)
Most orthogonal
Compound
Peptide Sequence
No.

IC50 against
GHSR-1a

IC50 against
GOAT

LCE
identifier

12

H-GS-Dap-Nal1-LSPT-NH2

>100 μM

6 ± 1 nM

LCE00500

14

H-Inp-S-(6FN-Dap)-1Nal-LSPT-NH2

0.11 nM

>100 μM

LCE00492

Figure 5.1. Orthogonal GHS-R1a and hGOAT selective ligands with associated IC50
demonstrate a discriminatory binding effect towards modifications. a) Structure of potent
ligands, showing key interactions at G1 and F4 positions in ghrelin mimetic ligand 14 that favor
binding towards GOAT enzyme versus the ghrelin receptor (purple dotted circle) in ligand 12. b)
Peptide sequence and IC50 of compounds 12 and 14 against GHSR-1a and hGOAT.
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5.2.6. Creation of fluorescent high-affinity selective GOAT ligand
Combining the most successful substitutions in these studies has generated a pair of
selective ligands for GOAT and the GHS-R1a with nanomolar affinity (Figure 5.1). Each of
these ligands exhibits >15,000-fold selectivity for its target over the other ghrelin-binding
protein. To fluorescently label our most potent GOAT ligand (14), we synthesized a far-red
ghrelin analog [(Dap), Lys9 (Cy5)]-ghrelin (1-9) (compound 15) containing a lysine at position 9
for fluorophore attachment (Figure 5.2a). Earlier studies of labeled Cy5-ghrelin (1–19) has
demonstrated strong binding to the GHS-R1a, with less susceptibility to photobleaching and high
detection of GHS-R expression in live differentiating cardiomyocytes.54 We characterized the
binding of our Cy5-ghrelin ligand to GOAT using our established hGOAT inhibitor assay
(described in Experimental Methods section). The Cy5-labeled ligand exhibited nanomolar
inhibition for hGOAT (Figure. 5.2b), supporting our ability to functionalize GOAT peptide
ligands without losing binding to GOAT compared to the unlabeled ghrelin ligand (14).
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b)

% hGOAT activity
(Normalized to vehicle)

a)

Ligand 15

[Ligand 15] (nM)

Figure 5.2. Fluorescent ligand designed for potent specific binding to hGOAT. a) Structure
of H-GS-Dap-Nal1-LSPTK (SulfoCy5) (ligand 15) containing far-red fluorophore Cy5 added to
position 9 lysine in the ghrelin peptide sequence. b) hGOAT inhibition plot with IC50 = 17 +/- 2
nM by fluorescently labeled derived ligand 15. All reported IC50 values represent the average of
three independent trials.
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5.2.7. Analyzing interaction of GOAT ligand 15 with cells expressing hGOAT
To demonstrate the interaction between ligand 15 and hGOAT in a biologically relevant
cellular setting, we characterized the binding of the Cy5-ghrelin compound to hGOAT with an in
vitro assay using fluorescence signal of HEK 293 cells transiently transfected with either FLAGtagged hGOAT construct or empty vector. Following live cell incubation with the fluorescent
ligand 15, cells were washed, fixed, and decorated with antibodies against FLAG. Using
spinning-disk confocal microscopy, cells expressing FLAG-hGOAT showed robust far-red
fluorescence when incubated with Cy5-ghrelin compound (Figure 5.3a, Table 5.6). Control cells
transfected with empty vector excluded compound 15, showing no far-red fluorescence at the
determined wavelength, consistent with GOAT expression being required for ligand binding and
cellular uptake. In contrast, cells transfected with empty vector demonstrating that this peptide is
not intrinsically cell permeable or nonspecifically associating with cellular membranes.
To explore ligand-enzyme interactions required for binding and cellular uptake, we have
introduced three alanine mutations to functionally essential amino acids (Figure 5.3b). These
three mutations previously have all resulted in complete loss of hGOAT enzyme activity, but
through impact on different aspects of the hGOAT catalytic cycle.55 We altered histidine 338,
which is an absolutely conserved histidine in MBOAT family members and is proposed to serve
as a general base interacting with the serine hydroxyl group.55-56 We propose that the interaction
between the Dap side chain amine and H338 is partially responsible for the tight binding
observed for Dap-containing peptide ligands to hGOAT. In contrast, both arginine 304 and
asparagine 307 form interactions within the octanoyl-CoA acyl donor-binding site, which would
not directly impact ghrelin-mimetic peptide binding to hGOAT (Figure 5 and Table 5.6).
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The H338A hGOAT variant did not maintain cell uptake of ligand 15 when expressed in
HEK293 cells, supporting that an interaction between the Dap amino group and H338 is required
for tight ligand binding. In contrast to the H338A variant, both R304A and N307A variants
supported ligand 15 internalization as expected for mutations predicted to compromise the
octanoyl-CoA binding pocket but not the ghrelin binding site within the hGOAT catalytic
channel.

164

a)

165

b)

R304

N307

H338

Figure 5.3. Cell imaging and scoring of ligand uptake by transfected HEK293 cells. a)
HEK293 cells were transfected with empty vector or FLAG-tagged hGOAT/ mutant hGOAT as
indicated. At 40 hr post-transfection, cells were incubated with Cy5-ghrelin ligand 15 (Purple)
for 30 min and immunostained with anti-FLAG (Cyan) for GOAT expression detection and
DAPI (Gray) displaying micronuclei within a single cell. Wild type, N307A, and R304A
hGOAT expressing cells showed binding and internalization of Cy5-ligand 15. Empty vector and
H338A hGOAT variants do not support peptide uptake. Scale bar, 10 μm. b) Quantification of
percent hGOAT-positive cells showing uptake of ligand 15 (n =100 cells, over n = 3
experiments) for wild type, R304A, N307A, and H338A hGOAT variants. The locations of R304
(olive green), N307 (forest green), and H338 (orange) are shown within the hGOAT structure.
Dotted lines denote the average percent of each group. One-way ANOVA comparison test
between wild type vs. H338A indicated significance with an adjusted P value < 0.0001 (*).

166

Table 5.6. Cell imaging and scoring for GOAT transfection and ligand 15 uptake.
Trial 1
hGOAT
variant
Wild type
Empty
Vector
H338A
R304A
N307A

Total cells
counted

100

# Cells displaying
hGOAT expression
(anti-FLAG
immunofluorescence)
20

# Cells displaying
ligand 15 uptake
(Cy5
fluorescence)
10

% of hGOATpositive cells
exhibiting ligand
15 uptake
50

100

0

0

N/A

100
100
100

13
26
28

0
6
8

N/A
23
29

Total cells
counted

100

# Cells displaying
hGOAT expression
(anti-FLAG
immunofluorescence)
21

# Cells displaying
ligand 15 uptake
(Cy5
fluorescence)
12

% of hGOATpositive cells
exhibiting ligand
15 uptake
57

100

0

0

N/A

100
100
100

16
28
24

0
10
9

N/A
36
38

Total cells
counted

100

# Cells displaying
hGOAT expression
(anti-FLAG
immunofluorescence)
26

# Cells displaying
ligand 15 uptake
(Cy5
fluorescence)
16

% of hGOATpositive cells
exhibiting ligand
15 uptake
62

100

0

0

N/A

100
100
100

10
21
22

0
8
9

N/A
38
41

(n)

Trial 2
hGOAT
variant
Wild type
Empty
Vector
H338A
R304A
N307A

(n)

Trial 3
hGOAT
variant
Wild type
Empty
Vector
H338A
R304A
N307A

(n)
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5.3. Discussion
Ghrelin and ghrelin receptor agonists have shown connections to main disorders
including anorexia nervosa, cancer cachexia, chronic heart failure, and other related processes.5760

Developing ghrelin-imaging agents could be useful for non-invasive imaging detection of

overexpressing GOAT systems. The two proteins most known for interacting with ghrelin,
GOAT and GHS-R1a, exhibiting both similarities and distinctions in recognition elements within
ghrelin which allows development of specific ligands for each protein. In this work, we have
developed a potent hGOAT ghrelin (1-9) ligand bearing a 2,3-diaminopropanoic acid (Dap)
moiety, which does not exhibit measurable binding to the GHS-R1a receptor. This compound
exploits the strong interaction of F4 aromatic groups to GOAT with a 1-naphylalanine (Nal1)
attached and a threonine mutation at position 8 that increased binding potency. Fluorophore
attachment at distal end of this potent GOAT inhibitor minimally impacted potency, suggesting
this peptide can serve as a platform for further development of GOAT ligands for imaging and
diagnosis.
With this work we have demonstrated compound interaction with GOAT, providing the
first functional connection between the active site of GOAT and ghrelin through the Dap amineH338 interaction. The enhancement in binding to hGOAT upon amine substitution at the
acylation site could be explained by a formation of a ground state hydrogen bond to an enzyme
side chain, which normally serves as a general base for serine acylation as shown in Figure 5.4.
Furthermore, the loss of ligand uptake in the presence of H338A hGOAT expression argues
against general loss of cell membrane integrity as the mechanism for ligand internalization.
Given the integral membrane nature of GOAT,55, 61 we considered it possible that hGOAT
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expression may destabilize or disrupt membrane integrity, which could allow ligand cell
penetration without requiring direct binding to hGOAT.
Originally assigned as an ER-resident enzyme responsible for acylating ghrelin during
hormone maturation prior to secretion,16 this study provides the first direct evidence for GOAT
exposure to the extracellular space and interaction with soluble peptides. This indicates the
presence of a subpopulation of GOAT available on the plasma membrane to interact with ghrelin
and desacyl ghrelin located outside the cell. This is consistent with observations of the presence
of GOAT in intracellular and plasma membranes of lipid trafficking vesicles in the blood
marrow.45 This supports a new branch of ghrelin signaling pathway involving local re-acylation
of desacyl ghrelin by plasma membrane exposed GOAT.62
This localization could also provide a novel mechanism for intracellular drug/cargo
delivery targeting GOAT expressing cells purposely. However, the GOAT ligand internalization
mechanism is still unclear and will be the subject of further study. It is possible that GOAT could
be serving as a pore or transporter to ghrelin mimetic peptides by undergoing a conformational
change involving its continuous internal channel.55 This process presents a new and
unanticipated function for integral membrane acyltransferases and argues for examining the
potential involvement of other integral membrane enzymes currently proposed to perform
exclusively intracellular roles in extracellular interactions, chemistry, and signaling.
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Figure 5.4. Proposed interactions within the GOAT active site of Ser3 with H338 and Dap3
with H338. Strong binding interaction of ligands 14 and 15 ghrelin-mimetic is proposed to arise
from interaction between the amine side chain of the Dap moiety and H338 in GOAT.
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5.4 Experimental Methods
General methods
5.4.1 Peptide synthesis and characterization
Note: Synthesis and characterization of all peptides were performed by collaborator Marina
Childs from the Len Luyt’s Laboratory (University of Western Ontario).
Peptide synthesis was carried out using standard Fmoc solid-phase peptide synthesis on a
Biotage SyroWave automated peptide synthesizer. Peptides were synthesized on a 0.1 mmol
scale using Rink amide MBHA resin (0.39 mmol/g). The resin was initially swelled with
dichloromethane (DCM), followed by Fmoc deprotection using 2 mL of 40% piperidine in N,Ndimethylformamide (DMF) for two cycles (3 min, 12 min). Amino acids were coupled with 4
equiv of Fmoc protected amino acid, 4 equiv. of O-(6-chlorobenzotriazol-1- yl)-N,N,N′,N′tetramethyluronium hexafluorophosphate (HCTU), and 8 equiv of N,Ndiisopropylethylamine
(DIPEA) in N-methylpyrrolidinone (NMP). The mixture was added to the resin and vortexed for
40 min. These cycles were repeated until all amino acids were coupled to the resin.
Allyloxycarbonyl deprotection of diaminopropionic acid was performed manually under
inert atmospheric N2 conditions. DCM was dried over sieves for 24 h before adding 4 mL to the
resin. An amount of 24 equiv of phenylsilane was then added to the peptide resin and shaken
for 5 min. An amount of 0.15 equiv of tetrakis(triphenylphosphine)-palladium(0) was then added
and allowed to react for 10 min. If desired, the resulting free amine was then acylated using 3
equiv of the corresponding acid (octanoic acid or 6-fluoro-2-naphthoic acid), 3 equiv of HCTU,
and 6 equiv of DIPEA in DMF. The reaction mixture was left to couple overnight.
Full deprotection of the synthesized peptide was performed by adding a 2 mL mixture of
95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIS), and 2.5% water to the resin and
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allowing it to mix for 5 h. The cleaved peptide was precipitated from solution using ice-cold
tertbutyl methyl ether (TBME) and centrifuged (3000 rpm, 10 min, 0 ˚C) resulting in a crude
peptide 15 pellet. The supernatant was decanted, and the resulting peptide pellet was dissolved in
20% acetonitrile in water, frozen at -78 °C, and lyophilized to a white crude powder. Purification
was performed using preparative HPLC-MS, and purity of the resulting peptides was analyzed
using analytical HPLC-MS. These results are summarized in Table 5.6, with all compounds
determined to have ≥95% purity.

Table 5.7 Analytical data for peptide ligands
Ligand

Peptide Sequence

[M+H]+
calcd

[M+H]+
found

Purity
(%)

Yield
(%)

2

H-GS-Dap-FLSPY-NH2

855.4365

855.3387

99

36

3

H-GS-(C8-Dap)-FLSPY-NH2

981.5409

981.4415

98

20

4

H-GS-(6FN-Dap)-FLSPY-NH2

1027.4689

1027.54

99

25

5

H-Aib-S-Dap-FLSPY-NH2

883.4678

883.3658

99

26

6

H-Inp-S-Dap-FLSPY-NH2

909.4834

909.4159

99

28

9

H-GS-(C8-Dap)-FLSPE-NH2

947.5202

947.82

96

22

10

H-GS-(C8-Dap)-FLSPN-NH2

932.5205

932.85

99

25

11

H-GS-(C8-Dap)-FLSPT-NH2

919.5253

919.8689

99

24

12

H-GS-Dap-Nal-1-LSPT-NH2

843.4365

843.3524

99

10

13

H-GS-Dap-Nal-2-LSPT-NH2

843.4365

843.3524

98

34

14

H-Inp-S-(6FN-Dap)-Nal-1LSPT-NH2

1069.5159

1069.5227

99

33

15

H-GS-Dap-Nal-1-LSPT(SulfoCy5-K)-NH2

[M+H]2+ =
798.3673

[M+H]2+ =
798.5341

95

7
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5.4.2 GHS-R1a receptor binding assays
Note: All GHS-R1a receptor-binding assays were performed by collaborator Marina Childs
from Len Luyt’s Laboratory (University of Western Ontario).
The affinity for the ghrelin receptor was determined using a radio ligand competitive
binding assay. 47 Assays were performed using GHS-R1a transfected HEK293 cells as receptor
source and human [125I]-ghrelin(1−28) (PerkinElmer Inc. NEX3888010UC) as the radioligand.
Human ghrelin(1−28) was used as reference to ensure the validity of the results. A suspension of
membrane from HEK293/GHS-R1a cells (100,000 cells per assay tube) were incubated with
ghrelin(1−8) peptide analogues (at concentrations of 10−6 M, 10−7 M, 10−8 M, 10−9 M, 10−10 M,
10−11 M and 10−12 M ) and [125I]-ghrelin (15 pM per assay tube) in binding buffer (25 mM
HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA, and 0.4% BSA, pH
7.4). The resulting suspension was incubated for 20 min under shaking (550 rpm) at 37 °C.
Unbound [125I]-ghrelin was removed and the amount of [125I]-ghrelin bound to the membranes
was measured by γ counter. IC50 values were determined by nonlinear regression analysis to fit a
four-parameter dose−response curve using Prism 6 (version 6.0c). All binding assays were
performed in triplicate.

5.4.3. hGOAT inhibition assays
Assays were performed using previously reported protocols.50, 63 For each assay,
membrane fraction from Sf9 cells expressing hGOAT was thawed on ice and homogenized by
passage through an 18-gauge needle 10 times. Assays were performed with 50 μg of membrane
protein, as determined by Bradford assay. Membrane fraction was pre-incubated with 1 mM
methyl arachidonyl fluorophosphonate (MAFP) and unlabeled peptide inhibitor or vehicle as
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indicated in 50 mM HEPES pH 7.0 for 30 minutes at room temperature prior to reaction
initiation64. All reactions were initiated by the addition of 1.5 μM GSSFLCAcDan and 300 μM
octanoyl CoA. Reactions were incubated for 30 minutes at room temperature under foil. All
assays were stopped with the addition of 50 μL of 20% acetic acid in isopropanol, and solutions
were clarified by protein precipitation with 16.7 μL of 20% trichloroacetic acid, followed by
centrifugation (1,000 x g, 2 minute). The supernatant was then analyzed using reverse-phase
HPLC with fluorescence detection as previously described.50, 63 Peak integrations for both
substrate and product peaks were calculated using Chemstation for LC (Agilent Technologies).
Data reported are the average of three independent determinations, with error as standard
deviation.
For determination of IC50 values, the percent activity at each inhibitor concentration was
calculated from HPLC integration data using equations 1 and 2: To determine an IC50 value for a
given inhibitor, the plot of % activity versus [inhibitor] was fit to equation 3, with % activity0
denoting hGOAT activity in the presence of the vehicle alone. All reported IC50 values represent
the average of a minimum of three independent trials.

(1) % activity =

% peptide acylation in presence of inhibitor
% peptide acylation in absence of inhibitor

(2) % peptide octanoylation =

Fluorescence of acylated peptide
Total peptide fluorescence (acylated and non‐acylated)

(3) % activity = % activity0 * (1‐

[inhibitor]
)
[inhibitor] + IC50
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5.4.4. Construction of hGOAT WT and mutants
Note: The pcDNA 3.1 (+) WT hGOAT used in this work was designed by Tasha Davis from
the Hougland Lab (Syracuse University).
Site-directed mutagenesis was performed on pcDNA 3.1 (+) mammalian expression
vector containing a hGOAT insert cloned from our previously reported pFastBacDual vector
(Invitrogen) using the EcoRI and XbaI restriction sites, resulting in pcDNA3.1_Mb4.WT
(hGOAT) construct.50 This construct contains a C-terminal FLAG epitope tag, a polyhistidine
(His6) tag, and 3x human influenza hemagglutinin (HA) tags appended downstream of a TEV
protease site.63

5.4.5 hGOAT (WT and mutants) transfection in HEK293 cells
Mammalian cell line HEK293 (ATCC) was maintained in 75 mL vented tissue culture
flasks (Celltreat) and kept to 70% confluency before splitting. All cells were cultivated in
complete DMEM (Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine
serum (FBS) and 1% (v/v) penicillin-streptomycin (MediaTech)) in a humidified atmosphere
with 5% CO2 at 37°C. For transfection of WT hGOAT, mutant hGOAT, and empty vector (EV)
the cells were plated at a density of 1 × 106 in 2 mL of complete DMEM in a 6-well plate per
well (Corning) with 1.5 glass coverslips 12 mm (Warne Instruments). The cells were incubated
for 16 hours prior transfection. DNA-transfection reagent complex was prepared by incubating 4
ug of the pcDNA3.1_Mb4.WT (hGOAT) or mutant plasmids in 9 μL of lipofectamine 2000
transfection reagent (Invitrogen) for a total volume of 500 μL supplement free DMEM with 30
minutes incubation at room temperature. The cells were then transfected with the prepared DNAtransfection reagent complex by drop wise addition into the wells of the plate wells.
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5.4.6. GOAT ligand labeling and immunofluorescence imaging
Note: This immunoblotting procedure was adapted from Dr. Heidi Hehnly Laboratory,
Syracuse University.
Following transfection for 40 hrs, coverslips with attached cells were removed from
wells, washed with 1x phosphate-buffered saline (PBS) (Cellgro), and incubated with 10 μM
Cy5-ghrelin (ligand 15) (500 μL/well) for 30 minutes at 37°C. Following washing with 1x PBS,
cells were incubated with 4% paraformaldehyde for 20 minutes at room temperature, washed
with 1x PBS, quenched in 50 mM NH4Cl for 10 minutes at room temperature, and washed with
1x PBS. For antibody staining, all steps were performed in a Parafilm dark chamber at room
temperature (unless specify) with humid atmosphere. Cells were blocked with PBSAT buffer
(PBS + 1% Bovine serum albumin, 0.1% triton) for 30 minutes in the dark chamber, following
aspiration of buffer avoiding coverslip to dry. Cells were then incubated with primary antibody
Rabbit anti FLAG (DYKDDDDK) antibody (Sigma, F7425) diluted in 1x PBS overnight in the
dark chamber at 4°C. The following day, cells were washed with 1x PBS and incubated with
secondary antibody Alexa Fluor 488-conjugated goat anti-rabbit (Jackson Immuno Research,
709-545-149) for 1 hour. Following antibody incubations, cells were washed three times,
mounted on slides using ProLong Diamond Antifade Mountant (Life Technologies) containing
DAPI, and analyzed by confocal microscopy. Images were taken on a Leica DMi8 STP800
(Leica, Bannockburn, IL) equipped with an 89 North–LDI laser with a Photometrics Prime-95B
camera taken with a Crest Optics: X-light V2 Confocal Unit spinning disk. Optics used were HC
PL APO 63×/1.40 NA oil CS2 Apo oil emersion objective.
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5.4.7. Image analysis
Note: Immunofluorescence imaging was performed with help of Erin Curtis from the Hehnly
Laboratory at Syracuse University. During these cell-imaging studies, we had consulted
Professor Heidi Hehnly for guidance in improving image quality and cell labeling.
The entire cell was imaged at 0.2-μm step-intervals and displayed as maximum
projections (ImageJ). The fluorescence range of intensity was adjusted identically for each image
series. Graphs and statistical analysis (analysis of variance [ANOVA] as labeled) were
completed using Graphpad Prism software. p < 0.0001 was considered to be statistically
significant. All images were set to a resolution of 300 DPI or greater after image analysis from
raw data.
5.4.8. Confirmation of hGOAT expression by Western blot
hGOAT transfected cells were harvested by treatment with 0.25% trypsin-EDTA at 37°C
for 5 minutes. Cells were transfer to an Eppendorf tube and collected by centrifugation at low
speed at room temperature. The media was aspirated and cells were resuspended in 1x sample
buffer (0.33 M Tris HCl, pH 6.8, 0.1 M SDS, 14% glycerol, and 0.5 M DTT) and 50 mM
HEPES pH 7.0 in a total volume of 45 μL. Samples were heated to 50.2 °C for 5 minutes and
then incubated at room temperature for 15 min prior to gel loading.63 Samples were loaded onto
a 12 % Tris-glycine SDS-polyacrylamide gel and run at 110 V for 1.5 hrs. Each gel was loaded
with a negative control (empty vector (EV) microsomal protein) and amino-terminal FLAG-BAP
Fusion protein as a positive control (Millipore Sigma, P7582-100UG, 1:200 dilution, 50 μL total
volume) as previously published protocol.63 Following SDS-polyacrylamide electrophoretic
separation, proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (BioRad,
Trans-Blot turbo RTA transfer kit). The PVDF membrane was activated with methanol
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incubation for 30 seconds followed by equilibration in transfer buffer (20% v/v methanol, 48
mM Tris base, 39 mM glycine and 0.034% v/v SDS) before transfer. Proteins were transferred to
the membrane for 30 minutes at 1.3 A / 25 V using a transfer kit per manufacturer’s instructions.
Following transfer electroblotting, the PVDF membrane was blocked for 3 hours with 5% v/v
nonfat milk in TBST buffer (Tris 10 buffered saline (TBS, 0.05M Tris and 0.14M NaCl) with
0.1% v/v Tween 20). FLAG antibody (HRP-conjugated DYKDDDDK Tag Antibody, Invitrogen
catalog number PA1-984B-HRP, 1:2000 dilution, 10 mL total volume) was prepared in 5%
nonfat milk in TBST buffer and membrane was incubated with the antibody overnight at 4 °C.
The membrane was washed with TBST (6 x 5 mL) and treated with West Pico
Chemiluminescent substrate-imaging reagent (Thermo Scientific), followed by imaging on a
ChemiDoc XRS+ gel documentation system (BioRad) (See figure 5.5).
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Figure 5.5 Western blot verification of hGOAT expression in HEK 293 cells. hGOAT
variant expression confirmation by anti-FLAG Western blotting with expected size of hGOAT
variants (49 kDa). Western blots were performed as described in the Experimental Methods
section. WT, wild type hGOAT; EV, empty vector expression; FLAG, FLAG-BAP fusion
protein positive control.
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Chapter 6: Investigation of a Predicted Functionally
Essential Loop Domain within Human Ghrelin OAcyltransferase
The work presented in this chapter is unpublished. In this chapter, there was an
experimental contribution from Natasha Tcheki-Jamgotchian (Syracuse University
undergraduate researcher) who assisted with expression of loop domain proteins.
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6.1 Introduction
Ghrelin is a peptide hormone whose signaling impacts the central nervous system while
regulating metabolism and energy balance.1 Ghrelin was discovered in 1999 by Kojima and
coworkers in their search for the endogenous ligand for the growth-hormone secretagogue
receptor (GHS-R1a).2 Originally linked to growth hormone (GH) secretion and stimulation of
appetite,3-4 ghrelin signaling has been linked to the gastrointestinal,5 cardiovascular,6 and
immune systems, memory consolidation,7-9 amongst others.10-11 Based on ghrelin involvement in
important signaling processes, inhibiting ghrelin signaling may offer a novel strategy for treating
multiple ghrelin-related health conditions.
Ghrelin is initially translated as a 117-amino acid precursor (preproghrelin), that is
trafficked to the endoplasmic reticulum (ER).12 To be biologically active, ghrelin requires a
unique posttranslational modification of the third serine (Ser3) of the precursor des-acyl
proghrelin, wherein this serine is acylated by an octanoyl (C8) fatty acid group (Figure. 6.1).2, 10
The enzyme that catalyzes ghrelin octanoylation, ghrelin O-acyltransferase (GOAT), was
discovered in 2008 by two research groups independently.12-13 GOAT is a member of the
membrane bound O-acyltransferase (MBOAT) enzyme superfamily.14-16 These enzymes transfer
fatty acids and other lipids onto hydroxyl groups of membrane-bound substrates.14 Three
MBOAT members (Porcupine (PORCN), Hedgehog acyltransferase (Hhat), and ghrelin Oacyltransferase (GOAT)) exclusively catalyze the transfer of a fatty acyl moiety onto secreted
signaling proteins.12-13, 16-17 All three of these enzymes are present in the endoplasmic reticulum
(ER) and acylate proteins within the luminal compartment as the substrate travels through the
secretory pathway. These family members share a conserved homological domain containing an
invariant histidine (H338 in GOAT) and highly conserved asparagine (N307 in GOAT).14
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Mutation of these conserved residues in the mouse form of GOAT (mGOAT) led to a loss of
ghrelin acylation activity demonstrating key participation in acylation.18
The active site structure and catalytic machinery of GOAT is not well understood.
Membrane proteins have been proven to be difficult to study owing to their hydrophobic
surfaces, flexibility, and lack of stability and crystallization of such membranes are extremely
difficult. Determination of the structure of functionally important domains within GOAT is a
critical step to define how GOAT binds to its substrate and catalyzes an octanoylation reaction.
Nevertheless, in 2013 Taylor and coworkers combined phylogenetic analysis, computational
calculations, epitope mapping, and induced glycosylation studies to establish the first topological
construction of mGOAT.19 They determined that mGOAT comprises 11 transmembrane domains
(TMDs) with one reentrant loop. Additionally, the enzyme contains numerous loop domains that
are not embedded in the membrane, with the invariant H338 located in the ER lumen and the
conserved Asn307 residue exposed to the cytosol (Figure. 6.2).19
Subsequent studies revealed a remarkable similarity in the topological structure of the
MBOAT member Hedgehog acyltransferase (Hhat) and GOAT, where the overall organization
and location of the TMDs and intermembrane loops is nearly identical in the C-terminal
“conserved MBOAT” domain (Figure 6.3).20-21 Within this homology, a large conserved loop
domain (residues I260-R316) resides within the cytoplasm, connecting helices 7 and 8 in GOAT.
This loop also encompasses one of the two highly conserved residues in MBOAT proteins, N307
in GOAT and D339 in Hhat. The topological similarity and conservation of functionally essential
residues in this loop domain, herein named the CARLi (Conserved Asp/Asn Required Loop,
intracytoplasmic) domain, make this region a compelling target for structural and biochemical
investigation.
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Figure 6.1. Ghrelin octanoylation by ghrelin O-acyltransferase (GOAT).
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In our hGOAT computational model, we have docked octanoyl-Co to hGOAT and
identified key interactions between the substrate and the enzyme.22 Amongst amino acids studied
by alanine mutagenesis in chapter 3; amino acids R304, W306, N307, and R315 showed a
complete loss of GOAT’s activity. These residues form part of this small domain (showed in
Figure 6.4), proposing the participation of this loop domain in acylation of GOAT, which
suggests CARLi as an acyl-CoA binding domain. The main goal of the proposed research is to
determine the functional role and structure of a conserved cytoplasmic loop domain within
hGOAT. These studies will complement our computational model and advance our mechanistic
understanding of this peptide-activating acyltransferase.
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Figure 6.2. GOAT model topology by Taylor et al. showing 11 transmembrane domains, one
reentrant loop, and multiple loops in both the cytoplasm and ER lumen. Figure reproduced with
permission from Reference 19 (Appendix XVII). © 2013 American Society for Biochemistry
and Molecular Biology.
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Figure 6.3. Membrane topology models for human Hhat (left) and GOAT (right). The
conserved His and Asp residues are shown in red and yellow, respectively and CARLi region is
enclosed in a box. The topological organization is most highly conserved between Hhat and
GOAT in their C-terminal domains, as shown below the dotted line. Figure reproduced with
permission from Reference 20 (Appendix XVIII). © 2015 The American Society for
Biochemistry and Molecular Biology, Inc.
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Figure 6.4. CARLi loop domain binds the octanoyl-CoA acyl donor for ghrelin acylation.
Pymol representation of CARLi loop domain (blue ribbon) with important residues (orange) that
abolished acylation of ghrelin under standard reaction conditions when mutated to alanine,
possibly interacting with octanoyl-CoA acyl donor.
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6.2 Results
6.2.1 Design of hGOAT loop variants. Expression of CARLi loop domain via a synthetic
split mini-intein gene.
Previous research in the Hougland lab constructed and expressed hGOAT loop domains
as fusion proteins coupled with maltose binding protein (MBP) or glutathione S-transferase
(GST) in order to increase the solubility and stability of these domains. However, this approach
did not yield any evidence for expression of the hGOAT loop fusion proteins, including the
CARLi loop domain.23 To aid in the expression and stabilization of hGOAT domains, a synthetic
DnaB split mini-intein gene was constructed for the cyclization of recombinant loop domain.
Protein splicing is a post-translational modification including deletion of the intein sequence and
connection of the flanking sequences (N- and C-exteins).24 While proteins are generally linear
arrangements of amino acid residues, studies using techniques such as NMR have shown that
cyclization between amino and carboxyl ends can increase protein stability.25-27 Stabilized
proteins with circular topology can remain folded for longer periods of time in the presence of
chaotropic agents.28-29 To study the function and structure of CARLi, we developed a bacterial
expression system to obtain the loop domain as a circularized protein using a split intein system
(Figure. 6.5).30-31 This method aids purification and expression procedures by mimicking the
topological constraint provided by transmembrane helices TM7 and TM8 in hGOAT. This
system has supported robust expression of CARLi compared to non-circularized constructs,
presumably through stabilization of the loop conformation.
A pNW1120 vector encoding the reversed split protein intein was provided by Nicholas
Dixon’s laboratory at the University of Queensland.30 The synthetic Synechocystis sp. PCC6803
DnaB split mini-intein gene was used to construct the in vivo cyclic form of the CARLi protein.
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This synthetic gene encodes a protein with the structure IntC-target-IntN, wherein the circularly
permuted split intein splices to create a cyclized protein with its NH2 and COOH termini linked
by a regular peptide bond and the combined excised intein. This approach has been demonstrated
to cyclize proteins and peptides in vivo in several Escherichia coli systems.32-34 Based on this
methodology, plasmid pNW1120_MB4_CARLi was constructed to directly express CARLi with
split intein abilities. However, expression trials with this vector did not provide any evidence for
expression of the loop domain intein fusion protein.
To explore an alternate route for expression of the loop domain with the split mini
inteins, we transferred the complete split intein-CARLi gene cassette from
pNW1120_MB4_CARLi to the pET system expression vector pET_23a(+).35 Following fusion
protein expression, splicing of the InteinC-CARLi-InteinN precursor (26.8 kDa) by formation of
an amide bond between the N and C intein domains termini is expected to yield the following
protein species: covalently linked InteinC-InteinN (14.1 kDa) and cyclized CARLi (8.8 kDa)
(Figure 6.5). To separate and detect these potential splicing products, expression of the InteinCCARLi-InteinN precursor was analyzed by Tris-tricine-SDS-PAGE with a color marker ultralow range ladder (M.W. 1,060-26,600)36(Figure 6.7a). Purification of the InteinC-CARLiInteinN precursor (26.8 kDa) was attempted by anion exchange chromatography (HiTrap DEAE
Sepharose Fast Flow) based on the predicted acidic pI of the cyclized CARLi protein (pI= 6.18).
However, the fusion protein displayed weak binding affinity to the anion exchange column.
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Figure 6.5. Circularization of CARLi by expression in a split intein construct. IntC-CARLiIntN precursor leads to production of a cyclized-protein with the connection of the flanking
sequences (N- and C-).
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6.2.2 Expression optimization of CARLi domain with a flexible internal hexahistidine
affinity-tag
Flexible protein linkers have been used to increase the accessibility of an epitope to
antibodies37 or to improve protein folding.38 Following this logic, flexible linkers using repeat
“GGS” tripeptide sequences were added to the loop domain construct to provide conformational
flexibility near the intein splicing junction/cyclization site, increase CARLi folding, and improve
purification utilizing a hexahistidine affinity-tag (Figure 6.6a). Three different loop constructs
were chosen based on multi sequence alignments and topological predictions: “long” loop
domain including portions of TM7 and TM8 (residues F238-W337); “medium” loop domain
including portions of TM7 and TM8 (residues W245-H320); and “small” cytosolic loop domain
(I260-R316) (Figure 6.6b). Expression of pET23a_CARLi_Long Domain-His6-(GGS)2 (LS
domain) and pET23a_CARLi_Small Domain-(GGS)-His6-(GGS) (SM domain) constructs was
confirmed by SDS-PAGE with two gel bands at 11.5 kDa and 9.3 kDa, respectively (Figure
6.7b). Comparison of these protein bands in the improved construct to the previous construct
described in section 6.2.1 indicated a more robust generation of spliced proteins by addition of a
more flexible linker (Figure 6.7). However, no protein bands or other evidence for expression of
the CARLi_Medium Domain-His6 construct were observed under all conditions explored.
Recombinant protein expression of splicing products of the CARLi_SM construct (Figure
6.8) were analyzed via immunoblotting using a 6x-His tag antibody. Both, the supernatant and
expression pellet were collected after cell disruption with BPER and examined in order to verify
the presence of the target protein. The supernatant was saved for gel investigation and the
insoluble pellet was resuspended with 6M guanidine hydrochloride (GuHCl) or 8M Urea.
Centrifugation of the resuspended pellet provided a denaturant solubilized supernatant that was
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saved for investigation. It was confirmed the presence of polyhistidine affinity tag recombinant
protein in two different bands that corresponds to cyclized CARLi_SM (9.3 kDa) shown in
figure 6.9 within the denaturing agents. This observation describes the accumulation of CARLi
protein in the aggregates or inclusion bodies of the insoluble portion of expression pellet.
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a)

b)

Figure 6.6. Optimization of loop domain constructs with flexible linkers. a) New linker IntCExtein-IntN construct to produce cyclized-CARLi protein. b) Loop domain construct design with
flexible GGS linker units (orange) between the loop domain, hexahistidine affinity-tag, and
intein N domain.
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Figure 6.7. Expression analysis of CARLi constructs in autoinduction media by 14% Tristricine-SDS-PAGE. a) Initial construct InteinC-CARLi-InteinN expression. A green box
highlights the spliced CARLi product from this construct. Lane 1: color marker ultra-low range.
Lane 2: pET23 empty vector B-PER lysis supernatant. Lane 3: pET23a_IntC-CARLi-IntN BPER
lysis supernatant. b) Expression of new loop domain CARLi constructs containing flexible GGS
linkers. Lane 1: color marker ultra-low range. Lane 2: pET23 empty vector B-PER lysis
supernatant. Lane 3: pET23a_CARLi_LS BPER lysis supernatant. Lane 4: pET23a_CARLi_SM
B-PER lysis supernatant. The blue and yellow boxes highlight the spliced loop domain CARLi
expected for each new construct. Sizes are represented with theit respective colors.
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Full length precursor of CARLi_SM (Small Domain Loop) (26,523 Da)
Intein C
MSPEIEKLSQSDIYWDSIVSITETGVEEVFDLTVPGPHNFVANDIIVH
NSIEFILDDSLLHAAGFGPELGQSPGEEGYVPDADIWTLERTHRISVF
SRKWNQSTARWLRRGSGGSHHHHHHGGSASTRESGCISGDSLISLAS
TGKRVSIKDLLDEKDFEIWAINEQTMKLESAKVSRVFSTGKKLVYIL
KTRLGRTIKATANHRFLTIDGWKRLDELSLKEHIALPRKLESSSLQL*
Protein Splicing

Intein N

Intein C- Intein N protein (13,072 Da)
MSPEIEKLSQSDIYWDSIVSITETGVEEVFDLTVPGPHNFAINEQTMK
LESAKVSRVFSTGKKLVYILKTRLGRTIKATANHRFLTIDGWKRLDE
LSLKEHIALPRKLESSSLQL*
Cyclic CARLI_SM (9,289 Da)
NSIEFILDDSLLHAAGFGPELGQSPGEEGYVPDADIWTLERTHRISVF
SRKWNQSTARWLRRGSGGSHHHHHHGGSASTRESGC

Figure 6.8. Predicted protein splicing products of the CARLi_SM (Small Domain Loop)
construct with flexible peptide linker and genetically encoded internal His6 tag. Green color
depicts Intein C, blue color depicts Inten N, red color depicts His6 tag. Connecting lines show the
new connection of flanking sequences after protein splicing. Expected sizes of the splicing
products are showed.
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Figure 6.9. Western blot analysis of small CARLi construct expression. Cell lysates from
expression trials were probed with an anti-His6 antibody in the context a BPER extract (soluble
protein), 8M Urea insoluble pellet resuspension, and 6M GuHCl insoluble pellet resuspension.
Lane 1: color marker ultra-low range (not shown). Lane 2: CARLi_SM (small construct) BPER
lysis supernatant. Lane 3: 1:3 dilution sample of 8M Urea resuspension. Lane 4: 1:4 dilution
sample of 8M Urea resuspension. Lane 5: 8M Urea resuspension only. Lane 6: pre-proghrelinHis6 BPER lysis supernatant (positive control for His6 antibody). Lane 7: 1:3 dilution sample of
6M GuHCl resuspension. Lane 8: 6M GuHCl only. The blue box represent the spliced loop
domain CARLi_SM expected size band.
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6.2.3 Purification of cyclized CARLi domain
The insoluble inclusion bodies containing the cyclized CARLi construct were separated
from soluble proteins by centrifugation and solubilized with 6M guanidine HCl. Direct
purification of polyhistidine-tagged proteins has been attempted with His60 Ni Sepharose 6 Fast
Flow Resin following a refolding step with 20 mM Tris buffer based on procedure of Kim et al.39
Refolding was completed by transitioning from the washing buffer to a refolding buffer, which
reduces the concentrating of the denaturing agent. All fractions with refolded CARLi were
pooled and concentrated to 2 mL using an Amicon Ultra-15 Centrifugal Filter Unit (3 kDa
MWCO). Figure 6.10 shows the ratio of protein in the soluble and insoluble fractions from the
cell pellet along with the refolded and purified CARLi_SM protein. The purified protein gave
two bands of ~26 and ~9 kDa. The molecular mass calculated for the precursor
IntC_CARLi_SM_IntN is 26.6 kDa and CARLi_SM is 9.3 kDa, in agreement with the band
sizes obtained by SDS–PAGE.
Isolated cyclized CARLi_SM obtained after Ni-IMAC purification was followed by size
exclusion chromatography (SEC) using a HiLoad 16/60 Superdex 75 pg column (Figure 6.11).
This purification led to isolation of a protein with single band purity with an estimated molecular
weight of 7 kDa by SDS-PAGE. We hypothesized the folded and cyclized CARLi domain may
run lower in SDS-PAGE than the expected size of 9.3 kDa as this protein cannot achieve the
approximately linear form assumed for proteins denatured by SDS.
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Figure 6.10. SDS-PAGE analysis of Carli_SM purification from inclusion bodies. Lane 1:
color marker ultra-low range. Lane 2: Supernantant after cell disruption with sonication. Lane 3:
Supernatant after resuspension with 2M Urea buffer. Lane 4: Supernantant after insoluble pellet
resuspension in 6M GuHCl buffer (sample used for CARLi purification). Lane 5: Flow through
following binding to Ni Sepharose 6 Fast Flow Resin. Lane 6: Washes with 20 mM Imidazole
buffer. Lane 7: Washes containing 6M Urea. Lane 8: Wash with refolding buffer containing 20
mM Tris-HCl. Lane 9: Elution buffer containing 500 mM Imidazole. Lane 10: Second wash with
elution buffer containing 500 mM Imidazole. The blue box represent the spliced loop domain
CARLi_SM expected size band.
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Figure 6.11. SDS-PAGE analysis of Carli_SM size exclusion purification. Lane 1: color
marker ultra-low range. Lane 2: Supernantant after resuspension with 6M GuHCl buffer (Sample
used for Ni purification). Lane 3: Over night nickel resin flow through. Lane 4: Low MW range
prestained protein ladder. Lane 5: Previously purified inteins spliced (~12 kDa). Lane 7:
Concentrated cyclic CARLi after SEC purification. The blue box represent the spliced loop
domain CARLi_SM expected size band.
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6.2.4 Circular dichroism analysis of CARLi_SM loop domain
Circular dichroism (CD) was applied to determine the presence of secondary structural
elements in purified CARLi. Analysis of the CD spectrum for CARLi supports partial α-helical
character as indicated by the decrease in ellipticity at 222 nm for the protein in buffer when
compared to spectra collected under denaturing conditions in the presence of 6M guanidium,
with the latter spectrum consistent with a random coil conformation (Figure 6.12). These results
indicate the presence of secondary structure within this conserved loop domain that potentially
plays a role in formation of the enzyme core and binding sites for hGOAT substrates.
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Figure 6.12. Circular dichroism analysis of circularized hGOAT CARLi domain. CARLi
samples (27 mM, pH 8.0) were prepared in 300 μL of 50 mM Tris. Spectra were collected over
the range of 200-260 nm. Pathlength of the quartz cuvette was 0.1 cm and three accumulations
were collected for each spectrum. CARLi protein is shown in the absence (blue) and presence of
5M GuHCl (green). Spectra support partial alpha-helical structure within the CARLi domain.
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6.3 Discussion and Conclusions
Multiple groups have described structural investigation of hGOAT and other MBOAT
protein members.20, 40-41 However, high-resolution structural data for this family of enzymes
remains elusive. Membrane topology studies of GOAT and Hhat revealed a common topology in
the C-terminal portion of these enzymes share, establishing a characteristic “MBOAT domain”.
Within this region, a conserved loop structure containing the highly conserved amino acid N307
in GOAT and D339 in Hhat in the cytoplasm was recognized. We have designed a system for
expression of this structural fragment of GOAT, denoted CARLi in our work, to investigate its
potential participation in the catalytic mechanism of GOAT. The bacterial expression system and
purification of CARLi resulted into a robust production of this protein domain by using a
synthetic DnaB split mini intein gene. The system was used to cyclize the loop domain,
stabilizing the nature of a linear protein into a circular one, mimicking the non-free protein
topology of this loop linking transmembrane helices 7 and 8 in hGOAT. Cyclization was found
to be efficient, with a small accumulation of precursor. The product was purified in high yield
using a two-step purification process including Ni Sepharose 6 Fast Flow and size exclusion
chromatography protocols. However, the purified product appeared at a smaller length than the
expected size of 9,289 Da during SDS-PAGE analysis.
Studies of this purified CARLi loop domain using circular dichroism support the
presence of an alpha helical secondary structure in this small protein. The structural signal
demonstrated by this small protein is of interest since CARLi loop domain is located in the
cytosol and shares a conserved sequence among MBOATs. Moreover, this domain is forming a
potential interface for acyl-CoA substrate binding of GOAT showed by computational
experiments in chapter 3. We suggest that this domain form potential key interactions between

212

cytosolic acyl-CoA donor and the enzyme, reiterating the participation of this loop domain in
acylation of GOAT. However, the precise roles played by residues in this loop domain during
ghrelin binding and acylation by hGOAT remain to be fully determined and represent a future
goal of this research.
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6.4 Experimental Methods
6.4.1 Design of CARLi domain variants with flexible internal hexahistidine affinity-tag
Three different genes sequences of different loop domain sizes with flexible
hexahistidine affinity-tag were commercially synthesized (Bio Basic), with the insert bracketed
by NdeI and XhoI restriction sites for subcloning.
Loop Domain Construct

CARLi_Long (F238-W337)
IntC-CARLi_L -(GGS)2 His6 (GGS)2-IntN

CARLi_Medium (W245-H320)
IntC-CARLi_M-(GGS) His6 (GGS)-IntN

CARLi_Small (I260-R316)
IntC-CARLi_S-(GGS) -His6 (GGS)-IntN

Gene sequence
MSPEIEKLSQSDIYWDSIVSITETGVEEVFDL
TVPGPHNFVANDIIVHNSIEFFECIYVVWTT
AGLFKLTYYSHWILDDSLLHAAGFGPELGQ
SPGEEGYVPDADIWTLERTHRISVFSRKWNQ
STARWLRRLVFQHSRAWPLLQTFAFSAWWG
SGGSGGSHHHHHHGGSGGSASTRESGCISG
DSLISLASTGKRVSIKDLLDEKDFEIWAINEQ
TMKLESAKVSRVFSTGKKLVYILKTRLGRTI
KATANHRFLTIDGWKRLDELSLKEHIALPRK
LESSSLQL*
MSPEIEKLSQSDIYWDSIVSITETGVEEVFDL
TVPGPHNFVANDIIVHNSIEFWTTAGLFKLT
YYSHWILDDSLLHAAGFGPELGQSPGEEGY
VPDADIWTLERTHRISVFSRKWNQSTARWL
RRLVFQHGSGGSHHHHHHGGSASTRESGCIS
GDSLISLASTGKRVSIKDLLDEKDFEIWAINE
QTMKLESAKVSRVFSTGKKLVYILKTRLGR
TIKATANHRFLTIDGWKRLDELSLKEHIALP
RKLESSSLQL*
MSPEIEKLSQSDIYWDSIVSITETGVEEVFDL
TVPGPHNFVANDIIVHNSIEFILDDSLLHAAG
FGPELGQSPGEEGYVPDADIWTLERTHRISV
FSRKWNQSTARWLRRGSGGSHHHHHHGGS
ASTRESGCISGDSLISLASTGKRVSIKDLLDE
KDFEIWAINEQTMKLESAKVSRVFSTGKKL
VYILKTRLGRTIKATANHRFLTIDGWKRLDE
LSLKEHIALPRKLESSSLQL*

6.4.2 Double digestion of pUC57-Amp and pET23a
pUC57-Amp vectors containing targeted genes constructs and pET23a vector were
double digested with NdeI and XhoI restriction enzymes. The double digest reactions were
performed under the following conditions: the first tube had a total volume of 50 L solution
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including pET23a (1.5 μg), NdeI (1 μL, 20 units), XhoI (1 μL, 20 units), NEB 10x Cutsmart
buffer (5 μL), and ultrapure H2O (18 μL). Second tube had a total volume 50 L solution
including pUC57_CARLi_constructs (2.0 μg), NdeI (1 μL, 20 units), XhoI (1 μL, 20 units), NEB
10x Cutsmart buffer (5 μL), and ultrapureH2O (18 μL). Reactions were incubated for 3 hours at
37C, followed by analysis of the vector digestions by agarose gel electrophoresis (0.8%
agarose, 1X TAE buffer) to verify the size of the linearized pET 23a and pUC57 insert genes.
The digested vector and insert genes cleaved from pUC57 were purified using an EZ-10 Spin
Column DNA Gel Extraction Kit (Bio Basic Inc.) per the manufacturer’s instructions.

6.4.3 DNA Ligation Procedure of insert gene for CARLi_constructs into pET23a(+) (New
England Biolabs© Quick Ligation Kit)
Ligations were performed using a 1:3 molar ratio of vector to insert performed under the
following conditions (20 μL total volume of ligation solution): double digested pET 23a (100
ng), double digested CARLi_constructs insert (100 ng), ultrapure H2O (1.2 μL), 2x Quick Ligase
buffer (10 μL), and T4 Quick Ligase (New England Biolabs, 1 μL). Solutions were then
incubated at room temperature (25°C) for 5 minutes. The ligation mixture was then stored at 20oC until use in transformation.

6.4.4 Plasmid transformation into DH5-alpha competent E.coli cells
DH5-alpha Z-competent cells were thawed on ice, followed by the addition of 5 μL of
quick ligation mixture prepared above to 100 μL competent cells aliquots. Cells were incubated
on ice for 15 minutes and then spread onto pre-warmed LB agar plates containing 100 μg/mL
ampicillin. The plates were incubated at 37°C O/N (overnight). Following, single colonies
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obtained were inoculated into LB media (5 mL) containing ampicillin (100 g/mL) in sterile
culture tubes. These cultures were incubated overnight at 37C with shaking (225 rpm). Plasmids
were purified from the saturated cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic
Inc.) per manufacturer’s instructions. The transformants were screened with digestion analysis
by restriction enzymes using NdeI and XhoI, and analyzed by DNA sequencing, confirming
successful ligation.

6.4.5 Plasmid transformation into BL21-DE3 E.coli cells
Purified pET23a_CARLi_constructs plasmids containing CARLi_construct genes and
BL21-DE3 Z-competent cells were thawed on ice, followed by addition of 200 ng of plasmid to
100 μL aliquout of Z-competent cells. Cells were incubated on ice for 15 minutes and then
spread onto pre-warmed LB-ampicillin plates (100 μg/mL). The plates were incubated at 37°C
overnight (O/N) and then screened for colonies, indicating transformation.

6.4.6 Expression of hGOAT CARLi_constructs (Small, Medium, and Long) using
autoinduction media
Following overnight incubation, single colonies were used to inoculate a 5 mL culture of
autoinduction media (1% tryptone, 0.5% yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50
mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.2x trace metals (0.01 mM FeCl3, 0.004 mM CaCl2,
0.002 mM MnCl27H2O, 0.002 mM ZnSO47H2O), 0.5% glycerol, 0.05% glucose, 0.2% α-Dlactose, and 100 g/mL ampicillin) in sterile culture tubes and incubated overnight at 37 C with
shaking (225 rpm). A 3 mL aliquot of this starting culture was used to inoculate 1 L autoinduction media prepared as above with 100 g/mL ampicillin and incubated at 28 C for 22
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hours for expression. Following growth, bacteria were harvested by centrifugation (6000 x g, 15
min), supernatant removed and the pellet was stored at -80C. Five 1 mL aliquots of bacterial
culture were taken for protein expression analysis SDS-PAGE. The 1 mL bacterial pellet was
resuspended in B-PER lysis reagent (Thermo Scientific, 150 µL) followed by vortexing for 1
minute and cell debris was separated by centrifugation (15,000 x g, 5 min) to remove residual
cell debris. Supernatant from B-PER lysis was prepared for analysis by 14 % Tricine-SDSPAGE gel by adding 3X SB (sample buffer) and incubated for 2 min at 95°C.

6.4.7 Purification and refolding for the solubilization of CARLi_SM protein expressed in
E.coli
The pellet from 1L culture was resuspended on lysis buffer (20 mM Tris–HCl pH 8.0,
500 mM NaCl, 2M urea, and 2% Triton X-100) and sonicated on ice using a sonicator (Misonix
Cell Disrupter) per the following protocol: power setting of 12; 8 cycles of sonication for 30
seconds followed by 30 seconds rest. The lysate was separated by centrifugation at 18,000xg for
10 min. The supernatant was saved for gel analysis and the insoluble fractions containing
insoluble proteins were resuspended again in 20 ml of ice-cold lysis buffer containing 20 mM
Tris–HCl pH 8.0, 500 mM NaCl, 2M urea and 2% Triton X-100). The insoluble material was
separated by centrifugation at 18,000xg for 10 min and the supernatant (SUP) was saved for
analysis. The resulting washed pellet was resuspended in 20 ml Binding buffer (20 mM Tris–
HCl pH 8.0, 500 mM NaCl, 6 M guanidine HCl, 5 mM imidazole and 1 mM 2-mercaptoethanol)
and incubated at room temperature for 10 min. The solution was centrifuged at 18,000xg for 10
min to remove unsolubilized material. The solubilized proteins were loaded onto a preequilibrated (binding buffered) His60 Ni Sepharose 6 Fast Flow Resin (GE Healthcare, bed
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volume, 5 ml) for purification and refolding of the protein. Resin and the sample were incubated
over night, at 4 degrees, rocking. The lysate was separated by centrifugation at 500xg for 5 min
and SUP saved. The resin was washed with 3 column volumes (CV) of binding buffer followed
by 3 CV of washing buffer (20 mM Tris–HCl pH 8.0, 500 mM NaCl, 6M urea, 20 mM imidazole
and 1 mM 2-mercaptoethanol). Refolding was completed by changing the washing buffer to a
refolding buffer (20 mM Tris–HCl pH 8.0, 500 mM NaCl and 20 mM imidazole) using a
gradient of 1:0, 1:1, and 0:1 binding buffer to refolding buffer respectively. After washing with 3
CV of refolding buffer, the protein was eluted with 3 CV of elution buffer (20 mM Tris–HCl pH
8.0, 500 mM NaCl and 500 mM imidazole). The fractions with refolded protein were pooled and
concentrated to 2 ml using an Amicon Ultra-15 Centrifugal Filter Unit (3K MWCO). The
concentrated samples were loaded on a HiLoad 16/60 Superdex 75 pg size exclusion column
(GE) and eluted with buffer (20 mM NaH2PO4, 200 mM NaCl). Buffer was continuously run
through the column for 120 mL after injection of 1 mL of sample and an elution profile was
obtained. Fractions (5 mL each) were then analyzed by SDS-PAGE.
6.4.8 SDS-PAGE analysis
3XSB lysis was performed by using cell lysate (50 μL) was mixed with 25 μL of 3X SDS
sample buffer and heated to 95 °C for 5 min, followed by centrifugation (10,000 x g, 5 min) to
pellet insoluble material. B-PER lysis was performed using BPER lysis reagent (Thermo
Scientific, 150 μL), vortexed on high for 1 min, and cell debris was removed by centrifugation
(12,000 x g, 5 mins). 25 μL of 3XSB was added and heated to 95 °C for 5 min, followed by
centrifugation (10,000 x g, 5 min) to pellet insoluble material. Protein standards ladder (Thermo
Scientific and Color Marker Ultra-low Ranging (M.W. 1,060-26,600), Sigma) and samples were
loaded onto a 14% tris-tricine polyacrylamide gel and run at 150 V for 1 hr 30 min, until the dye

218

band had migrated to the bottom of the gel. Total protein in cell lysate samples was visualized by
staining with Coomassie Blue stain and imaged on a ChemiDoc XRS+ BioRad gel imager.

6.4.9 Coomassie Blue staining procedure
Each 14% tris-tricine polyacrylamide gel was rinsed with ultrapure water and covered in
50 mL of destain solution (stock: 2 L water, 1.6 L methanol, 0.4 L acetic acid). The gel was
microwaved for 18 sec, at which point the destain solution was removed and approximately 50
mL of Coomassie blue stain was added (stock: 0.25g Coomassie Blue dye, 500 mL methanol, 75
mL acetic acid). The gel was microwaved for 30 sec and rocked for 5 min. The stain solution
was decanted, destain solution was added and rocked for 15 min, followed by wash of destain
addition and rocking for 15 min. The gel was then placed into ultra pure water rocked overnight.
Protein gels were then imaged using BioRad XRS+ gel imager.

6.4.10 Anti-His6 Western blotting of inclusion bodies in CARLi_SM purification
Cell lysates were run on a 14% Tris-Tricine gel as described above. A polyvinylidene
difluoride (PVDF) membrane was activated by immersion in methanol for 30 seconds, followed
by equilibration in transfer buffer (20%v/v methanol, 48 mM Tris base, 39 mM glycine and
0.034%v/v SDS) for 10 minutes. Filter papers and sponges were also soaked in transfer buffer.
The gel was assembled into a transfer cassette and proteins were transferred to the PVDF
membrane for 30 minutes at 350 mA, using a BioRad TransBlot Turbo RTA Transfer kit per
manufacturer’s instructions. Following electroblotting, the PVDF membrane was washed in tris
buffered saline (TBS, 0.05M Tris and 0.14M NaCl), TBST (TBS with 0.1% v/v Tween 20) and
blocked for 4 hours in 10% v/v nonfat milk in TBST. The membrane was then probed with an
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HRP-α- antiHis primary antibody (1:200 dilution, Rockland) in 10% milk TBST overnight at 4
degrees Celsius. Following washing in TBST, the membrane was treated with the West Pico
Chemiluminescent substrate-imaging reagent (Thermo Scientific) and imaged on a ChemiDoc
XRS+ BioRad gel documentation system.
6.4.11 Circular dichroism spectroscopy of circularized hGOAT CARLi domain
CARLi was purified to single band as assessed by SDS-PAGE from size-exclusion
chromatography. Purified sample were buffered exchanged into a final buffer composition of 25
mM Tris-HCl (pH 8.0) and protein concentration of 25 μM. Fractions were concentrated to 1/4
of the volume, supplemented with buffer to original volume, spun down (2,500 x g, 4 °C) to ¼ of
the volume, repeated until three volumes worth of buffer have been added. After buffer
exchanging an A280 was taken (ε=17990 M-1cm-1). Spectra were collected using 1mm Suprasil
High Resolution Quartz cuvet (Hellma Analytics, Müllheim, Germany). Three accumulations
were used for each spectra collection. CD and turbidity (dynode voltage) data were recorded by a
UV detector in a spectropolarimeter equipped with thermoelectric temperature control. Light
scattering was recorded at the same wavelength as CD by an additional UV detector that is
positioned at 90° to the direct beam and is a part of the fluorescence attachment; the filters from
this attachment were removed. The data were normalized to protein concentrations and
expressed in units of molar residue ellipticity.
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7.1 Introduction
The acylation of biological proteins is essential for intercellular and organismal processes
that are related to numerous diseases including diabetes and cancer.1-2 Ghrelin is a peptide
hormone primarily secreted by the stomach that undergoes an acylation modification to be
biological active and act as the endogenous ligand for the ghrelin receptor (GHS-R1a).3
Ghrelin’s most well known role is as a hormone that stimulates food intake and adiposity both in
rodents and humans.4-5 Similarly, this 28 amino acid peptide has been associated with
cardiovascular, gastrointestinal, neuroendocrine, and immune systems.6-7 These characteristics of
ghrelin make this hormone an attractive yet largely unexploited target for the investigation of
small-molecule therapeutics.
Ghrelin O-acyltransferase (GOAT) was discovered to catalyze the octanoylation of the
third serine (Ser3) of ghrelin side chain to generate the active form of this hormone.8-9 Therefore,
GOAT is considered as a potential target for treatment of obesity and other disorders linked to
the ghrelin peptide. Nevertheless, the active site architecture and mechanism for GOATcatalyzed ghrelin acylation are presently undetermined. Currently, the Hougland laboratory aims
to establish the catalytic mechanism of ghrelin acylation as a key step in understanding ghrelin’s
role in different disorders and targeting ghrelin-dependent pathways for therapeutic effect. The
objective of this work was to define the structural and chemical basis for ghrelin acylation by
GOAT within three main goals: determine the acyl donor and ghrelin binding sites within
hGOAT, define hGOAT’s catalytic mechanism of acylation, and aid GOAT’s inhibitor
development that targets essential ghrelin binding sites.
With this work we were able to provide crucial insights into GOAT’s structure by
developing the first functionally validated structural model for a MBOAT protein
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acyltransferase. We have also identified essential residues, which interact with ghrelin within the
proposed catalytic core of hGOAT. This dissertation has provided a better understanding of the
mechanism for transmembrane acylation by this enzyme. Hereafter, our work will establish a
groundbreaking approach for the investigation of structurally challenging membrane proteins and
advance the investigation of acylated secreted proteins as therapeutic targets for associated
disorders.
7.2 Development of the first structural model of human GOAT
As ghrelin requires acylation by GOAT to be biologically active, a detailed
understanding of this transmembrane enzyme is essential. However, membrane proteins are well
known for resisting structural studies due to their lack of solubility and instability in the absence
of lipids or detergents. This is a common limitation encountered with similar membrane proteins
that evade traditional methods of structure determination and underscore the need for new
approaches of investigation.10-11 In this work, we have employed an interdisciplinary
computational-biochemical approach to develop a three-dimensional model of GOAT. Using
chemical and biochemical assays, we experimentally validated this computation-derived
structure of hGOAT.12 We utilized metagenomics information of GOAT and related proteins to
generate a set of co-evolutionary constraints to produce ~ 30,000 potential hGOAT structures.1315

These structures were examined and exposed to molecular dynamics calculations to create an

energy-optimized structural model for hGOAT within a cellular membrane. 16
In this dissertation, we described our model as an eleven transmembrane domain enzyme
with an ellipsoidal cone shape and a narrow end facing the ER lumen. Within this cone, we
located an interior continuous channel connecting both the ER lumen and the cytoplasm. Inside
this channel, we observed the absolutely conserved histidine residue (H338), indispensable for
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GOAT's activity, indicating the significance of this amino acid in this pore. Moreover, we
validated our computational model by alanine mutagenesis investigation of 42 amino acids
together with our previously reported peptide-based acylation assay.17-18 By biochemical
examination, alanine mutants with residues’ side chain contacting the void inside the channel
produced significantly more loss of activity than the non void-contacting mutations with proven
expression of mutants by Western blotting.12 This mutation profile demonstrates a functionally
essential core within hGOAT, containing required amino acids for enzymatic activity. This new
structural mode of investigation resulted in a structure consistent with previously reported GOAT
mouse ortholog19 and the published crystal structure for the bacterial MBOAT DltB alanyl
transferase.20
This work has established and verified a novel approach for the rapid development and
validation of a structural model for an integral membrane protein, which can be applied to
decode the three-dimensional structural configurations of other difficult-to-purify membrane
enzymes like GOAT.
7.3 Exploring the acyl donor-binding site within hGOAT
Previous studies of the acyl binding site of hGOAT has revealed the uncommon selection
of a fatty acid bearing an eight-carbon chain as its acyl substrate however, other acylation
enzymes display a preference for longer acyl groups fatty chains such as 14- or 16-carbons.21-23
In fact, hGOAT differentiates against smaller and longer than eight-carbon chains,24 which
suggest a distinct binding pocket that can accommodate this C-8 substrate exclusively. To
investigate this selection by GOAT, we used our structural model described above to identify
amino acids that potentially form part of this acyl-binding site.12 Based on results obtained from
our model-oriented alanine mutagenesis, we have explored alterations that increase the potential
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binding site pocket groove. Our screening resulted with the loss of appreciable octanoylation
activity with amino acids W351 and F331 (Figure 7.1). Nevertheless, these mutations generated
recognition of longer acyl donors, gaining activity with the C12 and C14 acyl chains. This
altered selectivity demonstrated the modeled positions of W351 and F331 suggested to form the
end of the acyl groove.
Moreover, with this work we have identified two different binding sites for the acyl
substrate where previously described essential amino acids for GOAT’s activity have been
found.19 Mutants W306A, D358A, N307A, and R315A were shown to completely eliminate
GOAT activity at this sites, describing the direct potential interaction with the acyl-CoA
substrate. In our model, the highly conserved N307 formed polar contacts near the pantothenic
acid site of the acyl-CoA substrate, answering a long-lasting question of the location and
functional role of this highly MBOAT conserved amino acid.
While these studies provide the first description of various essential amino acids for
potential substrate binding to hGOAT, many aspects of the acyl transfer mechanism remain to be
defined by ongoing studies. Based on our modeling and chemical studies, we hypothesize that
the acyl substrate binds to GOAT inside the internal channel within the cytoplasmic side (See
Figure 7.1). Within this pore, octanoyl-CoA communicates with ghrelin and transfers the acyl
chain, with coenzyme A being released back to the cytoplasm following the acyl transfer
reaction. Moreover, this substrate binds to the enzyme with the phosphoadenosine group binding
into a discrete pocket while the phosphopantetheine chain is in contact with multiple polar amino
acid side chains in a different opening of the pore open to the cytoplasm. This understanding of
acyl-CoA recognition by GOAT can refine the hGOAT structural model by providing constrains
and advancing the development of acyl-CoA inhibitors.
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7.4 Identification of ghrelin binding to GOAT via cross-mutation analysis
Building upon multiple studies of ghrelin recognition by GOAT, the Hougland lab has
developed a schematic model of ghrelin interactions with GOAT involved in substrate
recognition.17, 24 For example, the lab has demonstrated important size recognition at several sites
in the GSSFLC sequence of ghrelin substrate.24 However, the location and relationship of these
interactions in a three-dimensional model have not been described. Using simultaneous alanine
mutagenesis in both the enzyme and ghrelin peptide substrate, we investigated interactions
between ghrelin and hGOAT. Several mutations presented rescue signals reflected by reactivity
enhancements calculations for each enzyme-substrate mutation pair relative to the wild type
enzyme and substrate. There was a significant enhancement of activity with amino acids S300
and F348 and mutations at G1 of ghrelin. We were able to rescue an alanine mutation in the first
glycine in ghrelin that previously has been proven to be detrimental for activity.17 By adding
alanine to amino acids S300 and F348 we were able to recover the activity of GOAT with the
enzyme, demonstrating an interaction within these regions of GOAT.
Similarly, amino acid S179 in GOAT presented the strongest signal for activity
enhancement, establishing a significant interaction of this amino acid with the second serine in
the ghrelin peptide. Incorporation of the hydrophobic side chain in valine at the S2 position
decreased hGOAT activity in previous investigations.17, 24 We observed enhanced octanoylation
activity with this substrate in the presence of an alanine mutation of S179, which we propose
creates a spatial opening in the enzyme that more readily accommodates the valine side chain.
Interactions of Y255, S300, and F302 with the F4 position were defined with rescue of
activity in our assay. Mutants Y255A and F302A demonstrated to be enhance steric tolerance,
accepting the unnatural amino acid cyclohexylalanine which indicated that planarity and/or

232

aromaticity might not play a role in recognition at this position. As previously determined, the
enzyme tolerates a range of bulky amino acids at this position.8, 17 Our investigation reiterated
this result by showing activity a substrate with incorporation of acrylodan at this site. Building
on this work, further investigations with conserved amino acid mutations are necessary to
investigate GOAT-substrate interactions and their role in acylation activity. However, the
findings in this work can provide direction in defining the specific location of recognition
elements within ghrelin and the nature of the interactions leading to increased peptide binding to
GOAT.

7.5 Development of specific ghrelin O-acyltransferase ligand that exposed a new method of
GOAT detection with extracellular peptides
Ghrelin, the endogenous ligand for the ghrelin growth hormone secretagogue receptor
(GHS-R1a), provides a significant template as a starting point for the development of strong
inhibitors. Moreover, since its discovery in 1999,3 ghrelin was found to be the only protein
containing a unique posttranslational modification and it was the only predicted GOAT substrate
in the human proteome.24 Given this and ghrelin’s role in metabolic regulation through binding
to the receptor and its enzyme, many groups have explored different avenues to produce strong
and specific hGOAT ghrelin inhibitors to control acylation by GOAT.
Recent students had identified expression of GHS-R receptors in human breast
carcinomas and cell lines25-27 and overexpression of GOAT has been detected in some tumor and
cancer tissues.28-29 All these new data argues towards GOAT and the receptor as available targets
for a cancer cell biomarkers. The Luyt lab at Western Ontario University has developed new
fluorescent imaging agents for the detection of GHS-R1a such as a truncated ghrelin analog
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containing acylated ghrelin (1–8) analogue for use in PET imaging.30-31 However, peptides
mimicking the sequence of octanoylated ghrelin effectively bind to both GOAT and the GHSR1a receptor,32-33 making them unsuitable for specific detection of GOAT.
To increase substrate specificity to hGOAT, we developed a new class of ghrelinmimetic inhibitors through incorporation of a free diaminopropanoic acid DAP amino group at
the third acylation serine hydroxyl site, with this substitution shown to dramatically increase
GOAT binding affinity.34 By combining this moiety and several other amino acid substitutions,
we generated a potent GOAT ligand (nanomolar IC50) when evaluated as an inhibitor with an
appended fluorescent group, which demonstrates our ability to functionalize GOAT peptide
ligands with imaging groups without compromising GOAT binding ability.
To further investigate ligand binding in a cellular system, transiently transfected HEK293
cells with hGOAT demonstrated uptake of our Cy5 fluorescence ligand; whereas empty vector
control expressing cells did not. These results demonstrating that GOAT expression in these cells
is essential for ligand binding. Moreover, GOAT is proposed to be restricted to the ER/Golgi
complex with an integral membrane nature,12, 19 so this work provided the first evidence for
GOAT exposure to the extracellular space. Nevertheless, we can also considered that hGOAT
overexpression in these cells could destabilize or disrupt membrane integrity that permits ligand
cell penetration without requiring direct binding to hGOAT. Overexpression of GOAT could
also lead to abnormal cell surface localization of the enzyme in the cells. However, when
transfected into HEK293 cells, the H338A hGOAT variant did not preserve cell uptake of the
fluorescent ligand, supportive of an interaction between the Dap amino group and H338 and
disputing against general loss of cell membrane integrity as the mechanism for ligand
internalization. Additionally, other alanine variants did not demonstrated internalization of our
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ligand, as expected for mutations not proposed to form part of the ghrelin-binding site within the
hGOAT catalytic channel found in our model.12 In the future, the Hougland lab will investigate
other cell lines that overexpress endogenously GOAT with methods including microscopy
imaging and flow cytometry probing these questions of GOAT trafficking and ligand uptake.
Our work demonstrates the creation of a potent GOAT inhibitor that can serve as the
foundation for an array of biostable high-affinity peptide ligands for detecting and imaging
GOAT in many tissues and disease models. Whether the mode of transport of the GOAT:ligand
complex into the cell is by membrane trafficking or GOAT serving as a pore/transporter using its
internal channel, this process presents a new and unforeseen function for integral membrane
acyltransferases and may provide a novel avenue for intracellular drug/cargo delivery targeting
cells expressing GOAT.
7.6 Define the structure and function of a catalytically required hGOAT loop domain
Structural studies of GOAT revealed a remarkable similarity in the topological structure
of (Hhat), where the location of the TMDs and loops are nearly identical in the C-terminal part of
the enzymes.35-36 Within this homology, a large cytosolic loop containing the highly conserved
Asn/Asp residue is located, making this region a compelling target for structural and biochemical
investigation to aid in the construction GOAT’s structure. In our study, we have described this
large conserved loop domain (residues I260-R316) within the cytoplasm that includes the highly
conserved N307 in GOAT. Our model describes this loop as located in the cytosol and
potentially forming an interface for acyl-CoA substrate binding of GOAT.
To study the function and structure of this loop, we expressed the conserved cytoplasmic
domain via a synthetic reverse DnaB split mini-intein, constructed for the cyclization and
stabilization of the protein to mimic the topological constraint provided by transmembrane

235

helices in hGOAT. We successfully expressed recombinant polyhistidine-tagged cyclic domain
within aggregates or inclusion bodies (IBs) in the expression pellet. With a direct purification of
the proteins solubilized in GuHCl and purified by His60 Ni Superflow Resin, we obtained two
different size proteins corresponding, the precursor parent and the loop domain. This circularized
loop expressed at levels sufficient to support structural and functional characterization and
circular dichroism (CD) of the purified domain has supported partial -helical structure
consistent with computational predictions for this domain.12 With these results we suggest that
this cytosolic loop provides a flexible region for essential contacts with the acyl-donor,
potentially providing a substrate passage to the ER membrane for acyl transfer to ghrelin,
however this hypothesis have not been proven with experiment data.

7.7 Summary and future directions
With this work we have made several advances in the study of ghrelin acylation by
hGOAT, including the development of the first high-resolution structural understanding of this
enzyme, uncovering key substrate bindings sites domains within hGOAT for acyl donor binding
as shown in Figure 7.1, determination of specific residues required for ghrelin interaction, and
the discovery of a new class of ghrelin-mimetic inhibitors. These outcomes will aid the
generation and testing of hypotheses regarding the mechanism for GOAT-catalyzed ghrelin
octanoylation. Moving forward, the Hougland lab will utilize these approaches to refine the
structural model for hGOAT. For example, other researchers are currently investigating the
potential involvement of a serine or threonine nucleophile in the acylation process of ghrelin as a
covalent catalyst. Likewise, the lab will investigate modeling structural interactions that will
stabilize GOAT structure for purification in a catalytically active form from the cell membrane.
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Moreover, these findings of GOAT could describe the acylation processes of other MBOAT
family members that are also intractable to current structural studies, especially those that also
acylate protein substrates and share remarkable similarities in their topologies like Hhat and
PORCN.
This work has laid the foundation for structure-based rational drug design targeting
hGOAT specifically; exploring new avenues of ghrelin binding. Another avenue of research that
is exciting from the Hougland lab is the development of a potential biomarker for non-invasive
detection of overexpression of ghrelin O-acyltransferase (GOAT) in cancer cells. By developing
GOAT specific ligands, our work has create biostable high-affinity peptide ligands for detecting
and imaging this enzyme and providing avenues for complementary studies of GOAT expression
in cell lines, tissues, and disease models. Preliminary data with our fluorescent ligand in (prostate
cancer) PC3 cells has shown a large subpopulation of PC3 cells that display membrane
associated Cy5 fluorescence. Even though this initial study does not conclusively demonstrate
plasma membrane-localized GOAT in the cells, it does support the potential of fluorescent
GOAT ligands to label GOAT in biological samples. In the future, the Hougland lab and
collaborators will investigate cell trafficking inside these cells via membrane staining and flow
cytometry for a complete investigation of ligand uptake by these cells. I believe this work will
influence molecular understandings concerning peptide ligand binding to GOAT and generate
brand new technology for detecting GOAT as a potential disease biomarker.
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Figure 7.1 Proposed model for substrate interaction with ghrelin O-acyltransferase. The
reaction is initiated by the binding of ghrelin (via the top, luminal side of the channel) and the
acyl donor (via bottom, cytosolic side) substrates to the active center of the membrane that is
formed in the channel within hGOAT’s core. Amino acids illustrated here have shown important
interactions between substrates and hGOAT. Essential amino acids shown in red abolish
acylation activity upon alanine mutagenesis. hGOAT residues shown in purple demonstrate
reduced acylation activity. Red and blue cylinders represent perimeter helices, the green cylinder
represents intramembrane domains forming the cytoplasmic surface of hGOAT including the
CARLi domain (TM7-TM8) presented in this work. Dotted lines represent binding interactions
between the octanoyl-CoA acyl donor and its binding site within hGOAT.
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